CINXE.COM

<!DOCTYPE html> <html lang="en" class="no-js"> <head> <meta charset="UTF-8"> <meta http-equiv="X-UA-Compatible" content="IE=edge"> <meta name="applicable-device" content="pc,mobile"> <meta name="viewport" content="width=device-width, initial-scale=1"> <title>Efficacy and safety of novel multiple-chain DAP-CAR-T cells targeting mesothelin in ovarian cancer and mesothelioma: a single-arm, open-label and first-in-human study | Genome Medicine | Full Text</title> <meta name="citation_abstract" content="Despite remarkable achievements in applying chimeric antigen receptor (CAR)-T cells to treat hematological malignancies, they remain much less effective against solid tumors, facing several challenges affecting their clinical use. We previously showed that multichain DNAX-activating protein (DAP) CAR structures could enhance the safety and efficacy of CAR-T cells when used against solid tumors. In particular, mesothelin (MSLN)-targeted CAR-T cell therapy has therapeutic potential in MSLN-positive solid tumors, including ovarian cancer and mesothelioma. In vitro cell killing assays and xenograft model were utilized to determine the anti-tumor efficacy of MSLN targeting DAP-CAR-T cells and other CAR-T cells. ELISA and flow cytometry analysis were used to assess the cytokine secretion capacity and proliferation ability. Eight patients with MSLN expression were enrolled to evaluate the safety and efficacy of MSLN-DAP CAR-T cell therapy. Single-cell sequencing was performed to explore the dynamics of immune cells in patients during treatment and to identify the transcriptomic signatures associated with efficacy and toxicity. We found that multichain DAP-CAR formed by combining a natural killer cell immunoglobulin-like receptor truncator and DAP12 exhibited better cytotoxicity and tumor-killing capacity than other natural killer cell-activated receptors associated with DAP12, DAP10, or CD3Z. The safety and efficacy of MSLN-DAP CAR-T cell therapy in patients with ovarian cancer and mesothelioma were evaluated in a single-arm, open-label clinical trial (ChiCTR2100046544); two patients achieved partial response, while four patients had a stable disease status. Furthermore, single-cell sequencing analysis indicated that KT032 CAR-T cell infusion could recruit more immune cells and temporarily remodel the TME. Our study highlights the safety and therapeutic efficacy of multiple-chain DAP-CAR-T cell therapy targeting MSLN to treat patients with ovarian cancer and mesothelioma. ChiCTR.org.cn, ChiCTR2100046544 . May 21, 2021."/> <meta name="journal_id" content="13073"/> <meta name="dc.title" content="Efficacy and safety of novel multiple-chain DAP-CAR-T cells targeting mesothelin in ovarian cancer and mesothelioma: a single-arm, open-label and first-in-human study"/> <meta name="dc.source" content="Genome Medicine 2024 16:1"/> <meta name="dc.format" content="text/html"/> <meta name="dc.publisher" content="BioMed Central"/> <meta name="dc.date" content="2024-11-15"/> <meta name="dc.type" content="OriginalPaper"/> <meta name="dc.language" content="En"/> <meta name="dc.copyright" content="2024 The Author(s)"/> <meta name="dc.rights" content="2024 The Author(s)"/> <meta name="dc.rightsAgent" content="reprints@biomedcentral.com"/> <meta name="dc.description" content="Despite remarkable achievements in applying chimeric antigen receptor (CAR)-T cells to treat hematological malignancies, they remain much less effective against solid tumors, facing several challenges affecting their clinical use. We previously showed that multichain DNAX-activating protein (DAP) CAR structures could enhance the safety and efficacy of CAR-T cells when used against solid tumors. In particular, mesothelin (MSLN)-targeted CAR-T cell therapy has therapeutic potential in MSLN-positive solid tumors, including ovarian cancer and mesothelioma. In vitro cell killing assays and xenograft model were utilized to determine the anti-tumor efficacy of MSLN targeting DAP-CAR-T cells and other CAR-T cells. ELISA and flow cytometry analysis were used to assess the cytokine secretion capacity and proliferation ability. Eight patients with MSLN expression were enrolled to evaluate the safety and efficacy of MSLN-DAP CAR-T cell therapy. Single-cell sequencing was performed to explore the dynamics of immune cells in patients during treatment and to identify the transcriptomic signatures associated with efficacy and toxicity. We found that multichain DAP-CAR formed by combining a natural killer cell immunoglobulin-like receptor truncator and DAP12 exhibited better cytotoxicity and tumor-killing capacity than other natural killer cell-activated receptors associated with DAP12, DAP10, or CD3Z. The safety and efficacy of MSLN-DAP CAR-T cell therapy in patients with ovarian cancer and mesothelioma were evaluated in a single-arm, open-label clinical trial (ChiCTR2100046544); two patients achieved partial response, while four patients had a stable disease status. Furthermore, single-cell sequencing analysis indicated that KT032 CAR-T cell infusion could recruit more immune cells and temporarily remodel the TME. Our study highlights the safety and therapeutic efficacy of multiple-chain DAP-CAR-T cell therapy targeting MSLN to treat patients with ovarian cancer and mesothelioma. ChiCTR.org.cn, ChiCTR2100046544 . May 21, 2021."/> <meta name="prism.issn" content="1756-994X"/> <meta name="prism.publicationName" content="Genome Medicine"/> <meta name="prism.publicationDate" content="2024-11-15"/> <meta name="prism.volume" content="16"/> <meta name="prism.number" content="1"/> <meta name="prism.section" content="OriginalPaper"/> <meta name="prism.startingPage" content="1"/> <meta name="prism.endingPage" content="17"/> <meta name="prism.copyright" content="2024 The Author(s)"/> <meta name="prism.rightsAgent" content="reprints@biomedcentral.com"/> <meta name="prism.url" content="https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-024-01405-5"/> <meta name="prism.doi" content="doi:10.1186/s13073-024-01405-5"/> <meta name="citation_pdf_url" content="https://genomemedicine.biomedcentral.com/counter/pdf/10.1186/s13073-024-01405-5"/> <meta name="citation_fulltext_html_url" content="https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-024-01405-5"/> <meta name="citation_journal_title" content="Genome Medicine"/> <meta name="citation_journal_abbrev" content="Genome Med"/> <meta name="citation_publisher" content="BioMed Central"/> <meta name="citation_issn" content="1756-994X"/> <meta name="citation_title" content="Efficacy and safety of novel multiple-chain DAP-CAR-T cells targeting mesothelin in ovarian cancer and mesothelioma: a single-arm, open-label and first-in-human study"/> <meta name="citation_volume" content="16"/> <meta name="citation_issue" content="1"/> <meta name="citation_publication_date" content="2024/12"/> <meta name="citation_online_date" content="2024/11/15"/> <meta name="citation_firstpage" content="1"/> <meta name="citation_lastpage" content="17"/> <meta name="citation_article_type" content="Research"/> <meta name="citation_fulltext_world_readable" content=""/> <meta name="citation_language" content="en"/> <meta name="dc.identifier" content="doi:10.1186/s13073-024-01405-5"/> <meta name="DOI" content="10.1186/s13073-024-01405-5"/> <meta name="size" content="208758"/> <meta name="citation_doi" content="10.1186/s13073-024-01405-5"/> <meta name="citation_springer_api_url" content="http://api.springer.com/xmldata/jats?q=doi:10.1186/s13073-024-01405-5&api_key="/> <meta name="description" content="Despite remarkable achievements in applying chimeric antigen receptor (CAR)-T cells to treat hematological malignancies, they remain much less effective against solid tumors, facing several challenges affecting their clinical use. We previously showed that multichain DNAX-activating protein (DAP) CAR structures could enhance the safety and efficacy of CAR-T cells when used against solid tumors. In particular, mesothelin (MSLN)-targeted CAR-T cell therapy has therapeutic potential in MSLN-positive solid tumors, including ovarian cancer and mesothelioma. In vitro cell killing assays and xenograft model were utilized to determine the anti-tumor efficacy of MSLN targeting DAP-CAR-T cells and other CAR-T cells. ELISA and flow cytometry analysis were used to assess the cytokine secretion capacity and proliferation ability. Eight patients with MSLN expression were enrolled to evaluate the safety and efficacy of MSLN-DAP CAR-T cell therapy. Single-cell sequencing was performed to explore the dynamics of immune cells in patients during treatment and to identify the transcriptomic signatures associated with efficacy and toxicity. We found that multichain DAP-CAR formed by combining a natural killer cell immunoglobulin-like receptor truncator and DAP12 exhibited better cytotoxicity and tumor-killing capacity than other natural killer cell-activated receptors associated with DAP12, DAP10, or CD3Z. The safety and efficacy of MSLN-DAP CAR-T cell therapy in patients with ovarian cancer and mesothelioma were evaluated in a single-arm, open-label clinical trial (ChiCTR2100046544); two patients achieved partial response, while four patients had a stable disease status. Furthermore, single-cell sequencing analysis indicated that KT032 CAR-T cell infusion could recruit more immune cells and temporarily remodel the TME. Our study highlights the safety and therapeutic efficacy of multiple-chain DAP-CAR-T cell therapy targeting MSLN to treat patients with ovarian cancer and mesothelioma. ChiCTR.org.cn, ChiCTR2100046544 . May 21, 2021."/> <meta name="dc.creator" content="Xu, Tongpeng"/> <meta name="dc.creator" content="Tian, Tian"/> <meta name="dc.creator" content="Wang, Chen"/> <meta name="dc.creator" content="Chen, Xiaofeng"/> <meta name="dc.creator" content="Zuo, Xiangrong"/> <meta name="dc.creator" content="Zhou, Hanyu"/> <meta name="dc.creator" content="Bai, Jianan"/> <meta name="dc.creator" content="Zhao, Chenhui"/> <meta name="dc.creator" content="Fu, Sujie"/> <meta name="dc.creator" content="Sun, Chongqi"/> <meta name="dc.creator" content="Wang, Ting"/> <meta name="dc.creator" content="Zhu, Ling"/> <meta name="dc.creator" content="Zhang, Jingzhi"/> <meta name="dc.creator" content="Wang, Enxiu"/> <meta name="dc.creator" content="Sun, Ming"/> <meta name="dc.creator" content="Shu, Yongqian"/> <meta name="dc.subject" content="Human Genetics"/> <meta name="dc.subject" content="Metabolomics"/> <meta name="dc.subject" content="Bioinformatics"/> <meta name="dc.subject" content="Medicine/Public Health, general"/> <meta name="dc.subject" content="Cancer Research"/> <meta name="dc.subject" content="Systems Biology"/> <meta name="citation_reference" content="citation_journal_title=Blood Cancer J; citation_title=CAR-T cell therapy: current limitations and potential strategies; citation_author=RC Sterner, RM Sterner; citation_volume=11; citation_publication_date=2021; citation_pages=69; citation_doi=10.1038/s41408-021-00459-7; citation_id=CR1"/> <meta name="citation_reference" content="citation_journal_title=Clin Pharmacol Ther; citation_title=CAR T-cell therapy in hematologic malignancies: a voyage in progress; citation_author=SA Holstein, MA Lunning; citation_volume=107; citation_publication_date=2020; citation_pages=112-122; citation_doi=10.1002/cpt.1674; citation_id=CR2"/> <meta name="citation_reference" content="citation_journal_title=N Engl J Med; citation_title=Cilta-cel or standard care in lenalidomide-refractory multiple myeloma; citation_author=J San-Miguel, B Dhakal, K Yong, A Spencer, S Anguille, MV Mateos, C Fernandez de Larrea, J Martinez-Lopez, P Moreau, C Touzeau; citation_volume=389; citation_publication_date=2023; citation_pages=335-347; citation_doi=10.1056/NEJMoa2303379; citation_id=CR3"/> <meta name="citation_reference" content="citation_journal_title=Journal For Immunotherapy of Cancer; citation_title=Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma; citation_author=X Qu, G An, W Sui, T Wang, X Zhang, J Yang, Y Zhang, L Zhang, D Zhu, J Huang; citation_volume=10; citation_publication_date=2022; citation_pages=e005145; citation_doi=10.1136/jitc-2022-005145; citation_id=CR4"/> <meta name="citation_reference" content="citation_journal_title=Front Immunol; citation_title=CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment; citation_author=M Martinez, EK Moon; citation_volume=10; citation_publication_date=2019; citation_pages=128; citation_doi=10.3389/fimmu.2019.00128; citation_id=CR5"/> <meta name="citation_reference" content="citation_journal_title=Mol Cancer; citation_title=Tumor buster - where will the CAR-T cell therapy 'missile' go?; citation_author=C Qu, H Zhang, H Cao, L Tang, H Mo, F Liu, L Zhang, Z Yi, L Long, L Yan; citation_volume=21; citation_publication_date=2022; citation_pages=201; citation_doi=10.1186/s12943-022-01669-8; citation_id=CR6"/> <meta name="citation_reference" content="citation_journal_title=Front Immunol; citation_title=CAR-T therapy for pediatric high-grade gliomas: peculiarities, current investigations and future strategies; citation_author=L Antonucci, G Canciani, A Mastronuzzi, A Carai, G Baldo, F Bufalo; citation_volume=13; citation_publication_date=2022; citation_pages=867154; citation_doi=10.3389/fimmu.2022.867154; citation_id=CR7"/> <meta name="citation_reference" content="citation_journal_title=Front Immunol; citation_title=Revolution of CAR engineering for next-generation immunotherapy in solid tumors; citation_author=T Yu, SK Yu, Y Xiang, KH Lu, M Sun; citation_volume=13; citation_publication_date=2022; citation_pages=936496; citation_doi=10.3389/fimmu.2022.936496; citation_id=CR8"/> <meta name="citation_reference" content="citation_journal_title=Cancer Cell; citation_title=Engineering CAR-T cells for next-generation cancer therapy; citation_author=M Hong, JD Clubb, YY Chen; citation_volume=38; citation_publication_date=2020; citation_pages=473-488; citation_doi=10.1016/j.ccell.2020.07.005; citation_id=CR9"/> <meta name="citation_reference" content="citation_journal_title=Cancer Discov; citation_title=The basic principles of chimeric antigen receptor design; citation_author=M Sadelain, R Brentjens, I Rivière; citation_volume=3; citation_publication_date=2013; citation_pages=388-398; citation_doi=10.1158/2159-8290.CD-12-0548; citation_id=CR10"/> <meta name="citation_reference" content="citation_journal_title=Nat Biotechnol; citation_title=Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo; citation_author=S Rafiq, OO Yeku, HJ Jackson, TJ Purdon, DG Leeuwen, DJ Drakes, M Song, MM Miele, Z Li, P Wang; citation_volume=36; citation_publication_date=2018; citation_pages=847-856; citation_doi=10.1038/nbt.4195; citation_id=CR11"/> <meta name="citation_reference" content="citation_journal_title=Nat Med; citation_title=4–1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors; citation_author=AH Long, WM Haso, JF Shern, KM Wanhainen, M Murgai, M Ingaramo, JP Smith, AJ Walker, ME Kohler, VR Venkateshwara; citation_volume=21; citation_publication_date=2015; citation_pages=581-590; citation_doi=10.1038/nm.3838; citation_id=CR12"/> <meta name="citation_reference" content="citation_journal_title=Annu Rev Biochem; citation_title=Nanobodies: natural single-domain antibodies; citation_author=S Muyldermans; citation_volume=82; citation_publication_date=2013; citation_pages=775-797; citation_doi=10.1146/annurev-biochem-063011-092449; citation_id=CR13"/> <meta name="citation_reference" content="citation_journal_title=Biomarker Research; citation_title=Nanobody-based CAR-T cells for cancer immunotherapy; citation_author=P Safarzadeh Kozani, A Naseri, SMJ Mirarefin, F Salem, M Nikbakht, S Evazi Bakhshi, P Safarzadeh Kozani; citation_volume=10; citation_publication_date=2022; citation_pages=24; citation_doi=10.1186/s40364-022-00371-7; citation_id=CR14"/> <meta name="citation_reference" content="citation_journal_title=Nat Biotechnol; citation_title=IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor; citation_author=K Adachi, Y Kano, T Nagai, N Okuyama, Y Sakoda, K Tamada; citation_volume=36; citation_publication_date=2018; citation_pages=346-351; citation_doi=10.1038/nbt.4086; citation_id=CR15"/> <meta name="citation_reference" content="citation_journal_title=Am J Hematol.; citation_title=A novel adoptive synthetic TCR and antigen receptor (STAR) T-Cell therapy for B-Cell acute lymphoblastic leukemia; citation_author=J Wang, X Zhang, Z Zhou, Y Liu, L Yu, L Jia, J Yang, J Li, H Yu, W Li; citation_volume=97; citation_issue=8; citation_publication_date=2022; citation_pages=992-1004; citation_doi=10.1002/ajh.26586; citation_id=CR16"/> <meta name="citation_reference" content="citation_journal_title=Cancer Immunol Res; citation_title=Generation of potent T-cell immunotherapy for cancer using DAP12-based, multichain, chimeric immunoreceptors; citation_author=E Wang, L-C Wang, C-Y Tsai, V Bhoj, Z Gershenson, E Moon, K Newick, J Sun, A Lo, T Baradet; citation_volume=3; citation_publication_date=2015; citation_pages=815-826; citation_doi=10.1158/2326-6066.CIR-15-0054; citation_id=CR17"/> <meta name="citation_reference" content="citation_journal_title=Immunotherapy; citation_title=Coexpression of c-Jun in multiple-chain DAP-CAR-engineered T-cells for solid tumor therapy; citation_author=T Xu, C Wang, X Chen, J Bai, E Wang, M Sun; citation_volume=14; citation_publication_date=2022; citation_pages=1457-1466; citation_doi=10.2217/imt-2022-0171; citation_id=CR18"/> <meta name="citation_reference" content="citation_journal_title=Can Res; citation_title=Discovery of mesothelin and exploiting it as a target for immunotherapy; citation_author=I Pastan, R Hassan; citation_volume=74; citation_publication_date=2014; citation_pages=2907-2912; citation_doi=10.1158/0008-5472.CAN-14-0337; citation_id=CR19"/> <meta name="citation_reference" content="citation_journal_title=J Hematol Oncol; citation_title=A novel mycobacterial Hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma; citation_author=J Yuan, S Kashiwagi, P Reeves, J Nezivar, Y Yang, NH Arrifin, M Nguyen, G Jean-Mary, X Tong, P Uppal; citation_volume=7; citation_publication_date=2014; citation_pages=15; citation_doi=10.1186/1756-8722-7-15; citation_id=CR20"/> <meta name="citation_reference" content="citation_journal_title=Expert Opin Biol Ther; citation_title=Mesothelin-targeted CAR-T cell therapy for solid tumors; citation_author=A Klampatsa, V Dimou, SM Albelda; citation_volume=21; citation_publication_date=2021; citation_pages=473-486; citation_doi=10.1080/14712598.2021.1843628; citation_id=CR21"/> <meta name="citation_reference" content="citation_journal_title=Can Res; citation_title=Mesothelin-specific CAR T cells target ovarian cancer; citation_author=E Schoutrop, I El-Serafi, T Poiret, Y Zhao, O Gultekin, R He, L Moyano-Galceran, JW Carlson, K Lehti, M Hassan; citation_volume=81; citation_publication_date=2021; citation_pages=3022-3035; citation_doi=10.1158/0008-5472.CAN-20-2701; citation_id=CR22"/> <meta name="citation_reference" content="citation_journal_title=Biomarker Research; citation_title=Anti-mesothelin CAR T cell therapy for malignant mesothelioma; citation_author=L Castelletti, D Yeo, N Zandwijk, JEJ Rasko; citation_volume=9; citation_publication_date=2021; citation_pages=11; citation_doi=10.1186/s40364-021-00264-1; citation_id=CR23"/> <meta name="citation_reference" content="citation_journal_title=Trends Biotechnol; citation_title=Leveraging single-cell sequencing for chimeric antigen receptor T cell therapies; citation_author=R Castellanos-Rueda, RB Roberto, FS Schlatter, ST Reddy; citation_volume=39; citation_publication_date=2021; citation_pages=1308-1320; citation_doi=10.1016/j.tibtech.2021.03.005; citation_id=CR24"/> <meta name="citation_reference" content="citation_journal_title=Clin Cancer Res; citation_title=A humanized Lym-1 CAR with novel DAP10/DAP12 signaling domains demonstrates reduced tonic signaling and increased antitumor activity in B-cell lymphoma models; citation_author=L Zheng, L Ren, A Kouhi, LA Khawli, P Hu, HR Kaslow, AL Epstein; citation_volume=26; citation_publication_date=2020; citation_pages=3694-3706; citation_doi=10.1158/1078-0432.CCR-19-3417; citation_id=CR25"/> <meta name="citation_reference" content="citation_journal_title=Nat Rev Clin Oncol; citation_title=Chimeric antigen receptor T-cell therapy - assessment and management of toxicities; citation_author=SS Neelapu, S Tummala, P Kebriaei, W Wierda, C Gutierrez, FL Locke, KV Komanduri, Y Lin, N Jain, N Daver; citation_volume=15; citation_publication_date=2018; citation_pages=47-62; citation_doi=10.1038/nrclinonc.2017.148; citation_id=CR26"/> <meta name="citation_reference" content="citation_journal_title=Front Immunol; citation_title=CAR-T cell therapy: mechanism, management, and mitigation of inflammatory toxicities; citation_author=JW Fischer, N Bhattarai; citation_volume=12; citation_publication_date=2021; citation_pages=693016; citation_doi=10.3389/fimmu.2021.693016; citation_id=CR27"/> <meta name="citation_reference" content="citation_journal_title=Curr Hematol Malig Rep.; citation_title=CAR-T cell therapy: the efficacy and toxicity balance; citation_author=KL Chohan, EL Siegler, SS Kenderian; citation_volume=18; citation_publication_date=2023; citation_pages=9-18; citation_doi=10.1007/s11899-023-00687-7; citation_id=CR28"/> <meta name="citation_reference" content="citation_journal_title=Blood; citation_title=Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity; citation_author=L Fultang, S Booth, O Yogev, B Martins da Costa, V Tubb, S Panetti, V Stavrou, U Scarpa, A Jankevics, G Lloyd; citation_volume=136; citation_publication_date=2020; citation_pages=1155-1160; citation_doi=10.1182/blood.2019004500; citation_id=CR29"/> <meta name="citation_reference" content="citation_journal_title=Mol Ther; citation_title=Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers; citation_author=AR Haas, JL Tanyi, MH O'Hara, WL Gladney, SF Lacey, DA Torigian, MC Soulen, L Tian, M McGarvey, AM Nelson; citation_volume=27; citation_publication_date=2019; citation_pages=1919-1929; citation_doi=10.1016/j.ymthe.2019.07.015; citation_id=CR30"/> <meta name="citation_reference" content="citation_journal_title=Cancer Immunol Immunother; citation_title=Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer; citation_author=J Chen, J Hu, L Gu, F Ji, F Zhang, M Zhang, J Li, Z Chen, L Jiang, Y Zhang; citation_volume=72; citation_publication_date=2023; citation_pages=409-425; citation_doi=10.1007/s00262-022-03238-w; citation_id=CR31"/> <meta name="citation_reference" content="Xu T, Shu Y, et al. Characterization of mesothelin targeting novel multiple chain DAP-CAR-T cells efficacy in patients with ovarian cancer and mesothelioma through single-cell transcriptomic analysis. HRA006416. 2024. https://bigd.big.ac.cn ."/> <meta name="citation_reference" content="Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-Seq data. Github. https://github.com/rcastelo/GSVA ."/> <meta name="citation_reference" content="Efremova M, Vento-Tormo M, Teichmann S, Vento-Tormo R. CellphoneDB v2: inferring cell-cell communication from combined expression of multi-subunit receptor-ligand complexes. Github. https://github.com/ventolab/CellphoneDB ."/> <meta name="citation_author" content="Xu, Tongpeng"/> <meta name="citation_author_institution" content="Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China"/> <meta name="citation_author" content="Tian, Tian"/> <meta name="citation_author_institution" content="Department of Geriatric Hematology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China"/> <meta name="citation_author" content="Wang, Chen"/> <meta name="citation_author_institution" content="Nanjing CART Medical Technology Co., Ltd, Nanjing, People’s Republic of China"/> <meta name="citation_author" content="Chen, Xiaofeng"/> <meta name="citation_author_institution" content="Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China"/> <meta name="citation_author" content="Zuo, Xiangrong"/> <meta name="citation_author_institution" content="Department of Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China"/> <meta name="citation_author" content="Zhou, Hanyu"/> <meta name="citation_author_institution" content="Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China"/> <meta name="citation_author_institution" content="Department of Oncology, Gusu School, Suzhou Municipal Hospital, the Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, People’s Republic of China"/> <meta name="citation_author" content="Bai, Jianan"/> <meta name="citation_author_institution" content="Department of Geriatric Gastroenterology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China"/> <meta name="citation_author" content="Zhao, Chenhui"/> <meta name="citation_author_institution" content="Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China"/> <meta name="citation_author" content="Fu, Sujie"/> <meta name="citation_author_institution" content="The Second Affiliated Hospitalof , Nanjing University of Chinese Medicine, Nanjing, People’s Republic of China"/> <meta name="citation_author" content="Sun, Chongqi"/> <meta name="citation_author_institution" content="Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China"/> <meta name="citation_author" content="Wang, Ting"/> <meta name="citation_author_institution" content="Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China"/> <meta name="citation_author" content="Zhu, Ling"/> <meta name="citation_author_institution" content="Department of Oncology, Xishan People’s Hospital of Wuxi City, Wuxi, People’s Republic of China"/> <meta name="citation_author" content="Zhang, Jingzhi"/> <meta name="citation_author_institution" content="Nanjing CART Medical Technology Co., Ltd, Nanjing, People’s Republic of China"/> <meta name="citation_author" content="Wang, Enxiu"/> <meta name="citation_author_institution" content="Nanjing CART Medical Technology Co., Ltd, Nanjing, People’s Republic of China"/> <meta name="citation_author" content="Sun, Ming"/> <meta name="citation_author_institution" content="Suzhou Cancer Center Core Laboratory, Gusu School, Suzhou Municipal Hospital, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, People’s Republic of China"/> <meta name="citation_author" content="Shu, Yongqian"/> <meta name="citation_author_institution" content="Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China"/> <meta name="format-detection" content="telephone=no"> <link rel="apple-touch-icon" sizes="180x180" href=/static/img/favicons/bmc/apple-touch-icon-582ef1d0f5.png> <link rel="icon" type="image/png" sizes="192x192" href=/static/img/favicons/bmc/android-chrome-192x192-9625b7cdba.png> <link rel="icon" type="image/png" sizes="32x32" href=/static/img/favicons/bmc/favicon-32x32-5d7879efe1.png> <link rel="icon" type="image/png" sizes="16x16" href=/static/img/favicons/bmc/favicon-16x16-c241ac1a2f.png> <link rel="shortcut icon" data-test="shortcut-icon" href=/static/img/favicons/bmc/favicon-1886637b78.ico> <link rel="manifest" href=/static/app-bmc/manifest-3bb9ad383b.json> <meta name="msapplication-config" content=/static/app-bmc/browserconfig-ecd9aa8205.xml> <meta name="msapplication-TileColor" content="#1b3051"> <meta name="msapplication-TileImage" content=/static/img/favicons/bmc/app-icon-144x144.png> <meta name="theme-color" content="#1b3051"> <script>(function(H){H.className=H.className.replace(/\bno-js\b/,'js')})(document.documentElement)</script> <link rel="stylesheet" media="screen" href=/static/app-bmc/css/core-article-f3872e738d.css> <link rel="stylesheet" media="screen" href=/static/app-bmc/css/core-eac3097aa4.css> <link rel="stylesheet" media="print" href=/static/app-bmc/css/print-b8af42253b.css>  <style>@media only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark) { button{line-height:inherit}html,label{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}html{-webkit-font-smoothing:subpixel-antialiased;box-sizing:border-box;color:#333;font-size:100%;height:100%;line-height:1.61803;overflow-y:scroll}*{box-sizing:inherit}body{background:#fff;margin:0;max-width:100%;min-height:100%}button,div,form,input,p{margin:0;padding:0}body{padding:0}a{color:#004b83;text-decoration:underline;text-decoration-skip-ink:auto}a>img{vertical-align:middle}h1,h2{color:#1b3051;font-style:normal;font-weight:700}h1{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:28px;line-height:1.4}html.webfonts-loaded h1,html.webfonts-loaded h2,html.webfonts-loaded h3{font-family:Europa,Trebuchet MS}h2{font-size:26px;margin-bottom:.5em}h2,h3{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;line-height:1.4}h3{color:#1b3051;font-size:18px;font-style:normal;margin-bottom:.7em}.c-navbar{background:#f2f2f2;border-bottom:1px solid #d9d9d9;border-top:1px solid #d9d9d9;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:14px;line-height:1.61803;padding:16px 0}.c-navbar--with-submit-button{padding-bottom:24px}@media only screen and (min-width:540px){.c-navbar--with-submit-button{padding-bottom:16px}}.c-navbar__container{display:flex;flex-wrap:wrap;justify-content:space-between;margin:0 auto;max-width:1280px;padding:0 16px}.c-navbar__content{display:flex;flex:0 1 auto}.c-navbar__nav{align-items:center;display:flex;flex-wrap:wrap;gap:16px 16px;list-style:none;margin:0;padding:0}.c-navbar__item{flex:0 0 auto}.c-navbar__link{background:0 0;border:0;color:currentcolor;display:block;text-decoration:none;text-transform:capitalize}.c-navbar__link--is-shown{text-decoration:underline}.c-ad{text-align:center}@media only screen and (min-width:320px){.c-ad{padding:8px}}.c-ad--728x90{background-color:#ccc;display:none}.c-ad--728x90 .c-ad__inner{min-height:calc(1.5em + 94px)}.c-ad--728x90 iframe{height:90px;max-width:970px}@media only screen and (min-width:768px){.js .c-ad--728x90{display:none}.js .u-show-following-ad+.c-ad--728x90{display:block}}.c-ad iframe{border:0;overflow:auto;vertical-align:top}.c-ad__label{color:#333;font-weight:400;line-height:1.5;margin-bottom:4px}.c-ad__label,.c-skip-link{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem}.c-skip-link{background:#dceaf6;bottom:auto;color:#004b83;padding:8px;position:absolute;text-align:center;transform:translateY(-100%);z-index:9999}@media (prefers-reduced-motion:reduce){.c-skip-link{transition:top .3s ease-in-out 0s}}@media print{.c-skip-link{display:none}}.c-skip-link:link{color:#004b83}.c-dropdown__button:after{border-color:transparent transparent transparent #fff;border-style:solid;border-width:4px 0 4px 14px;content:"";display:block;height:0;margin-left:3px;width:0}.c-dropdown{display:inline-block;position:relative}.c-dropdown__button{background-color:transparent;border:0;display:inline-block;padding:0;white-space:nowrap}.c-dropdown__button:after{border-color:currentcolor transparent transparent;border-width:5px 4px 0 5px;display:inline-block;margin-left:8px;vertical-align:middle}.c-dropdown__menu{background-color:#fff;border:1px solid #d9d9d9;border-radius:3px;box-shadow:0 2px 6px rgba(0,0,0,.1);font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:14px;line-height:1.4;list-style:none;margin:0;padding:8px 0;position:absolute;top:100%;transform:translateY(8px);width:180px;z-index:100}.c-dropdown__menu:after,.c-dropdown__menu:before{border-style:solid;bottom:100%;content:"";display:block;height:0;left:16px;position:absolute;width:0}.c-dropdown__menu:before{border-color:transparent transparent #d9d9d9;border-width:0 9px 9px;transform:translateX(-1px)}.c-dropdown__menu:after{border-color:transparent transparent #fff;border-width:0 8px 8px}.c-dropdown__menu--right{left:auto;right:0}.c-dropdown__menu--right:after,.c-dropdown__menu--right:before{left:auto;right:16px}.c-dropdown__menu--right:before{transform:translateX(1px)}.c-dropdown__link{background-color:transparent;color:#004b83;display:block;padding:4px 16px}.c-header{background-color:#1b3051;border-bottom:4px solid #1b3051;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:14px;padding:16px 0}.c-header__container,.c-header__menu{align-items:center;display:flex;flex-wrap:wrap}@supports (gap:2em){.c-header__container,.c-header__menu{gap:2em 2em}}.c-header__menu{list-style:none;margin:0;padding:0}.c-header__item{color:#fff}@supports not (gap:2em){.c-header__item{margin-left:24px}}.c-header__container{justify-content:space-between;margin:0 auto;max-width:1280px;padding:0 16px}@supports not (gap:2em){.c-header__brand{margin-right:48px}}.c-header__brand a{display:block;text-decoration:none}.c-header__link{color:#fff}.c-journal-title a{text-decoration:none}html.webfonts-loaded .c-journal-title{font-family:Europa,Trebuchet MS}.c-form-field{margin-bottom:1em}.c-form-field__label{color:#666;display:block;font-size:14px;margin-bottom:.4em}.c-form-field__input{border:1px solid #a6a6a6;border-radius:3px;box-shadow:inset 0 1px 3px 0 rgba(0,0,0,.21);font-size:14px;line-height:1.28571;padding:.75em 1em;vertical-align:middle;width:100%}.c-popup-search{background-color:#25426f;box-shadow:0 3px 3px -3px rgba(0,0,0,.21);padding:16px 0;position:relative;z-index:10}@media only screen and (min-width:1024px){.js .c-popup-search{position:absolute;top:100%;width:100%}.c-popup-search__container{margin:auto;max-width:70%}}.c-logo img{display:block}.ctx-search .c-form-field{margin-bottom:0}.ctx-search .c-form-field__label{color:#fff}.ctx-search .c-form-field__input{border-bottom-right-radius:0;border-top-right-radius:0;margin-right:0}.c-journal-header{overflow:hidden}.c-journal-header__inner{padding-bottom:8px;padding-top:8px}@media only screen and (min-width:540px){.c-journal-header__inner{display:flex;justify-content:space-between}}.c-journal-header__identity{background-size:auto 80px;min-height:16px;padding:6px 0}@media only screen and (min-width:540px){.c-journal-header__identity{background-position:0}}.c-journal-header__identity--default{background:url(/static/images/bmc/identities/patterns/default-7e3a6b1388.svg) 0 0 no-repeat #04caa8}.c-journal-title{color:#1b3051;display:flex;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:26px;font-style:normal;font-weight:700;line-height:1.4;margin-bottom:0}.c-journal-title>a{color:#0061a9;color:#1b3051;display:flex;text-decoration:none}.c-journal-title__text{align-self:center;display:block;flex:0 1 auto}.c-logo,.c-logo>a{align-items:baseline;display:flex}.c-logo__strapline{display:none}@media only screen and (min-width:540px){.c-logo__strapline{display:block;margin:0 0 0 16px;transform:translateY(1px)}}.c-logo{display:block}html.webfonts-loaded .u-h3,html.webfonts-loaded .u-h4{font-family:Europa,Trebuchet MS}.u-button{align-items:center;background-color:#f2f2f2;background-image:linear-gradient(#fff,#f2f2f2);border:1px solid #ccc;border-radius:2px;cursor:pointer;display:inline-flex;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;justify-content:center;line-height:1.3;margin:0;padding:8px;position:relative;text-decoration:none;transition:all .25s ease 0s,color .25s ease 0s,border-color .25s ease 0s;width:auto}.u-button svg,.u-button--primary svg,.u-button--tertiary svg{fill:currentcolor}.u-button{color:#004b83}.u-button--primary,.u-button--tertiary{background-color:#33629d;background-image:linear-gradient(#4d76a9,#33629d);border:1px solid rgba(0,59,132,.5);color:#fff}.u-button--tertiary{font-weight:400}.u-button--full-width{display:flex;width:100%}.u-clearfix:after,.u-clearfix:before{content:"";display:table}.u-clearfix:after{clear:both}.u-color-open-access{color:#b74616}.u-container{margin:0 auto;max-width:1280px;padding:0 16px}.u-display-flex{display:flex;width:100%}.u-align-items-center{align-items:center}.u-justify-content-space-between{justify-content:space-between}.u-flex-static{flex:0 0 auto}.u-display-none{display:none}.js .u-js-hide{display:none;visibility:hidden}@media print{.u-hide-print{display:none}}.u-icon{fill:currentcolor;display:inline-block;height:1em;transform:translate(0);vertical-align:text-top;width:1em}.u-list-reset{list-style:none;margin:0;padding:0}.u-position-relative{position:relative}.u-mt-32{margin-top:32px}.u-mr-24{margin-right:24px}.u-mr-48{margin-right:48px}.u-mb-32{margin-bottom:32px}.u-ml-8{margin-left:8px}.u-button-reset{background-color:transparent;border:0;padding:0}.u-text-sm{font-size:14px}.u-h3,.u-h4{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;line-height:1.4}.u-h3{color:#1b3051;font-size:18px;font-style:normal;margin-bottom:.7em}.u-h4{color:#1b3051;font-size:18px;font-style:italic;font-weight:700;margin-bottom:.7em}.u-vh-full{min-height:100vh}.u-hide{display:none;visibility:hidden}.u-hide:first-child+*{margin-block-start:0}@media only screen and (min-width:1024px){.u-hide-at-lg{display:none;visibility:hidden}}@media only screen and (max-width:1023px){.u-hide-at-lt-lg{display:none;visibility:hidden}.u-hide-at-lt-lg:first-child+*{margin-block-start:0}}.u-visually-hidden{clip:rect(0,0,0,0);border:0;height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}.u-button--tertiary{font-size:.875rem;padding:8px 16px}@media only screen and (max-width:539px){.u-button--alt-colour-on-mobile{background-color:#f2f2f2;background-image:linear-gradient(#fff,#f2f2f2);border:1px solid #ccc;color:#004b83}}body{font-size:1.125rem}.c-header__navigation{display:flex;gap:.5rem .5rem} }</style> <style>@media only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark) { button{line-height:inherit}html,label{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}html{-webkit-font-smoothing:subpixel-antialiased;box-sizing:border-box;color:#333;font-size:100%;height:100%;line-height:1.61803;overflow-y:scroll}*{box-sizing:inherit}body{background:#fff;margin:0;max-width:100%;min-height:100%}button,div,form,input,p{margin:0;padding:0}body{padding:0}a{color:#004b83;overflow-wrap:break-word;text-decoration:underline;text-decoration-skip-ink:auto;word-break:break-word}a>img{vertical-align:middle}h1,h2{color:#1b3051;font-style:normal;font-weight:700}h1{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:28px;line-height:1.4}html.webfonts-loaded h1,html.webfonts-loaded h2,html.webfonts-loaded h3{font-family:Europa,Trebuchet MS}h2{font-size:26px;margin-bottom:.5em}h2,h3{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;line-height:1.4}h3{color:#1b3051;font-size:18px;font-style:normal;margin-bottom:.7em}p{overflow-wrap:break-word;word-break:break-word}.u-h3{font-size:1.5rem}.u-h3,.u-h4{font-weight:700}.u-h4{font-size:1.25rem}.c-reading-companion__figure-title{font-size:1.25rem;font-weight:700}body{font-size:1.125rem}.c-article-header{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;margin-bottom:40px}.c-article-identifiers{color:#6f6f6f;display:flex;flex-wrap:wrap;font-size:1rem;line-height:1.3;list-style:none;margin:0 0 8px;padding:0}.c-article-identifiers__item{border-right:1px solid #6f6f6f;list-style:none;margin-right:8px;padding-right:8px}.c-article-identifiers__item:last-child{border-right:0;margin-right:0;padding-right:0}.c-article-title{font-size:1.5rem;line-height:1.25;margin-bottom:16px}@media only screen and (min-width:768px){.c-article-title{font-size:1.875rem;line-height:1.2}}.c-article-author-list{display:inline;font-size:1rem;list-style:none;margin:0 8px 0 0;padding:0;width:100%}.c-article-author-list__item{display:inline;padding-right:0}.c-article-author-list svg{margin-left:4px}.c-article-author-list__show-more{display:none;margin-right:4px}.c-article-author-list__button,.js .c-article-author-list__item--hide,.js .c-article-author-list__show-more{display:none}.js .c-article-author-list--long .c-article-author-list__show-more,.js .c-article-author-list--long+.c-article-author-list__button{display:inline}@media only screen and (max-width:539px){.js .c-article-author-list__item--hide-small-screen{display:none}.js .c-article-author-list--short .c-article-author-list__show-more,.js .c-article-author-list--short+.c-article-author-list__button{display:inline}}#uptodate-client,.js .c-article-author-list--expanded .c-article-author-list__show-more{display:none!important}.js .c-article-author-list--expanded .c-article-author-list__item--hide-small-screen{display:inline!important}.c-article-author-list__button,.c-button-author-list{background:#ebf1f5;border:4px solid #ebf1f5;border-radius:20px;color:#666;font-size:.875rem;line-height:1.4;padding:2px 11px 2px 8px;text-decoration:none}.c-article-author-list__button svg,.c-button-author-list svg{margin:1px 4px 0 0}.c-article-author-list__button:hover,.c-button-author-list:hover{background:#173962;border-color:transparent;color:#fff}.c-article-info-details{font-size:1rem;margin-bottom:8px;margin-top:16px}.c-article-info-details__cite-as{border-left:1px solid #6f6f6f;margin-left:8px;padding-left:8px}.c-article-metrics-bar{display:flex;flex-wrap:wrap;font-size:1rem;line-height:1.3}.c-article-metrics-bar__wrapper{margin:0 0 16px}.c-article-metrics-bar__item{align-items:baseline;border-right:1px solid #6f6f6f;margin-right:8px}.c-article-metrics-bar__item:last-child{border-right:0}.c-article-metrics-bar__count{font-weight:700;margin:0}.c-article-metrics-bar__label{color:#626262;font-style:normal;font-weight:400;margin:0 10px 0 5px}.c-article-metrics-bar__details{margin:0}.c-article-main-column{font-family:Georgia,Palatino,serif;margin-right:8.6%;width:60.2%}@media only screen and (max-width:1023px){.c-article-main-column{margin-right:0;width:100%}}.c-article-extras{float:left;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;width:31.2%}@media only screen and (max-width:1023px){.c-article-extras{display:none}}.c-article-associated-content__container .c-article-associated-content__title,.c-article-section__title{border-bottom:2px solid #d5d5d5;font-size:1.25rem;margin:0;padding-bottom:8px}@media only screen and (min-width:768px){.c-article-associated-content__container .c-article-associated-content__title,.c-article-section__title{font-size:1.5rem;line-height:1.24}}.c-article-associated-content__container .c-article-associated-content__title{margin-bottom:8px}.c-article-section{clear:both}.c-article-section__content{margin-bottom:40px;margin-top:0;padding-top:8px}@media only screen and (max-width:1023px){.c-article-section__content{padding-left:0}}.c-article__sub-heading{color:#222;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1.125rem;font-style:normal;font-weight:400;line-height:1.3;margin:24px 0 8px}@media only screen and (min-width:768px){.c-article__sub-heading{font-size:1.5rem;line-height:1.24}}.c-article__sub-heading:first-child{margin-top:0}.c-article-authors-search{margin-bottom:24px;margin-top:0}.c-article-authors-search__item,.c-article-authors-search__title{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}.c-article-authors-search__title{color:#626262;font-size:1.05rem;font-weight:700;margin:0;padding:0}.c-article-authors-search__item{font-size:1rem}.c-article-authors-search__text{margin:0}.c-article-share-box__no-sharelink-info{font-size:.813rem;font-weight:700;margin-bottom:24px;padding-top:4px}.c-article-share-box__only-read-input{border:1px solid #d5d5d5;box-sizing:content-box;display:inline-block;font-size:.875rem;font-weight:700;height:24px;margin-bottom:8px;padding:8px 10px}.c-article-share-box__button--link-like{background-color:transparent;border:0;color:#0067c5;cursor:pointer;font-size:.875rem;margin-bottom:8px;margin-left:10px}.c-article-associated-content__container .c-article-associated-content__collection-label{font-size:.875rem;line-height:1.4}.c-article-associated-content__container .c-article-associated-content__collection-title{line-height:1.3}.c-context-bar{box-shadow:0 0 10px 0 rgba(51,51,51,.2);position:relative;width:100%}.c-context-bar__title{display:none}.c-reading-companion{clear:both;min-height:389px}.c-reading-companion__sticky{max-width:389px}.c-reading-companion__scroll-pane{margin:0;min-height:200px;overflow:hidden auto}.c-reading-companion__tabs{display:flex;flex-flow:row nowrap;font-size:1rem;list-style:none;margin:0 0 8px;padding:0}.c-reading-companion__tabs>li{flex-grow:1}.c-reading-companion__tab{background-color:#eee;border:1px solid #d5d5d5;border-image:initial;border-left-width:0;color:#0067c5;font-size:1rem;padding:8px 8px 8px 15px;text-align:left;width:100%}.c-reading-companion__tabs li:first-child .c-reading-companion__tab{border-left-width:1px}.c-reading-companion__tab--active{background-color:#fff;border-bottom:1px solid #fff;color:#222;font-weight:700}.c-reading-companion__sections-list{list-style:none;padding:0}.c-reading-companion__figures-list,.c-reading-companion__references-list{list-style:none;min-height:389px;padding:0}.c-reading-companion__references-list--numeric{list-style:decimal inside}.c-reading-companion__sections-list{margin:0 0 8px;min-height:50px}.c-reading-companion__section-item{font-size:1rem;padding:0}.c-reading-companion__section-item a{display:block;line-height:1.5;overflow:hidden;padding:8px 0 8px 16px;text-overflow:ellipsis;white-space:nowrap}.c-reading-companion__figure-item{border-top:1px solid #d5d5d5;font-size:1rem;padding:16px 8px 16px 0}.c-reading-companion__figure-item:first-child{border-top:none;padding-top:8px}.c-reading-companion__reference-item{border-top:1px solid #d5d5d5;font-size:1rem;padding:8px 8px 8px 16px}.c-reading-companion__reference-item:first-child{border-top:none}.c-reading-companion__reference-item a{word-break:break-word}.c-reading-companion__reference-citation{display:inline}.c-reading-companion__reference-links{font-size:.813rem;font-weight:700;list-style:none;margin:8px 0 0;padding:0;text-align:right}.c-reading-companion__reference-links>a{display:inline-block;padding-left:8px}.c-reading-companion__reference-links>a:first-child{display:inline-block;padding-left:0}.c-reading-companion__figure-title{display:block;margin:0 0 8px}.c-reading-companion__figure-links{display:flex;justify-content:space-between;margin:8px 0 0}.c-reading-companion__figure-links>a{align-items:center;display:flex}.c-reading-companion__figure-full-link svg{height:.8em;margin-left:2px}.c-reading-companion__panel{border-top:none;display:none;margin-top:0;padding-top:0}.c-reading-companion__panel--active{display:block}.c-pdf-download__link .u-icon{padding-top:2px}.c-pdf-download{display:flex;margin-bottom:16px;max-height:48px}@media only screen and (min-width:540px){.c-pdf-download{max-height:none}}@media only screen and (min-width:1024px){.c-pdf-download{max-height:48px}}.c-pdf-download__link{display:flex;flex:1 1 0%;padding:13px 24px!important}.c-pdf-download__text{padding-right:4px}@media only screen and (max-width:539px){.c-pdf-download__text{text-transform:capitalize}}@media only screen and (min-width:540px){.c-pdf-download__text{padding-right:8px}}.c-pdf-container{display:flex;justify-content:flex-end}@media only screen and (max-width:539px){.c-pdf-container .c-pdf-download{display:flex;flex-basis:100%}}.c-article-associated-content__container a,.c-card__summary a{text-decoration:underline}.u-display-none{display:none}.js .u-js-hide,.u-hide{display:none;visibility:hidden}.u-hide:first-child+*{margin-block-start:0}.u-visually-hidden{clip:rect(0,0,0,0);border:0;height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}@media print{.u-hide-print{display:none}}@media only screen and (min-width:1024px){.u-hide-at-lg{display:none;visibility:hidden}}.u-icon{fill:currentcolor;display:inline-block;height:1em;transform:translate(0);vertical-align:text-top;width:1em}.u-list-reset{list-style:none;margin:0;padding:0}.hide{display:none;visibility:hidden}.c-article-associated-content__container .c-article-associated-content__collection.collection~.c-article-associated-content__collection.collection .c-article-associated-content__collection-label,.c-article-associated-content__container .c-article-associated-content__collection.section~.c-article-associated-content__collection.section .c-article-associated-content__collection-label,.c-article-associated-content__container .c-article-associated-content__title{display:none}.c-article-associated-content__container .c-article-associated-content__collection.collection .c-article-associated-content__collection-label,.c-article-associated-content__container .c-article-associated-content__collection.section .c-article-associated-content__collection-label{display:block}.c-article-associated-content__container .c-article-associated-content__collection.collection,.c-article-associated-content__container .c-article-associated-content__collection.section{margin-bottom:5px}.c-article-associated-content__container .c-article-associated-content__collection.section~.c-article-associated-content__collection.collection{margin-top:28px}.c-article-associated-content__container .c-article-associated-content__collection:first-child{margin-top:0}.c-article-associated-content__container .c-article-associated-content__collection:last-child{margin-bottom:2.4rem}.c-article-associated-content__container .c-article-associated-content__collection-label{color:#1b3051}.c-article-associated-content__container .c-article-associated-content__collection-title{font-size:1.063rem;font-weight:400}.webfonts-loaded .c-article__sub-heading{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif} }</style> <link rel="stylesheet" data-test="critical-css-handler" data-inline-css-source="critical-css" href="/static/app-bmc/css/enhanced-32c9abc865.css" media="print" onload="this.media='only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)';this.onload=null"> <link rel="stylesheet" data-test="critical-css-handler" data-inline-css-source="critical-css" href="/static/app-bmc/css/enhanced-article-215af16b37.css" media="print" onload="this.media='only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)';this.onload=null"> <script type="text/javascript"> config = { env: 'live', site: 'genomemedicine.biomedcentral.com', siteWithPath: 'genomemedicine.biomedcentral.com' + window.location.pathname, twitterHashtag: '', cmsPrefix: 'https://studio-cms.springernature.com/studio/', doi: '10.1186/s13073-024-01405-5', figshareScriptUrl: 'https://widgets.figshare.com/static/figshare.js', hasFigshareInvoked: false, publisherBrand: 'BioMed Central', mustardcut: false }; </script> <script type="text/javascript" data-test="dataLayer"> window.dataLayer = [{"content":{"article":{"doi":"10.1186/s13073-024-01405-5","articleType":"Research","peerReviewType":"Closed","supplement":null,"keywords":"MSLN;CAR-T cells;Ovarian cancer;Mesothelioma;Safety;Efficacy"},"contentInfo":{"imprint":"BioMed Central","title":"Efficacy and safety of novel multiple-chain DAP-CAR-T cells targeting mesothelin in ovarian cancer and mesothelioma: a single-arm, open-label and first-in-human study","publishedAt":1731628800000,"publishedAtDate":"2024-11-15","author":["Tongpeng Xu","Tian Tian","Chen Wang","Xiaofeng Chen","Xiangrong Zuo","Hanyu Zhou","Jianan Bai","Chenhui Zhao","Sujie Fu","Chongqi Sun","Ting Wang","Ling Zhu","Jingzhi Zhang","Enxiu Wang","Ming Sun","Yongqian Shu"],"collection":[{"collectionID":"AC_d308c5b632be4aa487e1bae48a74e346","collectionName":"Clinical trials resource"}]},"attributes":{"deliveryPlatform":"oscar","template":"rebrand","cms":null,"copyright":{"creativeCommonsType":"CC BY-NC-ND","openAccess":true},"environment":"live"},"journal":{"siteKey":"genomemedicine.biomedcentral.com","volume":"16","issue":"1","title":"Genome Medicine","type":"FLAGSHIP","journalID":13073,"section":[]},"category":{"pmc":{"primarySubject":"Biomedicine"},"contentType":"Research","publishingSegment":"BMC Flagships","snt":["Medical Genetics","Computational and Systems Biology","Bioinformatics","Public Health","Cancer Biology"]}},"session":{"authentication":{"authenticationID":[]}},"version":"1.0.0","page":{"category":{"pageType":"article"},"attributes":{"featureFlags":[],"environment":"live","darwin":false}},"japan":false,"event":"dataLayerCreated","collection":null,"publisherBrand":"BioMed Central"}]; </script> <script> window.dataLayer = window.dataLayer || []; window.dataLayer.push({ ga4MeasurementId: 'G-PJCTJWPV25', ga360TrackingId: 'UA-54492316-9', twitterId: 'o47a2', baiduId: 'd1b4bc3b5ada4eb7290535e72899bac1', ga4ServerUrl: 'https://collect.biomedcentral.com', imprint: 'biomedcentral' }); </script> <script> (function(w, d) { w.config = w.config || {}; w.config.mustardcut = false; if (w.matchMedia && w.matchMedia('only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)').matches) { w.config.mustardcut = true; d.classList.add('js'); d.classList.remove('grade-c'); d.classList.remove('no-js'); } })(window, document.documentElement); </script> <script> (function () { if ( typeof window.CustomEvent === "function" ) return false; function CustomEvent ( event, params ) { params = params || { bubbles: false, cancelable: false, detail: null }; var evt = document.createEvent( 'CustomEvent' ); evt.initCustomEvent( event, params.bubbles, params.cancelable, params.detail ); return evt; } CustomEvent.prototype = window.Event.prototype; window.CustomEvent = CustomEvent; })(); </script> <script class="js-entry"> if (window.config.mustardcut) { (function(w, d) { window.Component = {}; window.suppressShareButton = true; window.onArticlePage = true; var currentScript = d.currentScript || d.head.querySelector('script.js-entry'); function catchNoModuleSupport() { var scriptEl = d.createElement('script'); return (!('noModule' in scriptEl) && 'onbeforeload' in scriptEl) } var headScripts = [ {'src': '/static/js/polyfill-es5-bundle-572d4fec60.js', 'async': false} ]; var bodyScripts = [ {'src': '/static/js/app-es5-bundle-d0ac94c97e.js', 'async': false, 'module': false}, {'src': '/static/js/app-es6-bundle-5ee1a6879c.js', 'async': false, 'module': true} , {'src': '/static/js/global-article-es5-bundle-ae3b685a1c.js', 'async': false, 'module': false}, {'src': '/static/js/global-article-es6-bundle-f72e3cd2ca.js', 'async': false, 'module': true} ]; function createScript(script) { var scriptEl = d.createElement('script'); scriptEl.src = script.src; scriptEl.async = script.async; if (script.module === true) { scriptEl.type = "module"; if (catchNoModuleSupport()) { scriptEl.src = ''; } } else if (script.module === false) { scriptEl.setAttribute('nomodule', true) } if (script.charset) { scriptEl.setAttribute('charset', script.charset); } return scriptEl; } for (var i = 0; i < headScripts.length; ++i) { var scriptEl = createScript(headScripts[i]); currentScript.parentNode.insertBefore(scriptEl, currentScript.nextSibling); } d.addEventListener('DOMContentLoaded', function() { for (var i = 0; i < bodyScripts.length; ++i) { var scriptEl = createScript(bodyScripts[i]); d.body.appendChild(scriptEl); } }); // Webfont repeat view var config = w.config; if (config && config.publisherBrand && sessionStorage.fontsLoaded === 'true') { d.documentElement.className += ' webfonts-loaded'; } })(window, document); } </script> <script data-src="https://cdn.optimizely.com/js/27195530232.js" data-cc-script="C03"></script> <script data-test="gtm-head"> window.initGTM = function() { (function (w, d, s, l, i) { w[l] = w[l] || []; w[l].push({'gtm.start': new Date().getTime(), event: 'gtm.js'}); var f = d.getElementsByTagName(s)[0], j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src = 'https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f); })(window, document, 'script', 'dataLayer', 'GTM-MRVXSHQ'); } </script> <meta name="360-site-verification" content="2e1d87196f82c9ac5454a21aede69eda" /> <script> (function (w, d, t) { function cc() { var h = w.location.hostname; var e = d.createElement(t), s = d.getElementsByTagName(t)[0]; if (h.indexOf('springer.com') > -1 && h.indexOf('biomedcentral.com') === -1 && h.indexOf('springeropen.com') === -1) { if (h.indexOf('link-qa.springer.com') > -1 || h.indexOf('test-www.springer.com') > -1) { e.src = 'https://cmp.springer.com/production_live/en/consent-bundle-17-52.js'; e.setAttribute('onload', "initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')"); } else { e.src = 'https://cmp.springer.com/production_live/en/consent-bundle-17-52.js'; e.setAttribute('onload', "initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')"); } } else if (h.indexOf('biomedcentral.com') > -1) { if (h.indexOf('biomedcentral.com.qa') > -1) { e.src = 'https://cmp.biomedcentral.com/production_live/en/consent-bundle-15-36.js'; e.setAttribute('onload', "initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')"); } else { e.src = 'https://cmp.biomedcentral.com/production_live/en/consent-bundle-15-36.js'; e.setAttribute('onload', "initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')"); } } else if (h.indexOf('springeropen.com') > -1) { if (h.indexOf('springeropen.com.qa') > -1) { e.src = 'https://cmp.springernature.com/production_live/en/consent-bundle-16-34.js'; e.setAttribute('onload', "initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')"); } else { e.src = 'https://cmp.springernature.com/production_live/en/consent-bundle-16-34.js'; e.setAttribute('onload', "initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')"); } } else if (h.indexOf('springernature.com') > -1) { if (h.indexOf('beta-qa.springernature.com') > -1) { e.src = 'https://cmp.springernature.com/production_live/en/consent-bundle-49-43.js'; e.setAttribute('onload', "initGTM(window,document,'script','dataLayer','GTM-NK22KLS')"); } else { e.src = 'https://cmp.springernature.com/production_live/en/consent-bundle-49-43.js'; e.setAttribute('onload', "initGTM(window,document,'script','dataLayer','GTM-NK22KLS')"); } } else { e.src = '/static/js/cookie-consent-es5-bundle-cb57c2c98a.js'; e.setAttribute('data-consent', h); } s.insertAdjacentElement('afterend', e); } cc(); })(window, document, 'script'); </script> <link rel="canonical" href="https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-024-01405-5"/> <meta property="og:url" content="https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-024-01405-5"/> <meta property="og:type" content="article"/> <meta property="og:site_name" content="BioMed Central"/> <meta property="og:title" content="Efficacy and safety of novel multiple-chain DAP-CAR-T cells targeting mesothelin in ovarian cancer and mesothelioma: a single-arm, open-label and first-in-human study - Genome Medicine"/> <meta property="og:description" content="Background Despite remarkable achievements in applying chimeric antigen receptor (CAR)-T cells to treat hematological malignancies, they remain much less effective against solid tumors, facing several challenges affecting their clinical use. We previously showed that multichain DNAX-activating protein (DAP) CAR structures could enhance the safety and efficacy of CAR-T cells when used against solid tumors. In particular, mesothelin (MSLN)-targeted CAR-T cell therapy has therapeutic potential in MSLN-positive solid tumors, including ovarian cancer and mesothelioma. Methods In vitro cell killing assays and xenograft model were utilized to determine the anti-tumor efficacy of MSLN targeting DAP-CAR-T cells and other CAR-T cells. ELISA and flow cytometry analysis were used to assess the cytokine secretion capacity and proliferation ability. Eight patients with MSLN expression were enrolled to evaluate the safety and efficacy of MSLN-DAP CAR-T cell therapy. Single-cell sequencing was performed to explore the dynamics of immune cells in patients during treatment and to identify the transcriptomic signatures associated with efficacy and toxicity. Results We found that multichain DAP-CAR formed by combining a natural killer cell immunoglobulin-like receptor truncator and DAP12 exhibited better cytotoxicity and tumor-killing capacity than other natural killer cell-activated receptors associated with DAP12, DAP10, or CD3Z. The safety and efficacy of MSLN-DAP CAR-T cell therapy in patients with ovarian cancer and mesothelioma were evaluated in a single-arm, open-label clinical trial (ChiCTR2100046544); two patients achieved partial response, while four patients had a stable disease status. Furthermore, single-cell sequencing analysis indicated that KT032 CAR-T cell infusion could recruit more immune cells and temporarily remodel the TME. Conclusions Our study highlights the safety and therapeutic efficacy of multiple-chain DAP-CAR-T cell therapy targeting MSLN to treat patients with ovarian cancer and mesothelioma. Trial registration ChiCTR.org.cn, ChiCTR2100046544 . May 21, 2021."/> <meta property="og:image" content="https://static-content.springer.com/image/art%3A10.1186%2Fs13073-024-01405-5/MediaObjects/13073_2024_1405_Fig1_HTML.png"/> <script type="application/ld+json">{"mainEntity":{"headline":"Efficacy and safety of novel multiple-chain DAP-CAR-T cells targeting mesothelin in ovarian cancer and mesothelioma: a single-arm, open-label and first-in-human study","description":"Despite remarkable achievements in applying chimeric antigen receptor (CAR)-T cells to treat hematological malignancies, they remain much less effective against solid tumors, facing several challenges affecting their clinical use. We previously showed that multichain DNAX-activating protein (DAP) CAR structures could enhance the safety and efficacy of CAR-T cells when used against solid tumors. In particular, mesothelin (MSLN)-targeted CAR-T cell therapy has therapeutic potential in MSLN-positive solid tumors, including ovarian cancer and mesothelioma. In vitro cell killing assays and xenograft model were utilized to determine the anti-tumor efficacy of MSLN targeting DAP-CAR-T cells and other CAR-T cells. ELISA and flow cytometry analysis were used to assess the cytokine secretion capacity and proliferation ability. Eight patients with MSLN expression were enrolled to evaluate the safety and efficacy of MSLN-DAP CAR-T cell therapy. Single-cell sequencing was performed to explore the dynamics of immune cells in patients during treatment and to identify the transcriptomic signatures associated with efficacy and toxicity. We found that multichain DAP-CAR formed by combining a natural killer cell immunoglobulin-like receptor truncator and DAP12 exhibited better cytotoxicity and tumor-killing capacity than other natural killer cell-activated receptors associated with DAP12, DAP10, or CD3Z. The safety and efficacy of MSLN-DAP CAR-T cell therapy in patients with ovarian cancer and mesothelioma were evaluated in a single-arm, open-label clinical trial (ChiCTR2100046544); two patients achieved partial response, while four patients had a stable disease status. Furthermore, single-cell sequencing analysis indicated that KT032 CAR-T cell infusion could recruit more immune cells and temporarily remodel the TME. Our study highlights the safety and therapeutic efficacy of multiple-chain DAP-CAR-T cell therapy targeting MSLN to treat patients with ovarian cancer and mesothelioma. ChiCTR.org.cn, \n ChiCTR2100046544\n \n . May 21, 2021.","datePublished":"2024-11-15T00:00:00Z","dateModified":"2024-11-15T00:00:00Z","pageStart":"1","pageEnd":"17","license":"http://creativecommons.org/licenses/by-nc-nd/4.0/","sameAs":"https://doi.org/10.1186/s13073-024-01405-5","keywords":["MSLN","CAR-T cells","Ovarian cancer","Mesothelioma","Safety","Efficacy","Human Genetics","Metabolomics","Bioinformatics","Medicine/Public Health","general","Cancer Research","Systems Biology"],"image":["https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13073-024-01405-5/MediaObjects/13073_2024_1405_Fig1_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13073-024-01405-5/MediaObjects/13073_2024_1405_Fig2_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13073-024-01405-5/MediaObjects/13073_2024_1405_Fig3_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13073-024-01405-5/MediaObjects/13073_2024_1405_Fig4_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13073-024-01405-5/MediaObjects/13073_2024_1405_Fig5_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13073-024-01405-5/MediaObjects/13073_2024_1405_Fig6_HTML.png"],"isPartOf":{"name":"Genome Medicine","issn":["1756-994X"],"volumeNumber":"16","@type":["Periodical","PublicationVolume"]},"publisher":{"name":"BioMed Central","logo":{"url":"https://www.springernature.com/app-sn/public/images/logo-springernature.png","@type":"ImageObject"},"@type":"Organization"},"author":[{"name":"Tongpeng Xu","affiliation":[{"name":"The First Affiliated Hospital of Nanjing Medical University","address":{"name":"Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China","@type":"PostalAddress"},"@type":"Organization"}],"email":"tongpeng_xu_njmu@163.com","@type":"Person"},{"name":"Tian Tian","affiliation":[{"name":"The First Affiliated Hospital of Nanjing Medical University","address":{"name":"Department of Geriatric Hematology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Chen Wang","affiliation":[{"name":"Nanjing CART Medical Technology Co., Ltd","address":{"name":"Nanjing CART Medical Technology Co., Ltd, Nanjing, People’s Republic of China","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Xiaofeng Chen","affiliation":[{"name":"The First Affiliated Hospital of Nanjing Medical University","address":{"name":"Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Xiangrong Zuo","affiliation":[{"name":"The First Affiliated Hospital of Nanjing Medical University","address":{"name":"Department of Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Hanyu Zhou","affiliation":[{"name":"The First Affiliated Hospital of Nanjing Medical University","address":{"name":"Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China","@type":"PostalAddress"},"@type":"Organization"},{"name":"Suzhou Municipal Hospital, the Affiliated Suzhou Hospital of Nanjing Medical University","address":{"name":"Department of Oncology, Gusu School, Suzhou Municipal Hospital, the Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, People’s Republic of China","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Jianan Bai","affiliation":[{"name":"The First Affiliated Hospital of Nanjing Medical University","address":{"name":"Department of Geriatric Gastroenterology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Chenhui Zhao","affiliation":[{"name":"The First Affiliated Hospital of Nanjing Medical University","address":{"name":"Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Sujie Fu","affiliation":[{"name":"Nanjing University of Chinese Medicine","address":{"name":"The Second Affiliated Hospitalof\n, Nanjing University of Chinese Medicine, Nanjing, People’s Republic of China","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Chongqi Sun","affiliation":[{"name":"The First Affiliated Hospital of Nanjing Medical University","address":{"name":"Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Ting Wang","affiliation":[{"name":"The First Affiliated Hospital of Nanjing Medical University","address":{"name":"Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Ling Zhu","affiliation":[{"name":"Xishan People’s Hospital of Wuxi City","address":{"name":"Department of Oncology, Xishan People’s Hospital of Wuxi City, Wuxi, People’s Republic of China","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Jingzhi Zhang","affiliation":[{"name":"Nanjing CART Medical Technology Co., Ltd","address":{"name":"Nanjing CART Medical Technology Co., Ltd, Nanjing, People’s Republic of China","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Enxiu Wang","affiliation":[{"name":"Nanjing CART Medical Technology Co., Ltd","address":{"name":"Nanjing CART Medical Technology Co., Ltd, Nanjing, People’s Republic of China","@type":"PostalAddress"},"@type":"Organization"}],"email":"wangenxiu@cart-med.com","@type":"Person"},{"name":"Ming Sun","affiliation":[{"name":"Suzhou Municipal Hospital, The Affiliated Suzhou Hospital of Nanjing Medical University","address":{"name":"Suzhou Cancer Center Core Laboratory, Gusu School, Suzhou Municipal Hospital, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, People’s Republic of China","@type":"PostalAddress"},"@type":"Organization"}],"email":"sunming348@hotmail.com","@type":"Person"},{"name":"Yongqian Shu","affiliation":[{"name":"The First Affiliated Hospital of Nanjing Medical University","address":{"name":"Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China","@type":"PostalAddress"},"@type":"Organization"}],"email":"shuyongqian@csco.org.cn","@type":"Person"}],"isAccessibleForFree":true,"@type":"ScholarlyArticle"},"@context":"https://schema.org","@type":"WebPage"}</script> </head> <body class="journal journal-fulltext" > <div class="ctm"></div>  <noscript> <iframe src="https://www.googletagmanager.com/ns.html?id=GTM-MRVXSHQ" height="0" width="0" style="display:none;visibility:hidden"></iframe> </noscript>  <div class="u-visually-hidden" aria-hidden="true"> <?xml version="1.0" encoding="UTF-8"?><!DOCTYPE svg PUBLIC "-//W3C//DTD SVG 1.1//EN" "http://www.w3.org/Graphics/SVG/1.1/DTD/svg11.dtd"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><defs><path id="a" d="M0 .74h56.72v55.24H0z"/></defs><symbol id="icon-access" viewBox="0 0 18 18"><path d="m14 8c.5522847 0 1 .44771525 1 1v7h2.5c.2761424 0 .5.2238576.5.5v1.5h-18v-1.5c0-.2761424.22385763-.5.5-.5h2.5v-7c0-.55228475.44771525-1 1-1s1 .44771525 1 1v6.9996556h8v-6.9996556c0-.55228475.4477153-1 1-1zm-8 0 2 1v5l-2 1zm6 0v7l-2-1v-5zm-2.42653766-7.59857636 7.03554716 4.92488299c.4162533.29137735.5174853.86502537.226108 1.28127873-.1721584.24594054-.4534847.39241464-.7536934.39241464h-14.16284822c-.50810197 0-.92-.41189803-.92-.92 0-.30020869.1464741-.58153499.39241464-.75369337l7.03554714-4.92488299c.34432015-.2410241.80260453-.2410241 1.14692468 0zm-.57346234 2.03988748-3.65526982 2.55868888h7.31053962z" fill-rule="evenodd"/></symbol><symbol id="icon-account" viewBox="0 0 18 18"><path d="m10.2379028 16.9048051c1.3083556-.2032362 2.5118471-.7235183 3.5294683-1.4798399-.8731327-2.5141501-2.0638925-3.935978-3.7673711-4.3188248v-1.27684611c1.1651924-.41183641 2-1.52307546 2-2.82929429 0-1.65685425-1.3431458-3-3-3-1.65685425 0-3 1.34314575-3 3 0 1.30621883.83480763 2.41745788 2 2.82929429v1.27684611c-1.70347856.3828468-2.89423845 1.8046747-3.76737114 4.3188248 1.01762123.7563216 2.22111275 1.2766037 3.52946833 1.4798399.40563808.0629726.81921174.0951949 1.23790281.0951949s.83226473-.0322223 1.2379028-.0951949zm4.3421782-2.1721994c1.4927655-1.4532925 2.419919-3.484675 2.419919-5.7326057 0-4.418278-3.581722-8-8-8s-8 3.581722-8 8c0 2.2479307.92715352 4.2793132 2.41991895 5.7326057.75688473-2.0164459 1.83949951-3.6071894 3.48926591-4.3218837-1.14534283-.70360829-1.90918486-1.96796271-1.90918486-3.410722 0-2.209139 1.790861-4 4-4s4 1.790861 4 4c0 1.44275929-.763842 2.70711371-1.9091849 3.410722 1.6497664.7146943 2.7323812 2.3054378 3.4892659 4.3218837zm-5.580081 3.2673943c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"/></symbol><symbol id="icon-alert" viewBox="0 0 18 18"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill-rule="evenodd"/></symbol><symbol id="icon-arrow-broad" viewBox="0 0 16 16"><path d="m6.10307866 2.97190702v7.69043288l2.44965196-2.44676915c.38776071-.38730439 1.0088052-.39493524 1.38498697-.01919617.38609051.38563612.38643641 1.01053024-.00013864 1.39665039l-4.12239817 4.11754683c-.38616704.3857126-1.01187344.3861062-1.39846576-.0000311l-4.12258206-4.11773056c-.38618426-.38572979-.39254614-1.00476697-.01636437-1.38050605.38609047-.38563611 1.01018509-.38751562 1.4012233.00306241l2.44985644 2.4469734v-8.67638639c0-.54139983.43698413-.98042709.98493125-.98159081l7.89910522-.0043627c.5451687 0 .9871152.44142642.9871152.98595351s-.4419465.98595351-.9871152.98595351z" fill-rule="evenodd" transform="matrix(-1 0 0 -1 14 15)"/></symbol><symbol id="icon-arrow-down" viewBox="0 0 16 16"><path d="m3.28337502 11.5302405 4.03074001 4.176208c.37758093.3912076.98937525.3916069 1.367372-.0000316l4.03091977-4.1763942c.3775978-.3912252.3838182-1.0190815.0160006-1.4001736-.3775061-.39113013-.9877245-.39303641-1.3700683.003106l-2.39538585 2.4818345v-11.6147896l-.00649339-.11662112c-.055753-.49733869-.46370161-.88337888-.95867408-.88337888-.49497246 0-.90292107.38604019-.95867408.88337888l-.00649338.11662112v11.6147896l-2.39518594-2.4816273c-.37913917-.39282218-.98637524-.40056175-1.35419292-.0194697-.37750607.3911302-.37784433 1.0249269.00013556 1.4165479z" fill-rule="evenodd"/></symbol><symbol id="icon-arrow-left" viewBox="0 0 16 16"><path d="m4.46975946 3.28337502-4.17620792 4.03074001c-.39120768.37758093-.39160691.98937525.0000316 1.367372l4.1763942 4.03091977c.39122514.3775978 1.01908149.3838182 1.40017357.0160006.39113012-.3775061.3930364-.9877245-.00310603-1.3700683l-2.48183446-2.39538585h11.61478958l.1166211-.00649339c.4973387-.055753.8833789-.46370161.8833789-.95867408 0-.49497246-.3860402-.90292107-.8833789-.95867408l-.1166211-.00649338h-11.61478958l2.4816273-2.39518594c.39282216-.37913917.40056173-.98637524.01946965-1.35419292-.39113012-.37750607-1.02492687-.37784433-1.41654791.00013556z" fill-rule="evenodd"/></symbol><symbol id="icon-arrow-right" viewBox="0 0 16 16"><path d="m11.5302405 12.716625 4.176208-4.03074003c.3912076-.37758093.3916069-.98937525-.0000316-1.367372l-4.1763942-4.03091981c-.3912252-.37759778-1.0190815-.38381821-1.4001736-.01600053-.39113013.37750607-.39303641.98772445.003106 1.37006824l2.4818345 2.39538588h-11.6147896l-.11662112.00649339c-.49733869.055753-.88337888.46370161-.88337888.95867408 0 .49497246.38604019.90292107.88337888.95867408l.11662112.00649338h11.6147896l-2.4816273 2.39518592c-.39282218.3791392-.40056175.9863753-.0194697 1.3541929.3911302.3775061 1.0249269.3778444 1.4165479-.0001355z" fill-rule="evenodd"/></symbol><symbol id="icon-arrow-sub" viewBox="0 0 16 16"><path d="m7.89692134 4.97190702v7.69043288l-2.44965196-2.4467692c-.38776071-.38730434-1.0088052-.39493519-1.38498697-.0191961-.38609047.3856361-.38643643 1.0105302.00013864 1.3966504l4.12239817 4.1175468c.38616704.3857126 1.01187344.3861062 1.39846576-.0000311l4.12258202-4.1177306c.3861843-.3857298.3925462-1.0047669.0163644-1.380506-.3860905-.38563612-1.0101851-.38751563-1.4012233.0030624l-2.44985643 2.4469734v-8.67638639c0-.54139983-.43698413-.98042709-.98493125-.98159081l-7.89910525-.0043627c-.54516866 0-.98711517.44142642-.98711517.98595351s.44194651.98595351.98711517.98595351z" fill-rule="evenodd"/></symbol><symbol id="icon-arrow-up" viewBox="0 0 16 16"><path d="m12.716625 4.46975946-4.03074003-4.17620792c-.37758093-.39120768-.98937525-.39160691-1.367372.0000316l-4.03091981 4.1763942c-.37759778.39122514-.38381821 1.01908149-.01600053 1.40017357.37750607.39113012.98772445.3930364 1.37006824-.00310603l2.39538588-2.48183446v11.61478958l.00649339.1166211c.055753.4973387.46370161.8833789.95867408.8833789.49497246 0 .90292107-.3860402.95867408-.8833789l.00649338-.1166211v-11.61478958l2.39518592 2.4816273c.3791392.39282216.9863753.40056173 1.3541929.01946965.3775061-.39113012.3778444-1.02492687-.0001355-1.41654791z" fill-rule="evenodd"/></symbol><symbol id="icon-article" viewBox="0 0 18 18"><path d="m13 15v-12.9906311c0-.0073595-.0019884-.0093689.0014977-.0093689l-11.00158888.00087166v13.00506804c0 .5482678.44615281.9940603.99415146.9940603h10.27350412c-.1701701-.2941734-.2675644-.6357129-.2675644-1zm-12 .0059397v-13.00506804c0-.5562408.44704472-1.00087166.99850233-1.00087166h11.00299537c.5510129 0 .9985023.45190985.9985023 1.0093689v2.9906311h3v9.9914698c0 1.1065798-.8927712 2.0085302-1.9940603 2.0085302h-12.01187942c-1.09954652 0-1.99406028-.8927712-1.99406028-1.9940603zm13-9.0059397v9c0 .5522847.4477153 1 1 1s1-.4477153 1-1v-9zm-10-2h7v4h-7zm1 1v2h5v-2zm-1 4h7v1h-7zm0 2h7v1h-7zm0 2h7v1h-7z" fill-rule="evenodd"/></symbol><symbol id="icon-audio" viewBox="0 0 18 18"><path d="m13.0957477 13.5588459c-.195279.1937043-.5119137.193729-.7072234.0000551-.1953098-.193674-.1953346-.5077061-.0000556-.7014104 1.0251004-1.0168342 1.6108711-2.3905226 1.6108711-3.85745208 0-1.46604976-.5850634-2.83898246-1.6090736-3.85566829-.1951894-.19379323-.1950192-.50782531.0003802-.70141028.1953993-.19358497.512034-.19341614.7072234.00037709 1.2094886 1.20083761 1.901635 2.8250555 1.901635 4.55670148 0 1.73268608-.6929822 3.35779608-1.9037571 4.55880738zm2.1233994 2.1025159c-.195234.193749-.5118687.1938462-.7072235.0002171-.1953548-.1936292-.1954528-.5076613-.0002189-.7014104 1.5832215-1.5711805 2.4881302-3.6939808 2.4881302-5.96012998 0-2.26581266-.9046382-4.3883241-2.487443-5.95944795-.1952117-.19377107-.1950777-.50780316.0002993-.70141031s.5120117-.19347426.7072234.00029682c1.7683321 1.75528196 2.7800854 4.12911258 2.7800854 6.66056144 0 2.53182498-1.0120556 4.90597838-2.7808529 6.66132328zm-14.21898205-3.6854911c-.5523759 0-1.00016505-.4441085-1.00016505-.991944v-3.96777631c0-.54783558.44778915-.99194407 1.00016505-.99194407h2.0003301l5.41965617-3.8393633c.44948677-.31842296 1.07413994-.21516983 1.39520191.23062232.12116339.16823446.18629727.36981184.18629727.57655577v12.01603479c0 .5478356-.44778914.9919441-1.00016505.9919441-.20845738 0-.41170538-.0645985-.58133413-.184766l-5.41965617-3.8393633zm0-.991944h2.32084805l5.68047235 4.0241292v-12.01603479l-5.68047235 4.02412928h-2.32084805z" fill-rule="evenodd"/></symbol><symbol id="icon-block" viewBox="0 0 24 24"><path d="m0 0h24v24h-24z" fill-rule="evenodd"/></symbol><symbol id="icon-book" viewBox="0 0 18 18"><path d="m4 13v-11h1v11h11v-11h-13c-.55228475 0-1 .44771525-1 1v10.2675644c.29417337-.1701701.63571286-.2675644 1-.2675644zm12 1h-13c-.55228475 0-1 .4477153-1 1s.44771525 1 1 1h13zm0 3h-13c-1.1045695 0-2-.8954305-2-2v-12c0-1.1045695.8954305-2 2-2h13c.5522847 0 1 .44771525 1 1v14c0 .5522847-.4477153 1-1 1zm-8.5-13h6c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm1 2h4c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-4c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"/></symbol><symbol id="icon-broad" viewBox="0 0 24 24"><path d="m9.18274226 7.81v7.7999954l2.48162734-2.4816273c.3928221-.3928221 1.0219731-.4005617 1.4030652-.0194696.3911301.3911301.3914806 1.0249268-.0001404 1.4165479l-4.17620796 4.1762079c-.39120769.3912077-1.02508144.3916069-1.41671995-.0000316l-4.1763942-4.1763942c-.39122514-.3912251-.39767006-1.0190815-.01657798-1.4001736.39113012-.3911301 1.02337106-.3930364 1.41951349.0031061l2.48183446 2.4818344v-8.7999954c0-.54911294.4426881-.99439484.99778758-.99557515l8.00221246-.00442485c.5522847 0 1 .44771525 1 1s-.4477153 1-1 1z" fill-rule="evenodd" transform="matrix(-1 0 0 -1 20.182742 24.805206)"/></symbol><symbol id="icon-calendar" viewBox="0 0 18 18"><path d="m12.5 0c.2761424 0 .5.21505737.5.49047852v.50952148h2c1.1072288 0 2 .89451376 2 2v12c0 1.1072288-.8945138 2-2 2h-12c-1.1072288 0-2-.8945138-2-2v-12c0-1.1072288.89451376-2 2-2h1v1h-1c-.55393837 0-1 .44579254-1 1v3h14v-3c0-.55393837-.4457925-1-1-1h-2v1.50952148c0 .27088381-.2319336.49047852-.5.49047852-.2761424 0-.5-.21505737-.5-.49047852v-3.01904296c0-.27088381.2319336-.49047852.5-.49047852zm3.5 7h-14v8c0 .5539384.44579254 1 1 1h12c.5539384 0 1-.4457925 1-1zm-11 6v1h-1v-1zm3 0v1h-1v-1zm3 0v1h-1v-1zm-6-2v1h-1v-1zm3 0v1h-1v-1zm6 0v1h-1v-1zm-3 0v1h-1v-1zm-3-2v1h-1v-1zm6 0v1h-1v-1zm-3 0v1h-1v-1zm-5.5-9c.27614237 0 .5.21505737.5.49047852v.50952148h5v1h-5v1.50952148c0 .27088381-.23193359.49047852-.5.49047852-.27614237 0-.5-.21505737-.5-.49047852v-3.01904296c0-.27088381.23193359-.49047852.5-.49047852z" fill-rule="evenodd"/></symbol><symbol id="icon-cart" viewBox="0 0 18 18"><path d="m5 14c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm10 0c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm-10 1c-.55228475 0-1 .4477153-1 1s.44771525 1 1 1 1-.4477153 1-1-.44771525-1-1-1zm10 0c-.5522847 0-1 .4477153-1 1s.4477153 1 1 1 1-.4477153 1-1-.4477153-1-1-1zm-12.82032249-15c.47691417 0 .88746157.33678127.98070211.80449199l.23823144 1.19501025 13.36277974.00045554c.5522847.00001882.9999659.44774934.9999659 1.00004222 0 .07084994-.0075361.14150708-.022474.2107727l-1.2908094 5.98534344c-.1007861.46742419-.5432548.80388386-1.0571651.80388386h-10.24805106c-.59173366 0-1.07142857.4477153-1.07142857 1 0 .5128358.41361449.9355072.94647737.9932723l.1249512.0067277h10.35933776c.2749512 0 .4979349.2228539.4979349.4978051 0 .2749417-.2227336.4978951-.4976753.4980063l-10.35959736.0041886c-1.18346732 0-2.14285714-.8954305-2.14285714-2 0-.6625717.34520317-1.24989198.87690425-1.61383592l-1.63768102-8.19004794c-.01312273-.06561364-.01950005-.131011-.0196107-.19547395l-1.71961253-.00064219c-.27614237 0-.5-.22385762-.5-.5 0-.27614237.22385763-.5.5-.5zm14.53193359 2.99950224h-13.11300004l1.20580469 6.02530174c.11024034-.0163252.22327998-.02480398.33844139-.02480398h10.27064786z"/></symbol><symbol id="icon-chevron-less" viewBox="0 0 10 10"><path d="m5.58578644 4-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" fill-rule="evenodd" transform="matrix(0 -1 -1 0 9 9)"/></symbol><symbol id="icon-chevron-more" viewBox="0 0 10 10"><path d="m5.58578644 6-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4.00000002c-.39052429.3905243-1.02368927.3905243-1.41421356 0s-.39052429-1.02368929 0-1.41421358z" fill-rule="evenodd" transform="matrix(0 1 -1 0 11 1)"/></symbol><symbol id="icon-chevron-right" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"/></symbol><symbol id="icon-circle-fill" viewBox="0 0 16 16"><path d="m8 14c-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6 6 2.6862915 6 6-2.6862915 6-6 6z" fill-rule="evenodd"/></symbol><symbol id="icon-circle" viewBox="0 0 16 16"><path d="m8 12c2.209139 0 4-1.790861 4-4s-1.790861-4-4-4-4 1.790861-4 4 1.790861 4 4 4zm0 2c-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6 6 2.6862915 6 6-2.6862915 6-6 6z" fill-rule="evenodd"/></symbol><symbol id="icon-citation" viewBox="0 0 18 18"><path d="m8.63593473 5.99995183c2.20913897 0 3.99999997 1.79084375 3.99999997 3.99996146 0 1.40730761-.7267788 2.64486871-1.8254829 3.35783281 1.6240224.6764218 2.8754442 2.0093871 3.4610603 3.6412466l-1.0763845.000006c-.5310008-1.2078237-1.5108121-2.1940153-2.7691712-2.7181346l-.79002167-.329052v-1.023992l.63016577-.4089232c.8482885-.5504661 1.3698342-1.4895187 1.3698342-2.51898361 0-1.65683828-1.3431457-2.99996146-2.99999997-2.99996146-1.65685425 0-3 1.34312318-3 2.99996146 0 1.02946491.52154569 1.96851751 1.36983419 2.51898361l.63016581.4089232v1.023992l-.79002171.329052c-1.25835905.5241193-2.23817037 1.5103109-2.76917113 2.7181346l-1.07638453-.000006c.58561612-1.6318595 1.8370379-2.9648248 3.46106024-3.6412466-1.09870405-.7129641-1.82548287-1.9505252-1.82548287-3.35783281 0-2.20911771 1.790861-3.99996146 4-3.99996146zm7.36897597-4.99995183c1.1018574 0 1.9950893.89353404 1.9950893 2.00274083v5.994422c0 1.10608317-.8926228 2.00274087-1.9950893 2.00274087l-3.0049107-.0009037v-1l3.0049107.00091329c.5490631 0 .9950893-.44783123.9950893-1.00275046v-5.994422c0-.55646537-.4450595-1.00275046-.9950893-1.00275046h-14.00982141c-.54906309 0-.99508929.44783123-.99508929 1.00275046v5.9971821c0 .66666024.33333333.99999036 1 .99999036l2-.00091329v1l-2 .0009037c-1 0-2-.99999041-2-1.99998077v-5.9971821c0-1.10608322.8926228-2.00274083 1.99508929-2.00274083zm-8.5049107 2.9999711c.27614237 0 .5.22385547.5.5 0 .2761349-.22385763.5-.5.5h-4c-.27614237 0-.5-.2238651-.5-.5 0-.27614453.22385763-.5.5-.5zm3 0c.2761424 0 .5.22385547.5.5 0 .2761349-.2238576.5-.5.5h-1c-.27614237 0-.5-.2238651-.5-.5 0-.27614453.22385763-.5.5-.5zm4 0c.2761424 0 .5.22385547.5.5 0 .2761349-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238651-.5-.5 0-.27614453.2238576-.5.5-.5z" fill-rule="evenodd"/></symbol><symbol id="icon-close" viewBox="0 0 16 16"><path d="m2.29679575 12.2772478c-.39658757.3965876-.39438847 1.0328109-.00062148 1.4265779.39651227.3965123 1.03246768.3934888 1.42657791-.0006214l4.27724782-4.27724787 4.2772478 4.27724787c.3965876.3965875 1.0328109.3943884 1.4265779.0006214.3965123-.3965122.3934888-1.0324677-.0006214-1.4265779l-4.27724787-4.2772478 4.27724787-4.27724782c.3965875-.39658757.3943884-1.03281091.0006214-1.42657791-.3965122-.39651226-1.0324677-.39348875-1.4265779.00062148l-4.2772478 4.27724782-4.27724782-4.27724782c-.39658757-.39658757-1.03281091-.39438847-1.42657791-.00062148-.39651226.39651227-.39348875 1.03246768.00062148 1.42657791l4.27724782 4.27724782z" fill-rule="evenodd"/></symbol><symbol id="icon-collections" viewBox="0 0 18 18"><path d="m15 4c1.1045695 0 2 .8954305 2 2v9c0 1.1045695-.8954305 2-2 2h-8c-1.1045695 0-2-.8954305-2-2h1c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h8c.5128358 0 .9355072-.3860402.9932723-.8833789l.0067277-.1166211v-9c0-.51283584-.3860402-.93550716-.8833789-.99327227l-.1166211-.00672773h-1v-1zm-4-3c1.1045695 0 2 .8954305 2 2v9c0 1.1045695-.8954305 2-2 2h-8c-1.1045695 0-2-.8954305-2-2v-9c0-1.1045695.8954305-2 2-2zm0 1h-8c-.51283584 0-.93550716.38604019-.99327227.88337887l-.00672773.11662113v9c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h8c.5128358 0 .9355072-.3860402.9932723-.8833789l.0067277-.1166211v-9c0-.51283584-.3860402-.93550716-.8833789-.99327227zm-1.5 7c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm0-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm0-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"/></symbol><symbol id="icon-compare" viewBox="0 0 18 18"><path d="m12 3c3.3137085 0 6 2.6862915 6 6s-2.6862915 6-6 6c-1.0928452 0-2.11744941-.2921742-2.99996061-.8026704-.88181407.5102749-1.90678042.8026704-3.00003939.8026704-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6c1.09325897 0 2.11822532.29239547 3.00096303.80325037.88158756-.51107621 1.90619177-.80325037 2.99903697-.80325037zm-6 1c-2.76142375 0-5 2.23857625-5 5 0 2.7614237 2.23857625 5 5 5 .74397391 0 1.44999672-.162488 2.08451611-.4539116-1.27652344-1.1000812-2.08451611-2.7287264-2.08451611-4.5460884s.80799267-3.44600721 2.08434391-4.5463015c-.63434719-.29121054-1.34037-.4536985-2.08434391-.4536985zm6 0c-.7439739 0-1.4499967.16248796-2.08451611.45391156 1.27652341 1.10008123 2.08451611 2.72872644 2.08451611 4.54608844s-.8079927 3.4460072-2.08434391 4.5463015c.63434721.2912105 1.34037001.4536985 2.08434391.4536985 2.7614237 0 5-2.2385763 5-5 0-2.76142375-2.2385763-5-5-5zm-1.4162763 7.0005324h-3.16744736c.15614659.3572676.35283837.6927622.58425872 1.0006671h1.99892988c.23142036-.3079049.42811216-.6433995.58425876-1.0006671zm.4162763-2.0005324h-4c0 .34288501.0345146.67770871.10025909 1.0011864h3.79948181c.0657445-.32347769.1002591-.65830139.1002591-1.0011864zm-.4158423-1.99953894h-3.16831543c-.13859957.31730812-.24521946.651783-.31578599.99935097h3.79988742c-.0705665-.34756797-.1771864-.68204285-.315786-.99935097zm-1.58295822-1.999926-.08316107.06199199c-.34550042.27081213-.65446126.58611297-.91825862.93727862h2.00044041c-.28418626-.37830727-.6207872-.71499149-.99902072-.99927061z" fill-rule="evenodd"/></symbol><symbol id="icon-download-file" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm0 1h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v14.00982141c0 .5500396.44491393.9950893.99406028.9950893h12.01187942c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717zm-1.5046024 4c.27614237 0 .5.21637201.5.49209595v6.14827645l1.7462789-1.77990922c.1933927-.1971171.5125222-.19455839.7001689-.0069117.1932998.19329992.1910058.50899492-.0027774.70277812l-2.59089271 2.5908927c-.19483374.1948337-.51177825.1937771-.70556873-.0000133l-2.59099079-2.5909908c-.19484111-.1948411-.19043735-.5151448-.00279066-.70279146.19329987-.19329987.50465175-.19237083.70018565.00692852l1.74638684 1.78001764v-6.14827695c0-.27177709.23193359-.49209595.5-.49209595z" fill-rule="evenodd"/></symbol><symbol id="icon-download" viewBox="0 0 16 16"><path d="m12.9975267 12.999368c.5467123 0 1.0024733.4478567 1.0024733 1.000316 0 .5563109-.4488226 1.000316-1.0024733 1.000316h-9.99505341c-.54671233 0-1.00247329-.4478567-1.00247329-1.000316 0-.5563109.44882258-1.000316 1.00247329-1.000316zm-4.9975267-11.999368c.55228475 0 1 .44497754 1 .99589209v6.80214418l2.4816273-2.48241149c.3928222-.39294628 1.0219732-.4006883 1.4030652-.01947579.3911302.39125371.3914806 1.02525073-.0001404 1.41699553l-4.17620792 4.17752758c-.39120769.3913313-1.02508144.3917306-1.41671995-.0000316l-4.17639421-4.17771394c-.39122513-.39134876-.39767006-1.01940351-.01657797-1.40061601.39113012-.39125372 1.02337105-.3931606 1.41951349.00310701l2.48183446 2.48261871v-6.80214418c0-.55001601.44386482-.99589209 1-.99589209z" fill-rule="evenodd"/></symbol><symbol id="icon-editors" viewBox="0 0 18 18"><path d="m8.72592184 2.54588137c-.48811714-.34391207-1.08343326-.54588137-1.72592184-.54588137-1.65685425 0-3 1.34314575-3 3 0 1.02947485.5215457 1.96853646 1.3698342 2.51900785l.6301658.40892721v1.02400182l-.79002171.32905522c-1.93395773.8055207-3.20997829 2.7024791-3.20997829 4.8180274v.9009805h-1v-.9009805c0-2.5479714 1.54557359-4.79153984 3.82548288-5.7411543-1.09870406-.71297106-1.82548288-1.95054399-1.82548288-3.3578652 0-2.209139 1.790861-4 4-4 1.09079823 0 2.07961816.43662103 2.80122451 1.1446278-.37707584.09278571-.7373238.22835063-1.07530267.40125357zm-2.72592184 14.45411863h-1v-.9009805c0-2.5479714 1.54557359-4.7915398 3.82548288-5.7411543-1.09870406-.71297106-1.82548288-1.95054399-1.82548288-3.3578652 0-2.209139 1.790861-4 4-4s4 1.790861 4 4c0 1.40732121-.7267788 2.64489414-1.8254829 3.3578652 2.2799093.9496145 3.8254829 3.1931829 3.8254829 5.7411543v.9009805h-1v-.9009805c0-2.1155483-1.2760206-4.0125067-3.2099783-4.8180274l-.7900217-.3290552v-1.02400184l.6301658-.40892721c.8482885-.55047139 1.3698342-1.489533 1.3698342-2.51900785 0-1.65685425-1.3431458-3-3-3-1.65685425 0-3 1.34314575-3 3 0 1.02947485.5215457 1.96853646 1.3698342 2.51900785l.6301658.40892721v1.02400184l-.79002171.3290552c-1.93395773.8055207-3.20997829 2.7024791-3.20997829 4.8180274z" fill-rule="evenodd"/></symbol><symbol id="icon-email" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587h-14.00982141c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm0 1h-14.00982141c-.54871518 0-.99508929.44887827-.99508929 1.00585866v9.98828264c0 .5572961.44630695 1.0058587.99508929 1.0058587h14.00982141c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-.0049107 2.55749512v1.44250488l-7 4-7-4v-1.44250488l7 4z" fill-rule="evenodd"/></symbol><symbol id="icon-error" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm2.8630343 4.71100931-2.8630343 2.86303426-2.86303426-2.86303426c-.39658757-.39658757-1.03281091-.39438847-1.4265779-.00062147-.39651227.39651226-.39348876 1.03246767.00062147 1.4265779l2.86303426 2.86303426-2.86303426 2.8630343c-.39658757.3965875-.39438847 1.0328109-.00062147 1.4265779.39651226.3965122 1.03246767.3934887 1.4265779-.0006215l2.86303426-2.8630343 2.8630343 2.8630343c.3965875.3965876 1.0328109.3943885 1.4265779.0006215.3965122-.3965123.3934887-1.0324677-.0006215-1.4265779l-2.8630343-2.8630343 2.8630343-2.86303426c.3965876-.39658757.3943885-1.03281091.0006215-1.4265779-.3965123-.39651227-1.0324677-.39348876-1.4265779.00062147z" fill-rule="evenodd"/></symbol><symbol id="icon-ethics" viewBox="0 0 18 18"><path d="m6.76384967 1.41421356.83301651-.8330165c.77492941-.77492941 2.03133823-.77492941 2.80626762 0l.8330165.8330165c.3750728.37507276.8837806.58578644 1.4142136.58578644h1.3496361c1.1045695 0 2 .8954305 2 2v1.34963611c0 .53043298.2107137 1.03914081.5857864 1.41421356l.8330165.83301651c.7749295.77492941.7749295 2.03133823 0 2.80626762l-.8330165.8330165c-.3750727.3750728-.5857864.8837806-.5857864 1.4142136v1.3496361c0 1.1045695-.8954305 2-2 2h-1.3496361c-.530433 0-1.0391408.2107137-1.4142136.5857864l-.8330165.8330165c-.77492939.7749295-2.03133821.7749295-2.80626762 0l-.83301651-.8330165c-.37507275-.3750727-.88378058-.5857864-1.41421356-.5857864h-1.34963611c-1.1045695 0-2-.8954305-2-2v-1.3496361c0-.530433-.21071368-1.0391408-.58578644-1.4142136l-.8330165-.8330165c-.77492941-.77492939-.77492941-2.03133821 0-2.80626762l.8330165-.83301651c.37507276-.37507275.58578644-.88378058.58578644-1.41421356v-1.34963611c0-1.1045695.8954305-2 2-2h1.34963611c.53043298 0 1.03914081-.21071368 1.41421356-.58578644zm-1.41421356 1.58578644h-1.34963611c-.55228475 0-1 .44771525-1 1v1.34963611c0 .79564947-.31607052 1.55871121-.87867966 2.12132034l-.8330165.83301651c-.38440512.38440512-.38440512 1.00764896 0 1.39205408l.8330165.83301646c.56260914.5626092.87867966 1.3256709.87867966 2.1213204v1.3496361c0 .5522847.44771525 1 1 1h1.34963611c.79564947 0 1.55871121.3160705 2.12132034.8786797l.83301651.8330165c.38440512.3844051 1.00764896.3844051 1.39205408 0l.83301646-.8330165c.5626092-.5626092 1.3256709-.8786797 2.1213204-.8786797h1.3496361c.5522847 0 1-.4477153 1-1v-1.3496361c0-.7956495.3160705-1.5587112.8786797-2.1213204l.8330165-.83301646c.3844051-.38440512.3844051-1.00764896 0-1.39205408l-.8330165-.83301651c-.5626092-.56260913-.8786797-1.32567087-.8786797-2.12132034v-1.34963611c0-.55228475-.4477153-1-1-1h-1.3496361c-.7956495 0-1.5587112-.31607052-2.1213204-.87867966l-.83301646-.8330165c-.38440512-.38440512-1.00764896-.38440512-1.39205408 0l-.83301651.8330165c-.56260913.56260914-1.32567087.87867966-2.12132034.87867966zm3.58698944 11.4960218c-.02081224.002155-.04199226.0030286-.06345763.002542-.98766446-.0223875-1.93408568-.3063547-2.75885125-.8155622-.23496767-.1450683-.30784554-.4531483-.16277726-.688116.14506827-.2349677.45314827-.3078455.68811595-.1627773.67447084.4164161 1.44758575.6483839 2.25617384.6667123.01759529.0003988.03495764.0017019.05204365.0038639.01713363-.0017748.03452416-.0026845.05212715-.0026845 2.4852814 0 4.5-2.0147186 4.5-4.5 0-1.04888973-.3593547-2.04134635-1.0074477-2.83787157-.1742817-.21419731-.1419238-.5291218.0722736-.70340353.2141973-.17428173.5291218-.14192375.7034035.07227357.7919032.97327203 1.2317706 2.18808682 1.2317706 3.46900153 0 3.0375661-2.4624339 5.5-5.5 5.5-.02146768 0-.04261937-.0013529-.06337445-.0039782zm1.57975095-10.78419583c.2654788.07599731.419084.35281842.3430867.61829728-.0759973.26547885-.3528185.419084-.6182973.3430867-.37560116-.10752146-.76586237-.16587951-1.15568824-.17249193-2.5587807-.00064534-4.58547766 2.00216524-4.58547766 4.49928198 0 .62691557.12797645 1.23496.37274865 1.7964426.11035133.2531347-.0053975.5477984-.25853224.6581497-.25313473.1103514-.54779841-.0053975-.65814974-.2585322-.29947131-.6869568-.45606667-1.43097603-.45606667-2.1960601 0-3.05211432 2.47714695-5.50006595 5.59399617-5.49921198.48576182.00815502.96289603.0795037 1.42238033.21103795zm-1.9766658 6.41091303 2.69835-2.94655317c.1788432-.21040373.4943901-.23598862.7047939-.05714545.2104037.17884318.2359886.49439014.0571454.70479387l-3.01637681 3.34277395c-.18039088.1999106-.48669547.2210637-.69285412.0478478l-1.93095347-1.62240047c-.21213845-.17678204-.24080048-.49206439-.06401844-.70420284.17678204-.21213844.49206439-.24080048.70420284-.06401844z" fill-rule="evenodd"/></symbol><symbol id="icon-expand"><path d="M7.498 11.918a.997.997 0 0 0-.003-1.411.995.995 0 0 0-1.412-.003l-4.102 4.102v-3.51A1 1 0 0 0 .98 10.09.992.992 0 0 0 0 11.092V17c0 .554.448 1.002 1.002 1.002h5.907c.554 0 1.002-.45 1.002-1.003 0-.539-.45-.978-1.006-.978h-3.51zm3.005-5.835a.997.997 0 0 0 .003 1.412.995.995 0 0 0 1.411.003l4.103-4.103v3.51a1 1 0 0 0 1.001 1.006A.992.992 0 0 0 18 6.91V1.002A1 1 0 0 0 17 0h-5.907a1.003 1.003 0 0 0-1.002 1.003c0 .539.45.978 1.006.978h3.51z" fill-rule="evenodd"/></symbol><symbol id="icon-explore" viewBox="0 0 18 18"><path d="m9 17c4.418278 0 8-3.581722 8-8s-3.581722-8-8-8-8 3.581722-8 8 3.581722 8 8 8zm0 1c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9zm0-2.5c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5c2.969509 0 5.400504-2.3575119 5.497023-5.31714844.0090007-.27599565.2400359-.49243782.5160315-.48343711.2759957.0090007.4924378.2400359.4834371.51603155-.114093 3.4985237-2.9869632 6.284554-6.4964916 6.284554zm-.29090657-12.99359748c.27587424-.01216621.50937715.20161139.52154336.47748563.01216621.27587423-.20161139.50937715-.47748563.52154336-2.93195733.12930094-5.25315116 2.54886451-5.25315116 5.49456849 0 .27614237-.22385763.5-.5.5s-.5-.22385763-.5-.5c0-3.48142406 2.74307146-6.34074398 6.20909343-6.49359748zm1.13784138 8.04763908-1.2004882-1.20048821c-.19526215-.19526215-.19526215-.51184463 0-.70710678s.51184463-.19526215.70710678 0l1.20048821 1.2004882 1.6006509-4.00162734-4.50670359 1.80268144-1.80268144 4.50670359zm4.10281269-6.50378907-2.6692597 6.67314927c-.1016411.2541026-.3029834.4554449-.557086.557086l-6.67314927 2.6692597 2.66925969-6.67314926c.10164107-.25410266.30298336-.45544495.55708602-.55708602z" fill-rule="evenodd"/></symbol><symbol id="icon-filter" viewBox="0 0 16 16"><path d="m14.9738641 0c.5667192 0 1.0261359.4477136 1.0261359 1 0 .24221858-.0902161.47620768-.2538899.65849851l-5.6938314 6.34147206v5.49997973c0 .3147562-.1520673.6111434-.4104543.7999971l-2.05227171 1.4999945c-.45337535.3313696-1.09655869.2418269-1.4365902-.1999993-.13321514-.1730955-.20522717-.3836284-.20522717-.5999978v-6.99997423l-5.69383133-6.34147206c-.3731872-.41563511-.32996891-1.0473954.09653074-1.41107611.18705584-.15950448.42716133-.2474224.67571519-.2474224zm-5.9218641 8.5h-2.105v6.491l.01238459.0070843.02053271.0015705.01955278-.0070558 2.0532976-1.4990996zm-8.02585008-7.5-.01564945.00240169 5.83249953 6.49759831h2.313l5.836-6.499z"/></symbol><symbol id="icon-home" viewBox="0 0 18 18"><path d="m9 5-6 6v5h4v-4h4v4h4v-5zm7 6.5857864v4.4142136c0 .5522847-.4477153 1-1 1h-5v-4h-2v4h-5c-.55228475 0-1-.4477153-1-1v-4.4142136c-.25592232 0-.51184464-.097631-.70710678-.2928932l-.58578644-.5857864c-.39052429-.3905243-.39052429-1.02368929 0-1.41421358l8.29289322-8.29289322 8.2928932 8.29289322c.3905243.39052429.3905243 1.02368928 0 1.41421358l-.5857864.5857864c-.1952622.1952622-.4511845.2928932-.7071068.2928932zm-7-9.17157284-7.58578644 7.58578644.58578644.5857864 7-6.99999996 7 6.99999996.5857864-.5857864z" fill-rule="evenodd"/></symbol><symbol id="icon-image" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm-3.49645283 10.1752453-3.89407257 6.7495552c.11705545.048464.24538859.0751995.37998328.0751995h10.60290092l-2.4329715-4.2154691-1.57494129 2.7288098zm8.49779013 6.8247547c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v13.98991071l4.50814957-7.81026689 3.08089884 5.33809539 1.57494129-2.7288097 3.5875735 6.2159812zm-3.0059397-11c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm0 1c-.5522847 0-1 .44771525-1 1s.4477153 1 1 1 1-.44771525 1-1-.4477153-1-1-1z" fill-rule="evenodd"/></symbol><symbol id="icon-info" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm0 7h-1.5l-.11662113.00672773c-.49733868.05776511-.88337887.48043643-.88337887.99327227 0 .47338693.32893365.86994729.77070917.97358929l.1126697.01968298.11662113.00672773h.5v3h-.5l-.11662113.0067277c-.42082504.0488782-.76196299.3590206-.85696816.7639815l-.01968298.1126697-.00672773.1166211.00672773.1166211c.04887817.4208251.35902055.761963.76398144.8569682l.1126697.019683.11662113.0067277h3l.1166211-.0067277c.4973387-.0577651.8833789-.4804365.8833789-.9932723 0-.4733869-.3289337-.8699473-.7707092-.9735893l-.1126697-.019683-.1166211-.0067277h-.5v-4l-.00672773-.11662113c-.04887817-.42082504-.35902055-.76196299-.76398144-.85696816l-.1126697-.01968298zm0-3.25c-.69035594 0-1.25.55964406-1.25 1.25s.55964406 1.25 1.25 1.25 1.25-.55964406 1.25-1.25-.55964406-1.25-1.25-1.25z" fill-rule="evenodd"/></symbol><symbol id="icon-institution" viewBox="0 0 18 18"><path d="m7 16.9998189v-2.0003623h4v2.0003623h2v-3.0005434h-8v3.0005434zm-3-10.00181122h-1.52632364c-.27614237 0-.5-.22389817-.5-.50009056 0-.13995446.05863589-.27350497.16166338-.36820841l1.23156713-1.13206327h-2.36690687v12.00217346h3v-2.0003623h-3v-1.0001811h3v-1.0001811h1v-4.00072448h-1zm10 0v2.00036224h-1v4.00072448h1v1.0001811h3v1.0001811h-3v2.0003623h3v-12.00217346h-2.3695309l1.2315671 1.13206327c.2033191.186892.2166633.50325042.0298051.70660631-.0946863.10304615-.2282126.16169266-.3681417.16169266zm3-3.00054336c.5522847 0 1 .44779634 1 1.00018112v13.00235456h-18v-13.00235456c0-.55238478.44771525-1.00018112 1-1.00018112h3.45499992l4.20535144-3.86558216c.19129876-.17584288.48537447-.17584288.67667324 0l4.2053514 3.86558216zm-4 3.00054336h-8v1.00018112h8zm-2 6.00108672h1v-4.00072448h-1zm-1 0v-4.00072448h-2v4.00072448zm-3 0v-4.00072448h-1v4.00072448zm8-4.00072448c.5522847 0 1 .44779634 1 1.00018112v2.00036226h-2v-2.00036226c0-.55238478.4477153-1.00018112 1-1.00018112zm-12 0c.55228475 0 1 .44779634 1 1.00018112v2.00036226h-2v-2.00036226c0-.55238478.44771525-1.00018112 1-1.00018112zm5.99868798-7.81907007-5.24205601 4.81852671h10.48411203zm.00131202 3.81834559c-.55228475 0-1-.44779634-1-1.00018112s.44771525-1.00018112 1-1.00018112 1 .44779634 1 1.00018112-.44771525 1.00018112-1 1.00018112zm-1 11.00199236v1.0001811h2v-1.0001811z" fill-rule="evenodd"/></symbol><symbol id="icon-location" viewBox="0 0 18 18"><path d="m9.39521328 16.2688008c.79596342-.7770119 1.59208152-1.6299956 2.33285652-2.5295081 1.4020032-1.7024324 2.4323601-3.3624519 2.9354918-4.871847.2228715-.66861448.3364384-1.29323246.3364384-1.8674457 0-3.3137085-2.6862915-6-6-6-3.36356866 0-6 2.60156856-6 6 0 .57421324.11356691 1.19883122.3364384 1.8674457.50313169 1.5093951 1.53348863 3.1694146 2.93549184 4.871847.74077492.8995125 1.53689309 1.7524962 2.33285648 2.5295081.13694479.1336842.26895677.2602648.39521328.3793207.12625651-.1190559.25826849-.2456365.39521328-.3793207zm-.39521328 1.7311992s-7-6-7-11c0-4 3.13400675-7 7-7 3.8659932 0 7 3.13400675 7 7 0 5-7 11-7 11zm0-8c-1.65685425 0-3-1.34314575-3-3s1.34314575-3 3-3c1.6568542 0 3 1.34314575 3 3s-1.3431458 3-3 3zm0-1c1.1045695 0 2-.8954305 2-2s-.8954305-2-2-2-2 .8954305-2 2 .8954305 2 2 2z" fill-rule="evenodd"/></symbol><symbol id="icon-minus" viewBox="0 0 16 16"><path d="m2.00087166 7h11.99825664c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-11.99825664c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"/></symbol><symbol id="icon-newsletter" viewBox="0 0 18 18"><path d="m9 11.8482489 2-1.1428571v-1.7053918h-4v1.7053918zm-3-1.7142857v-2.1339632h6v2.1339632l3-1.71428574v-6.41967746h-12v6.41967746zm10-5.3839632 1.5299989.95624934c.2923814.18273835.4700011.50320827.4700011.8479983v8.44575236c0 1.1045695-.8954305 2-2 2h-14c-1.1045695 0-2-.8954305-2-2v-8.44575236c0-.34479003.1776197-.66525995.47000106-.8479983l1.52999894-.95624934v-2.75c0-.55228475.44771525-1 1-1h12c.5522847 0 1 .44771525 1 1zm0 1.17924764v3.07075236l-7 4-7-4v-3.07075236l-1 .625v8.44575236c0 .5522847.44771525 1 1 1h14c.5522847 0 1-.4477153 1-1v-8.44575236zm-10-1.92924764h6v1h-6zm-1 2h8v1h-8z" fill-rule="evenodd"/></symbol><symbol id="icon-orcid" viewBox="0 0 18 18"><path d="m9 1c4.418278 0 8 3.581722 8 8s-3.581722 8-8 8-8-3.581722-8-8 3.581722-8 8-8zm-2.90107518 5.2732337h-1.41865256v7.1712107h1.41865256zm4.55867178.02508949h-2.99247027v7.14612121h2.91062487c.7673039 0 1.4476365-.1483432 2.0410182-.445034s1.0511995-.7152915 1.3734671-1.2558144c.3222677-.540523.4833991-1.1603247.4833991-1.85942385 0-.68545815-.1602789-1.30270225-.4808414-1.85175082-.3205625-.54904856-.7707074-.97532211-1.3504481-1.27883343-.5797408-.30351132-1.2413173-.45526471-1.9847495-.45526471zm-.1892674 1.07933542c.7877654 0 1.4143875.22336734 1.8798852.67010873.4654977.44674138.698243 1.05546001.698243 1.82617415 0 .74343221-.2310402 1.34447791-.6931277 1.80315511-.4620874.4586773-1.0750688.6880124-1.8389625.6880124h-1.46810075v-4.98745039zm-5.08652545-3.71099194c-.21825533 0-.410525.08444276-.57681478.25333081-.16628977.16888806-.24943341.36245684-.24943341.58071218 0 .22345188.08314364.41961891.24943341.58850696.16628978.16888806.35855945.25333082.57681478.25333082.233845 0 .43390938-.08314364.60019916-.24943342.16628978-.16628977.24943342-.36375592.24943342-.59240436 0-.233845-.08314364-.43131115-.24943342-.59240437s-.36635416-.24163862-.60019916-.24163862z" fill-rule="evenodd"/></symbol><symbol id="icon-plus" viewBox="0 0 16 16"><path d="m2.00087166 7h4.99912834v-4.99912834c0-.55276616.44386482-1.00087166 1-1.00087166.55228475 0 1 .44463086 1 1.00087166v4.99912834h4.9991283c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-4.9991283v4.9991283c0 .5527662-.44386482 1.0008717-1 1.0008717-.55228475 0-1-.4446309-1-1.0008717v-4.9991283h-4.99912834c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"/></symbol><symbol id="icon-print" viewBox="0 0 18 18"><path d="m16.0049107 5h-14.00982141c-.54941618 0-.99508929.4467783-.99508929.99961498v6.00077002c0 .5570958.44271433.999615.99508929.999615h1.00491071v-3h12v3h1.0049107c.5494162 0 .9950893-.4467783.9950893-.999615v-6.00077002c0-.55709576-.4427143-.99961498-.9950893-.99961498zm-2.0049107-1v-2.00208688c0-.54777062-.4519464-.99791312-1.0085302-.99791312h-7.9829396c-.55661731 0-1.0085302.44910695-1.0085302.99791312v2.00208688zm1 10v2.0018986c0 1.103521-.9019504 1.9981014-2.0085302 1.9981014h-7.9829396c-1.1092806 0-2.0085302-.8867064-2.0085302-1.9981014v-2.0018986h-1.00491071c-1.10185739 0-1.99508929-.8874333-1.99508929-1.999615v-6.00077002c0-1.10435686.8926228-1.99961498 1.99508929-1.99961498h1.00491071v-2.00208688c0-1.10341695.90195036-1.99791312 2.0085302-1.99791312h7.9829396c1.1092806 0 2.0085302.89826062 2.0085302 1.99791312v2.00208688h1.0049107c1.1018574 0 1.9950893.88743329 1.9950893 1.99961498v6.00077002c0 1.1043569-.8926228 1.999615-1.9950893 1.999615zm-1-3h-10v5.0018986c0 .5546075.44702548.9981014 1.0085302.9981014h7.9829396c.5565964 0 1.0085302-.4491701 1.0085302-.9981014zm-9 1h8v1h-8zm0 2h5v1h-5zm9-5c-.5522847 0-1-.44771525-1-1s.4477153-1 1-1 1 .44771525 1 1-.4477153 1-1 1z" fill-rule="evenodd"/></symbol><symbol id="icon-search" viewBox="0 0 22 22"><path d="M21.697 20.261a1.028 1.028 0 01.01 1.448 1.034 1.034 0 01-1.448-.01l-4.267-4.267A9.812 9.811 0 010 9.812a9.812 9.811 0 1117.43 6.182zM9.812 18.222A8.41 8.41 0 109.81 1.403a8.41 8.41 0 000 16.82z" fill-rule="evenodd"/></symbol><symbol id="icon-social-facebook" viewBox="0 0 24 24"><path d="m6.00368507 20c-1.10660471 0-2.00368507-.8945138-2.00368507-1.9940603v-12.01187942c0-1.10128908.89451376-1.99406028 1.99406028-1.99406028h12.01187942c1.1012891 0 1.9940603.89451376 1.9940603 1.99406028v12.01187942c0 1.1012891-.88679 1.9940603-2.0032184 1.9940603h-2.9570132v-6.1960818h2.0797387l.3114113-2.414723h-2.39115v-1.54164807c0-.69911803.1941355-1.1755439 1.1966615-1.1755439l1.2786739-.00055875v-2.15974763l-.2339477-.02492088c-.3441234-.03134957-.9500153-.07025255-1.6293054-.07025255-1.8435726 0-3.1057323 1.12531866-3.1057323 3.19187953v1.78079225h-2.0850778v2.414723h2.0850778v6.1960818z" fill-rule="evenodd"/></symbol><symbol id="icon-social-twitter" viewBox="0 0 24 24"><path d="m18.8767135 6.87445248c.7638174-.46908424 1.351611-1.21167363 1.6250764-2.09636345-.7135248.43394112-1.50406.74870123-2.3464594.91677702-.6695189-.73342162-1.6297913-1.19486605-2.6922204-1.19486605-2.0399895 0-3.6933555 1.69603749-3.6933555 3.78628909 0 .29642457.0314329.58673729.0942985.8617704-3.06469922-.15890802-5.78835241-1.66547825-7.60988389-3.9574208-.3174714.56076194-.49978171 1.21167363-.49978171 1.90536824 0 1.31404706.65223085 2.47224203 1.64236444 3.15218497-.60350999-.0198635-1.17401554-.1925232-1.67222562-.47366811v.04583885c0 1.83355406 1.27302891 3.36609966 2.96411421 3.71294696-.31118484.0886217-.63651445.1329326-.97441718.1329326-.2357461 0-.47149219-.0229194-.69466516-.0672303.47149219 1.5065703 1.83253297 2.6036468 3.44975116 2.632678-1.2651707 1.0160946-2.85724264 1.6196394-4.5891906 1.6196394-.29861172 0-.59093688-.0152796-.88011875-.0504227 1.63450624 1.0726291 3.57548241 1.6990934 5.66104951 1.6990934 6.79263079 0 10.50641749-5.7711113 10.50641749-10.7751859l-.0094298-.48894775c.7229547-.53478659 1.3516109-1.20250585 1.8419628-1.96190282-.6632323.30100846-1.3751855.50422736-2.1217148.59590507z" fill-rule="evenodd"/></symbol><symbol id="icon-social-youtube" viewBox="0 0 24 24"><path d="m10.1415 14.3973208-.0005625-5.19318431 4.863375 2.60554491zm9.963-7.92753362c-.6845625-.73643756-1.4518125-.73990314-1.803375-.7826454-2.518875-.18714178-6.2971875-.18714178-6.2971875-.18714178-.007875 0-3.7861875 0-6.3050625.18714178-.352125.04274226-1.1188125.04620784-1.8039375.7826454-.5394375.56084773-.7149375 1.8344515-.7149375 1.8344515s-.18 1.49597903-.18 2.99138042v1.4024082c0 1.495979.18 2.9913804.18 2.9913804s.1755 1.2736038.7149375 1.8344515c.685125.7364376 1.5845625.7133337 1.9850625.7901542 1.44.1420891 6.12.1859866 6.12.1859866s3.78225-.005776 6.301125-.1929178c.3515625-.0433198 1.1188125-.0467854 1.803375-.783223.5394375-.5608477.7155-1.8344515.7155-1.8344515s.18-1.4954014.18-2.9913804v-1.4024082c0-1.49540139-.18-2.99138042-.18-2.99138042s-.1760625-1.27360377-.7155-1.8344515z" fill-rule="evenodd"/></symbol><symbol id="icon-subject-medicine" viewBox="0 0 18 18"><path d="m12.5 8h-6.5c-1.65685425 0-3 1.34314575-3 3v1c0 1.6568542 1.34314575 3 3 3h1v-2h-.5c-.82842712 0-1.5-.6715729-1.5-1.5s.67157288-1.5 1.5-1.5h1.5 2 1 2c1.6568542 0 3-1.34314575 3-3v-1c0-1.65685425-1.3431458-3-3-3h-2v2h1.5c.8284271 0 1.5.67157288 1.5 1.5s-.6715729 1.5-1.5 1.5zm-5.5-1v-1h-3.5c-1.38071187 0-2.5-1.11928813-2.5-2.5s1.11928813-2.5 2.5-2.5h1.02786405c.46573528 0 .92507448.10843528 1.34164078.31671843l1.13382424.56691212c.06026365-1.05041141.93116291-1.88363055 1.99667093-1.88363055 1.1045695 0 2 .8954305 2 2h2c2.209139 0 4 1.790861 4 4v1c0 2.209139-1.790861 4-4 4h-2v1h2c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2h-2c0 1.1045695-.8954305 2-2 2s-2-.8954305-2-2h-1c-2.209139 0-4-1.790861-4-4v-1c0-2.209139 1.790861-4 4-4zm0-2v-2.05652691c-.14564246-.03538148-.28733393-.08714006-.42229124-.15461871l-1.15541752-.57770876c-.27771087-.13885544-.583937-.21114562-.89442719-.21114562h-1.02786405c-.82842712 0-1.5.67157288-1.5 1.5s.67157288 1.5 1.5 1.5zm4 1v1h1.5c.2761424 0 .5-.22385763.5-.5s-.2238576-.5-.5-.5zm-1 1v-5c0-.55228475-.44771525-1-1-1s-1 .44771525-1 1v5zm-2 4v5c0 .5522847.44771525 1 1 1s1-.4477153 1-1v-5zm3 2v2h2c.5522847 0 1-.4477153 1-1s-.4477153-1-1-1zm-4-1v-1h-.5c-.27614237 0-.5.2238576-.5.5s.22385763.5.5.5zm-3.5-9h1c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"/></symbol><symbol id="icon-success" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm3.4860198 4.98163161-4.71802968 5.50657859-2.62834168-2.02300024c-.42862421-.36730544-1.06564993-.30775346-1.42283677.13301307-.35718685.44076653-.29927542 1.0958383.12934879 1.46314377l3.40735508 2.7323063c.42215801.3385221 1.03700951.2798252 1.38749189-.1324571l5.38450527-6.33394549c.3613513-.43716226.3096573-1.09278382-.115462-1.46437175-.4251192-.37158792-1.0626796-.31842941-1.4240309.11873285z" fill-rule="evenodd"/></symbol><symbol id="icon-table" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587l-4.0059107-.001.001.001h-1l-.001-.001h-5l.001.001h-1l-.001-.001-3.00391071.001c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm-11.0059107 5h-3.999v6.9941413c0 .5572961.44630695 1.0058587.99508929 1.0058587h3.00391071zm6 0h-5v8h5zm5.0059107-4h-4.0059107v3h5.001v1h-5.001v7.999l4.0059107.001c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-12.5049107 9c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.2238576.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238576-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm-6-2c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.2238576.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238576-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm-6-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.22385763-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm1.499-5h-5v3h5zm-6 0h-3.00391071c-.54871518 0-.99508929.44887827-.99508929 1.00585866v1.99414134h3.999z" fill-rule="evenodd"/></symbol><symbol id="icon-tick-circle" viewBox="0 0 24 24"><path d="m12 2c5.5228475 0 10 4.4771525 10 10s-4.4771525 10-10 10-10-4.4771525-10-10 4.4771525-10 10-10zm0 1c-4.97056275 0-9 4.02943725-9 9 0 4.9705627 4.02943725 9 9 9 4.9705627 0 9-4.0294373 9-9 0-4.97056275-4.0294373-9-9-9zm4.2199868 5.36606669c.3613514-.43716226.9989118-.49032077 1.424031-.11873285s.4768133 1.02720949.115462 1.46437175l-6.093335 6.94397871c-.3622945.4128716-.9897871.4562317-1.4054264.0971157l-3.89719065-3.3672071c-.42862421-.3673054-.48653564-1.0223772-.1293488-1.4631437s.99421256-.5003185 1.42283677-.1330131l3.11097438 2.6987741z" fill-rule="evenodd"/></symbol><symbol id="icon-tick" viewBox="0 0 16 16"><path d="m6.76799012 9.21106946-3.1109744-2.58349728c-.42862421-.35161617-1.06564993-.29460792-1.42283677.12733148s-.29927541 1.04903009.1293488 1.40064626l3.91576307 3.23873978c.41034319.3393961 1.01467563.2976897 1.37450571-.0948578l6.10568327-6.660841c.3613513-.41848908.3096572-1.04610608-.115462-1.4018218-.4251192-.35571573-1.0626796-.30482786-1.424031.11366122z" fill-rule="evenodd"/></symbol><symbol id="icon-update" viewBox="0 0 18 18"><path d="m1 13v1c0 .5522847.44771525 1 1 1h14c.5522847 0 1-.4477153 1-1v-1h-1v-10h-14v10zm16-1h1v2c0 1.1045695-.8954305 2-2 2h-14c-1.1045695 0-2-.8954305-2-2v-2h1v-9c0-.55228475.44771525-1 1-1h14c.5522847 0 1 .44771525 1 1zm-1 0v1h-4.5857864l-1 1h-2.82842716l-1-1h-4.58578644v-1h5l1 1h2l1-1zm-13-8h12v7h-12zm1 1v5h10v-5zm1 1h4v1h-4zm0 2h4v1h-4z" fill-rule="evenodd"/></symbol><symbol id="icon-upload" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm0 1h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v14.00982141c0 .5500396.44491393.9950893.99406028.9950893h12.01187942c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717zm-1.85576936 4.14572769c.19483374-.19483375.51177826-.19377714.70556874.00001334l2.59099082 2.59099079c.1948411.19484112.1904373.51514474.0027906.70279143-.1932998.19329987-.5046517.19237083-.7001856-.00692852l-1.74638687-1.7800176v6.14827687c0 .2717771-.23193359.492096-.5.492096-.27614237 0-.5-.216372-.5-.492096v-6.14827641l-1.74627892 1.77990922c-.1933927.1971171-.51252214.19455839-.70016883.0069117-.19329987-.19329988-.19100584-.50899493.00277731-.70277808z" fill-rule="evenodd"/></symbol><symbol id="icon-video" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587h-14.00982141c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm0 1h-14.00982141c-.54871518 0-.99508929.44887827-.99508929 1.00585866v9.98828264c0 .5572961.44630695 1.0058587.99508929 1.0058587h14.00982141c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-8.30912922 2.24944486 4.60460462 2.73982242c.9365543.55726659.9290753 1.46522435 0 2.01804082l-4.60460462 2.7398224c-.93655425.5572666-1.69578148.1645632-1.69578148-.8937585v-5.71016863c0-1.05087579.76670616-1.446575 1.69578148-.89375851zm-.67492769.96085624v5.5750128c0 .2995102-.10753745.2442517.16578928.0847713l4.58452283-2.67497259c.3050619-.17799716.3051624-.21655446 0-.39461026l-4.58452283-2.67497264c-.26630747-.15538481-.16578928-.20699944-.16578928.08477139z" fill-rule="evenodd"/></symbol><symbol id="icon-warning" viewBox="0 0 18 18"><path d="m9 11.75c.69035594 0 1.25.5596441 1.25 1.25s-.55964406 1.25-1.25 1.25-1.25-.5596441-1.25-1.25.55964406-1.25 1.25-1.25zm.41320045-7.75c.55228475 0 1.00000005.44771525 1.00000005 1l-.0034543.08304548-.3333333 4c-.043191.51829212-.47645714.91695452-.99654578.91695452h-.15973424c-.52008864 0-.95335475-.3986624-.99654576-.91695452l-.33333333-4c-.04586475-.55037702.36312325-1.03372649.91350028-1.07959124l.04148683-.00259031zm-.41320045 14c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"/></symbol><symbol id="icon-arrow-left-bullet" viewBox="0 0 8 16"><path d="M3 8l5 5v3L0 8l8-8v3L3 8z"/></symbol><symbol id="icon-chevron-down" viewBox="0 0 16 16"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" fill-rule="evenodd" transform="matrix(0 1 -1 0 11 3)"/></symbol><symbol id="icon-download-rounded"><path d="M0 13c0-.556.449-1 1.002-1h9.996a.999.999 0 110 2H1.002A1.006 1.006 0 010 13zM7 1v6.8l2.482-2.482c.392-.392 1.022-.4 1.403-.02a1.001 1.001 0 010 1.417l-4.177 4.177a1.001 1.001 0 01-1.416 0L1.115 6.715a.991.991 0 01-.016-1.4 1 1 0 011.42.003L5 7.8V1c0-.55.444-.996 1-.996.552 0 1 .445 1 .996z"/></symbol><symbol id="icon-ext-link" viewBox="0 0 16 16"><path d="M12.9 16H3.1C1.4 16 0 14.6 0 12.9V3.2C0 1.4 1.4 0 3.1 0h3.7v1H3.1C2 1 1 2 1 3.2v9.7C1 14 2 15 3.1 15h9.7c1.2 0 2.1-1 2.1-2.1V8.7h1v4.2c.1 1.7-1.3 3.1-3 3.1z"/><path d="M12.8 2.5l.7.7-9 8.9-.7-.7 9-8.9z"/><path d="M9.7 0L16 6.2V0z"/></symbol><symbol id="icon-remove" viewBox="-296 388 18 18"><path d="M-291.7 396.1h9v2h-9z"/><path d="M-287 405.5c-4.7 0-8.5-3.8-8.5-8.5s3.8-8.5 8.5-8.5 8.5 3.8 8.5 8.5-3.8 8.5-8.5 8.5zm0-16c-4.1 0-7.5 3.4-7.5 7.5s3.4 7.5 7.5 7.5 7.5-3.4 7.5-7.5-3.4-7.5-7.5-7.5z"/></symbol><symbol id="icon-rss" viewBox="0 0 18 18"><path d="m.97480857 6.01583891.11675372.00378391c5.75903295.51984988 10.34261021 5.10537458 10.85988231 10.86480098.0494035.5500707-.3564674 1.0360406-.906538 1.0854441-.5500707.0494036-1.0360406-.3564673-1.08544412-.906538-.43079083-4.7965248-4.25151132-8.61886853-9.04770289-9.05180573-.55004837-.04965115-.95570047-.53580366-.90604933-1.08585203.04610464-.5107592.46858035-.89701345.96909831-.90983323zm1.52519143 6.95474179c1.38071187 0 2.5 1.1192881 2.5 2.5s-1.11928813 2.5-2.5 2.5-2.5-1.1192881-2.5-2.5 1.11928813-2.5 2.5-2.5zm-1.43253846-12.96884168c9.09581416.53242539 16.37540296 7.8163886 16.90205336 16.91294558.0319214.5513615-.389168 1.0242056-.9405294 1.056127-.5513615.0319214-1.0242057-.389168-1.0561271-.9405294-.4679958-8.08344784-6.93949306-14.55883389-15.02226722-15.03196077-.55134101-.03227286-.97212889-.50538538-.93985602-1.05672639.03227286-.551341.50538538-.97212888 1.05672638-.93985602z" fill-rule="evenodd"/></symbol><symbol id="icon-springer-arrow-left"><path d="M15 7a1 1 0 000-2H3.385l2.482-2.482a.994.994 0 00.02-1.403 1.001 1.001 0 00-1.417 0L.294 5.292a1.001 1.001 0 000 1.416l4.176 4.177a.991.991 0 001.4.016 1 1 0 00-.003-1.42L3.385 7H15z"/></symbol><symbol id="icon-springer-arrow-right"><path d="M1 7a1 1 0 010-2h11.615l-2.482-2.482a.994.994 0 01-.02-1.403 1.001 1.001 0 011.417 0l4.176 4.177a1.001 1.001 0 010 1.416l-4.176 4.177a.991.991 0 01-1.4.016 1 1 0 01.003-1.42L12.615 7H1z"/></symbol><symbol id="icon-springer-collections" viewBox="3 3 32 32"><path fill-rule="evenodd" d="M25.583333,30.1249997 L25.583333,7.1207574 C25.583333,7.10772495 25.579812,7.10416665 25.5859851,7.10416665 L6.10400517,7.10571021 L6.10400517,30.1355179 C6.10400517,31.1064087 6.89406744,31.8958329 7.86448169,31.8958329 L26.057145,31.8958329 C25.7558021,31.374901 25.583333,30.7700915 25.583333,30.1249997 Z M4.33333333,30.1355179 L4.33333333,7.10571021 C4.33333333,6.12070047 5.12497502,5.33333333 6.10151452,5.33333333 L25.5859851,5.33333333 C26.5617372,5.33333333 27.3541664,6.13359035 27.3541664,7.1207574 L27.3541664,12.4166666 L32.6666663,12.4166666 L32.6666663,30.1098941 C32.6666663,32.0694626 31.0857174,33.6666663 29.1355179,33.6666663 L7.86448169,33.6666663 C5.91736809,33.6666663 4.33333333,32.0857174 4.33333333,30.1355179 Z M27.3541664,14.1874999 L27.3541664,30.1249997 C27.3541664,31.1030039 28.1469954,31.8958329 29.1249997,31.8958329 C30.1030039,31.8958329 30.8958329,31.1030039 30.8958329,30.1249997 L30.8958329,14.1874999 L27.3541664,14.1874999 Z M9.64583326,10.6458333 L22.0416665,10.6458333 L22.0416665,17.7291665 L9.64583326,17.7291665 L9.64583326,10.6458333 Z M11.4166666,12.4166666 L11.4166666,15.9583331 L20.2708331,15.9583331 L20.2708331,12.4166666 L11.4166666,12.4166666 Z M9.64583326,19.4999998 L22.0416665,19.4999998 L22.0416665,21.2708331 L9.64583326,21.2708331 L9.64583326,19.4999998 Z M9.64583326,23.0416665 L22.0416665,23.0416665 L22.0416665,24.8124997 L9.64583326,24.8124997 L9.64583326,23.0416665 Z M9.64583326,26.583333 L22.0416665,26.583333 L22.0416665,28.3541664 L9.64583326,28.3541664 L9.64583326,26.583333 Z"/></symbol><symbol id="icon-springer-download" viewBox="-301 390 9 14"><path d="M-301 395.6l4.5 5.1 4.5-5.1h-3V390h-3v5.6h-3zm0 6.5h9v1.9h-9z"/></symbol><symbol id="icon-springer-info" viewBox="0 0 24 24"><g id="V&I" stroke="none" stroke-width="1" fill-rule="evenodd"><g id="info" fill-rule="nonzero"><path d="M12,0 C18.627417,0 24,5.372583 24,12 C24,18.627417 18.627417,24 12,24 C5.372583,24 0,18.627417 0,12 C0,5.372583 5.372583,0 12,0 Z M12.5540543,9.1 L11.5540543,9.1 C11.0017696,9.1 10.5540543,9.54771525 10.5540543,10.1 L10.5540543,10.1 L10.5540543,18.1 C10.5540543,18.6522847 11.0017696,19.1 11.5540543,19.1 L11.5540543,19.1 L12.5540543,19.1 C13.1063391,19.1 13.5540543,18.6522847 13.5540543,18.1 L13.5540543,18.1 L13.5540543,10.1 C13.5540543,9.54771525 13.1063391,9.1 12.5540543,9.1 L12.5540543,9.1 Z M12,5 C11.5356863,5 11.1529412,5.14640523 10.8517647,5.43921569 C10.5505882,5.73202614 10.4,6.11546841 10.4,6.58954248 C10.4,7.06361656 10.5505882,7.45054466 10.8517647,7.7503268 C11.1529412,8.05010893 11.5356863,8.2 12,8.2 C12.4768627,8.2 12.8627451,8.05010893 13.1576471,7.7503268 C13.452549,7.45054466 13.6,7.06361656 13.6,6.58954248 C13.6,6.11546841 13.452549,5.73202614 13.1576471,5.43921569 C12.8627451,5.14640523 12.4768627,5 12,5 Z" id="Combined-Shape"/></g></g></symbol><symbol id="icon-springer-tick-circle" viewBox="0 0 24 24"><g id="Page-1" stroke="none" stroke-width="1" fill-rule="evenodd"><g id="springer-tick-circle" fill-rule="nonzero"><path d="M12,24 C5.372583,24 0,18.627417 0,12 C0,5.372583 5.372583,0 12,0 C18.627417,0 24,5.372583 24,12 C24,18.627417 18.627417,24 12,24 Z M7.657,10.79 C7.45285634,10.6137568 7.18569967,10.5283283 6.91717333,10.5534259 C6.648647,10.5785236 6.40194824,10.7119794 6.234,10.923 C5.87705269,11.3666969 5.93445559,12.0131419 6.364,12.387 L10.261,15.754 C10.6765468,16.112859 11.3037113,16.0695601 11.666,15.657 L17.759,8.713 C18.120307,8.27302248 18.0695334,7.62621189 17.644,7.248 C17.4414817,7.06995024 17.1751516,6.9821166 16.9064461,7.00476032 C16.6377406,7.02740404 16.3898655,7.15856958 16.22,7.368 L10.768,13.489 L7.657,10.79 Z" id="path-1"/></g></g></symbol><symbol id="icon-updates" viewBox="0 0 18 18"><g fill-rule="nonzero"><path d="M16.98 3.484h-.48c-2.52-.058-5.04 1.161-7.44 2.903-2.46-1.8-4.74-2.903-8.04-2.903-.3 0-.54.29-.54.58v9.813c0 .29.24.523.54.581 2.76.348 4.86 1.045 7.62 2.903.24.116.54.116.72 0 2.76-1.858 4.86-2.555 7.62-2.903.3-.058.54-.29.54-.58V4.064c0-.29-.24-.523-.54-.581zm-15.3 1.22c2.34 0 4.86 1.509 6.72 2.786v8.478c-2.34-1.394-4.38-2.09-6.72-2.439V4.703zm14.58 8.767c-2.34.348-4.38 1.045-6.72 2.439V7.374C12 5.632 14.1 4.645 16.26 4.645v8.826z"/><path d="M9 .058c-1.56 0-2.76 1.22-2.76 2.671C6.24 4.181 7.5 5.4 9 5.4c1.5 0 2.76-1.22 2.76-2.671 0-1.452-1.2-2.67-2.76-2.67zm0 4.413c-.96 0-1.8-.755-1.8-1.742C7.2 1.8 7.98.987 9 .987s1.8.755 1.8 1.742c0 .93-.84 1.742-1.8 1.742z"/></g></symbol><symbol id="icon-checklist-banner" viewBox="0 0 56.69 56.69"><path style="fill:none" d="M0 0h56.69v56.69H0z"/><clipPath id="b"><use xlink:href="#a" style="overflow:visible"/></clipPath><path d="M21.14 34.46c0-6.77 5.48-12.26 12.24-12.26s12.24 5.49 12.24 12.26-5.48 12.26-12.24 12.26c-6.76-.01-12.24-5.49-12.24-12.26zm19.33 10.66 10.23 9.22s1.21 1.09 2.3-.12l2.09-2.32s1.09-1.21-.12-2.3l-10.23-9.22m-19.29-5.92c0-4.38 3.55-7.94 7.93-7.94s7.93 3.55 7.93 7.94c0 4.38-3.55 7.94-7.93 7.94-4.38-.01-7.93-3.56-7.93-7.94zm17.58 12.99 4.14-4.81" style="clip-path:url(#b);fill:none;stroke:#01324b;stroke-width:2;stroke-linecap:round"/><path d="M8.26 9.75H28.6M8.26 15.98H28.6m-20.34 6.2h12.5m14.42-5.2V4.86s0-2.93-2.93-2.93H4.13s-2.93 0-2.93 2.93v37.57s0 2.93 2.93 2.93h15.01M8.26 9.75H28.6M8.26 15.98H28.6m-20.34 6.2h12.5" style="clip-path:url(#b);fill:none;stroke:#01324b;stroke-width:2;stroke-linecap:round;stroke-linejoin:round"/></symbol><symbol id="icon-submit-closed" viewBox="0 0 18 18"><path d="m15 0c1.1045695 0 2 .8954305 2 2v4.5c0 .27614237-.2238576.5-.5.5s-.5-.22385763-.5-.5v-4.5c0-.51283584-.3860402-.93550716-.8833789-.99327227l-.1166211-.00672773h-9v3c0 1.1045695-.8954305 2-2 2h-3v10c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h4.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-4.5c-1.1045695 0-2-.8954305-2-2v-10.17157288c0-.53043297.21071368-1.0391408.58578644-1.41421356l3.82842712-3.82842712c.37507276-.37507276.88378059-.58578644 1.41421356-.58578644zm-2.5 7c3.0375661 0 5.5 2.46243388 5.5 5.5 0 3.0375661-2.4624339 5.5-5.5 5.5-3.03756612 0-5.5-2.4624339-5.5-5.5 0-3.03756612 2.46243388-5.5 5.5-5.5zm0 1c-2.4852814 0-4.5 2.0147186-4.5 4.5s2.0147186 4.5 4.5 4.5 4.5-2.0147186 4.5-4.5-2.0147186-4.5-4.5-4.5zm2.3087379 2.1912621c.2550161.2550162.2550161.668479 0 .9234952l-1.3859024 1.3845831 1.3859024 1.3859023c.2550161.2550162.2550161.668479 0 .9234952-.2550162.2550161-.668479.2550161-.9234952 0l-1.3859023-1.3859024-1.3845831 1.3859024c-.2550162.2550161-.668479.2550161-.9234952 0-.25501614-.2550162-.25501614-.668479 0-.9234952l1.3845831-1.3859023-1.3845831-1.3845831c-.25501614-.2550162-.25501614-.668479 0-.9234952.2550162-.25501614.668479-.25501614.9234952 0l1.3845831 1.3845831 1.3859023-1.3845831c.2550162-.25501614.668479-.25501614.9234952 0zm-9.8087379-8.7782621-3.587 3.587h2.587c.55228475 0 1-.44771525 1-1z"/></symbol><symbol id="icon-submit-open" viewBox="0 0 18 18"><path d="m15 0c1.1045695 0 2 .8954305 2 2v5.5c0 .27614237-.2238576.5-.5.5s-.5-.22385763-.5-.5v-5.5c0-.51283584-.3860402-.93550716-.8833789-.99327227l-.1166211-.00672773h-9v3c0 1.1045695-.8954305 2-2 2h-3v10c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h7.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-7.5c-1.1045695 0-2-.8954305-2-2v-10.17157288c0-.53043297.21071368-1.0391408.58578644-1.41421356l3.82842712-3.82842712c.37507276-.37507276.88378059-.58578644 1.41421356-.58578644zm-.5442863 8.18867991 3.3545404 3.35454039c.2508994.2508994.2538696.6596433.0035959.909917-.2429543.2429542-.6561449.2462671-.9065387-.0089489l-2.2609825-2.3045251.0010427 7.2231989c0 .3569916-.2898381.6371378-.6473715.6371378-.3470771 0-.6473715-.2852563-.6473715-.6371378l-.0010428-7.2231995-2.2611222 2.3046654c-.2531661.2580415-.6562868.2592444-.9065605.0089707-.24295423-.2429542-.24865597-.6576651.0036132-.9099343l3.3546673-3.35466731c.2509089-.25090888.6612706-.25227691.9135302-.00001728zm-.9557137-3.18867991c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm-8.5-3.587-3.587 3.587h2.587c.55228475 0 1-.44771525 1-1zm8.5 1.587c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z"/></symbol><symbol id="icon-submit-upcoming" viewBox="0 0 18 18"><path d="m15 0c1.1045695 0 2 .8954305 2 2v4.5c0 .27614237-.2238576.5-.5.5s-.5-.22385763-.5-.5v-4.5c0-.51283584-.3860402-.93550716-.8833789-.99327227l-.1166211-.00672773h-9v3c0 1.1045695-.8954305 2-2 2h-3v10c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h4.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-4.5c-1.1045695 0-2-.8954305-2-2v-10.17157288c0-.53043297.21071368-1.0391408.58578644-1.41421356l3.82842712-3.82842712c.37507276-.37507276.88378059-.58578644 1.41421356-.58578644zm-2.5 7c3.0375661 0 5.5 2.46243388 5.5 5.5 0 3.0375661-2.4624339 5.5-5.5 5.5-3.03756612 0-5.5-2.4624339-5.5-5.5 0-1.6607442.73606908-3.14957021 1.89976608-4.15803695l-1.51549374.02214397c-.27613212.00263356-.49998143-.22483432-.49998143-.49020681 0-.24299316.17766103-.44509007.40961587-.48700057l.08928713-.00797472h2.66407569c.2449213 0 .4486219.17766776.490865.40963137l.008038.08929051v2.6642143c0 .275547-.2296028.4989219-.4949753.4989219-.24299317 0-.44342617-.1744719-.4830969-.4093269l-.00710993-.0906783.01983146-1.46576707c-.96740882.82538117-1.58082193 2.05345007-1.58082193 3.42478927 0 2.4852814 2.0147186 4.5 4.5 4.5s4.5-2.0147186 4.5-4.5-2.0147186-4.5-4.5-4.5c-.7684937 0-.7684937-1 0-1zm0 2.85c.3263501 0 .5965265.2405082.6429523.5539478l.0070477.0960522v1.731l.8096194.8093806c.2284567.2284567.2513024.5846637.068537.8386705l-.068537.0805683c-.2284567.2284567-.5846637.2513024-.8386705.068537l-.0805683-.068537-.9707107-.9707107c-.1125218-.1125218-.1855975-.257116-.2103268-.412296l-.0093431-.1180341v-1.9585786c0-.3589851.2910149-.65.65-.65zm-7.5-8.437-3.587 3.587h2.587c.55228475 0 1-.44771525 1-1z"/></symbol><symbol id="icon-facebook-bordered" viewBox="463.812 263.868 32 32"><path d="M479.812,263.868c-8.837,0-16,7.163-16,16s7.163,16,16,16s16-7.163,16-16S488.649,263.868,479.812,263.868z M479.812,293.868c-7.732,0-14-6.269-14-14s6.268-14,14-14s14,6.269,14,14S487.545,293.868,479.812,293.868z"/><path d="M483.025,280.48l0.32-2.477h-2.453v-1.582c0-0.715,0.199-1.207,1.227-1.207h1.311v-2.213 c-0.227-0.029-1.003-0.098-1.907-0.098c-1.894,0-3.186,1.154-3.186,3.271v1.826h-2.142v2.477h2.142v6.354h2.557v-6.354 L483.025,280.48L483.025,280.48z"/></symbol><symbol id="icon-twitter-bordered" viewBox="463.812 263.868 32 32"><g><path d="M486.416,276.191c-0.483,0.215-1.007,0.357-1.554,0.429c0.558-0.338,0.991-0.868,1.19-1.502 c-0.521,0.308-1.104,0.536-1.72,0.657c-0.494-0.526-1.2-0.854-1.979-0.854c-1.496,0-2.711,1.213-2.711,2.71 c0,0.212,0.023,0.419,0.069,0.616c-2.252-0.111-4.25-1.19-5.586-2.831c-0.231,0.398-0.365,0.866-0.365,1.361 c0,0.94,0.479,1.772,1.204,2.257c-0.441-0.015-0.861-0.138-1.227-0.339v0.031c0,1.314,0.937,2.41,2.174,2.656 c-0.227,0.062-0.47,0.098-0.718,0.098c-0.171,0-0.343-0.018-0.511-0.049c0.35,1.074,1.347,1.859,2.531,1.883 c-0.928,0.726-2.095,1.16-3.366,1.16c-0.22,0-0.433-0.014-0.644-0.037c1.2,0.768,2.621,1.215,4.155,1.215 c4.983,0,7.71-4.129,7.71-7.711c0-0.115-0.004-0.232-0.006-0.351C485.592,277.212,486.054,276.734,486.416,276.191z"/></g><path d="M479.812,263.868c-8.837,0-16,7.163-16,16s7.163,16,16,16s16-7.163,16-16S488.649,263.868,479.812,263.868z M479.812,293.868c-7.732,0-14-6.269-14-14s6.268-14,14-14s14,6.269,14,14S487.545,293.868,479.812,293.868z"/></symbol><symbol id="icon-weibo-bordered" viewBox="463.812 263.868 32 32"><path d="M479.812,263.868c-8.838,0-16,7.163-16,16s7.162,16,16,16c8.837,0,16-7.163,16-16S488.649,263.868,479.812,263.868z M479.812,293.868c-7.732,0-14-6.269-14-14s6.268-14,14-14c7.731,0,14,6.269,14,14S487.545,293.868,479.812,293.868z"/><g><path d="M478.552,285.348c-2.616,0.261-4.876-0.926-5.044-2.649c-0.167-1.722,1.814-3.33,4.433-3.588 c2.609-0.263,4.871,0.926,5.041,2.647C483.147,283.479,481.164,285.089,478.552,285.348 M483.782,279.63 c-0.226-0.065-0.374-0.109-0.259-0.403c0.25-0.639,0.276-1.188,0.005-1.581c-0.515-0.734-1.915-0.693-3.521-0.021 c0,0-0.508,0.224-0.378-0.181c0.247-0.798,0.209-1.468-0.178-1.852c-0.87-0.878-3.194,0.032-5.183,2.027 c-1.489,1.494-2.357,3.082-2.357,4.453c0,2.619,3.354,4.213,6.631,4.213c4.297,0,7.154-2.504,7.154-4.493 C485.697,280.594,484.689,279.911,483.782,279.63"/><path d="M486.637,274.833c-1.039-1.154-2.57-1.592-3.982-1.291l0,0c-0.325,0.068-0.532,0.391-0.465,0.72 c0.068,0.328,0.391,0.537,0.72,0.466c1.005-0.215,2.092,0.104,2.827,0.92c0.736,0.818,0.938,1.939,0.625,2.918l0,0 c-0.102,0.318,0.068,0.661,0.39,0.762c0.32,0.104,0.658-0.069,0.763-0.391v-0.001C487.953,277.558,487.674,275.985,486.637,274.833 "/><path d="M485.041,276.276c-0.504-0.562-1.25-0.774-1.938-0.63c-0.279,0.06-0.461,0.339-0.396,0.621 c0.062,0.281,0.335,0.461,0.617,0.398l0,0c0.336-0.071,0.702,0.03,0.947,0.307s0.312,0.649,0.207,0.979l0,0 c-0.089,0.271,0.062,0.565,0.336,0.654c0.274,0.09,0.564-0.062,0.657-0.336C485.686,277.604,485.549,276.837,485.041,276.276"/><path d="M478.694,282.227c-0.09,0.156-0.293,0.233-0.451,0.166c-0.151-0.062-0.204-0.235-0.115-0.389 c0.093-0.155,0.284-0.229,0.44-0.168C478.725,281.892,478.782,282.071,478.694,282.227 M477.862,283.301 c-0.253,0.405-0.795,0.58-1.202,0.396c-0.403-0.186-0.521-0.655-0.27-1.051c0.248-0.39,0.771-0.566,1.176-0.393 C477.979,282.423,478.109,282.889,477.862,283.301 M478.812,280.437c-1.244-0.326-2.65,0.294-3.19,1.396 c-0.553,1.119-0.021,2.369,1.236,2.775c1.303,0.42,2.84-0.225,3.374-1.436C480.758,281.989,480.1,280.77,478.812,280.437"/></g></symbol></svg> </div> <div class="u-vh-full"> <a class="c-skip-link" href="#main-content">Skip to main content</a> <div class="u-hide u-show-following-ad"></div> <aside class="adsbox c-ad c-ad--728x90" data-component-mpu> <div class="c-ad__inner"> <p class="c-ad__label">Advertisement</p> <div id="div-gpt-ad-LB1" data-ad-type="LB1" data-test="LB1-ad" data-pa11y-ignore data-gpt data-gpt-unitpath="/270604982/bmc/genomemedicine/articles" data-gpt-sizes="728x90,970x90" data-gpt-targeting="pos=LB1;doi=10.1186/s13073-024-01405-5;type=article;kwrd=MSLN,CAR-T cells,Ovarian cancer,Mesothelioma,Safety,Efficacy;pmc=B12008,L15030,L15001,H00007,B11001,L15010;sponsored=ctr;" > <noscript> <a href="//pubads.g.doubleclick.net/gampad/jump?iu=/270604982/bmc/genomemedicine/articles&sz=728x90,970x90&pos=LB1&doi=10.1186/s13073-024-01405-5&type=article&kwrd=MSLN,CAR-T cells,Ovarian cancer,Mesothelioma,Safety,Efficacy&pmc=B12008,L15030,L15001,H00007,B11001,L15010&sponsored=ctr&"> <img data-test="gpt-advert-fallback-img" src="//pubads.g.doubleclick.net/gampad/ad?iu=/270604982/bmc/genomemedicine/articles&sz=728x90,970x90&pos=LB1&doi=10.1186/s13073-024-01405-5&type=article&kwrd=MSLN,CAR-T cells,Ovarian cancer,Mesothelioma,Safety,Efficacy&pmc=B12008,L15030,L15001,H00007,B11001,L15010&sponsored=ctr&" alt="Advertisement" width="728" height="90"> </a> </noscript> </div> </div> </aside> <div id="membership-message-loader-desktop" class="placeholder" data-placeholder="/placeholder/v1/membership/message"></div> <div id="top" class="u-position-relative"> <header class="c-header" data-test="publisher-header"> <div class="c-header__container"> <div class="c-header__brand u-mr-48" itemscope itemtype="http://schema.org/Organization" data-test="navbar-logo-header"> <div class="c-logo"> <a href="https://www.biomedcentral.com" itemprop="url"> <img alt="BMC" itemprop="logo" width="76" height="18" role="img" src=/static/images/bmc/logos/logo-bmc-white-flagship-6c54473310.svg> <div class="c-logo__strapline"> <img alt="Part of Springer Nature" width="173" height="16" role="img" src=/static/images/bmc/logos/logo-bmc-white-strapline-sn-f224388d67.svg> </div> </a> </div> </div> <div class="c-header__navigation"> <button type="button" class="c-header__link u-button-reset u-mr-24" data-expander data-expander-target="#publisher-header-search" data-expander-autofocus="firstTabbable" data-test="header-search-button" aria-controls="publisher-header-search" aria-expanded="false"> <span class="u-display-flex u-align-items-center"> <span>Search</span> <svg class="u-icon u-flex-static u-ml-8" aria-hidden="true" focusable="false"> <use xlink:href="#icon-search"></use> </svg> </span> </button> <nav> <ul class="c-header__menu" data-enhanced-menu data-test="publisher-navigation"> <li class="c-header__item u-hide-at-lt-lg"> <a class="c-header__link" href="//www.biomedcentral.com/journals"> Explore journals </a> </li> <li class="c-header__item u-hide-at-lt-lg"> <a class="c-header__link" href="//www.biomedcentral.com/getpublished"> Get published </a> </li> <li class="c-header__item u-hide-at-lt-lg"> <a class="c-header__link" href="//www.biomedcentral.com/about"> About BMC </a> </li> <li class="c-header__item"> <a data-enhanced-account class="c-header__link" href="https://www.biomedcentral.com/account" data-test="login-link"> My account </a> </li> </ul> </nav> </div> </div> </header> <div class="c-popup-search u-js-hide" id="publisher-header-search"> <div class="u-container"> <div class="c-popup-search__container"> <div class="ctx-search"> <form role="search" class="c-form-field js-skip-validation" method="GET" action="//www.biomedcentral.com/search" data-track="search" data-track-context="pop out website-wide search in bmc website header" data-track-category="Search and Results" data-track-action="Submit search" data-dynamic-track-label data-track-label="" data-test="global-search"> <label for="publisherSearch" class="c-form-field__label">Search all BMC articles</label> <div class="u-display-flex"> <input id="publisherSearch" class="c-form-field__input" data-search-input autocomplete="off" role="textbox" data-test="search-input" name="query" type="text" value=""/> <div> <button class="u-button" type="submit" data-test="search-submit-button"> <span class="u-visually-hidden">Search</span> <svg class="u-icon u-flex-static" width="16" height="16" aria-hidden="true" focusable="false"> <use xlink:href="#icon-search"></use> </svg> </button> </div> </div> <input type="hidden" name="searchType" value="publisherSearch"/> </form> </div> </div> </div> </div> </div> <header class="c-journal-header c-journal-header--genome-medicine ctx-journal-header"> <div class="u-container"> <div class="c-journal-header__inner c-journal-header__inner--featured-journal"> <div class="c-journal-title" id="journalTitle"> <a href="/"> <span class="c-journal-title__text u-visually-hidden">Genome Medicine</span> <div class="c-journal-title__featured-journal-lines c-journal-title__featured-journal-lines--genome-medicine"> <img src=/static/images/bmc/logos/genome-medicine-logo-24b9193f4f.svg class="c-journal-title__featured-journal-logo" alt="Genome Medicine logo" itemprop="logo" role="img"> </div> </a> </div> </div> </div> <div class="c-navbar c-navbar--with-submit-button"> <div class="c-navbar__container"> <div class="c-navbar__content"> <nav class="c-navbar__nav"> <ul class="c-navbar__nav c-navbar__nav--journal" role="menu" data-test="site-navigation"> <li class="c-navbar__item" role="menuitem"> <a class="c-navbar__link" data-track="click" data-track-category="Home" data-track-action="Clicked journal navigation link" href='/'>Home</a> </li> <li class="c-navbar__item" role="menuitem"> <a class="c-navbar__link" data-track="click" data-track-category="About" data-track-action="Clicked journal navigation link" href='/about'>About</a> </li> <li class="c-navbar__item" role="menuitem"> <a class="c-navbar__link c-navbar__link--is-shown" data-track="click" data-track-category="Articles" data-track-action="Clicked journal navigation link" href='/articles'>Articles</a> </li> <li class="c-navbar__item" role="menuitem"> <a class="c-navbar__link" data-track="click" data-track-category="Submission Guidelines" data-track-action="Clicked journal navigation link" href='/submission-guidelines'>Submission Guidelines</a> </li> <li class="c-navbar__item" role="menuitem" data-test="journal-header-submit-button"> <div class=""> <a class="u-button u-button--tertiary u-button--alt-colour-on-mobile" href="https://submission.springernature.com/new-submission/13073/3" data-track="click_submit_manuscript" data-track-action="manuscript submission" data-track-category="article" data-track-label="button in journal nav" data-track-context="journal header on article page" data-track-external data-test="submit-manuscript-button">Submit manuscript<svg class="u-ml-8" width="15" height="16" aria-hidden="true" focusable="false"><use xlink:href="#icon-submit-open"></use></svg></a> </div> </li> </ul> </nav> </div> </div> </div> <div class="c-journal-header__identity c-journal-header__identity--featured-journal"> </div> </header> <div class="u-container u-mt-32 u-mb-32 u-clearfix" id="main-content" data-component="article-container"> <main class="c-article-main-column u-float-left js-main-column" data-track-component="article body"> <div class="c-context-bar u-hide" data-test="context-bar" data-context-bar aria-hidden="true"> <div class="c-context-bar__container u-container" data-track-context="sticky banner"> <div class="c-context-bar__title"> Efficacy and safety of novel multiple-chain DAP-CAR-T cells targeting mesothelin in ovarian cancer and mesothelioma: a single-arm, open-label and first-in-human study </div> <div class="c-pdf-container"> <div class="c-pdf-download u-clear-both"> <a href="//genomemedicine.biomedcentral.com/counter/pdf/10.1186/s13073-024-01405-5.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="pdf-link" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external download> <span class="c-pdf-download__text">Download PDF</span> <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"/></svg> </a> </div> </div> </div> </div> <div class="c-pdf-button__container u-hide-at-lg js-context-bar-sticky-point-mobile"> <div class="c-pdf-container" data-track-context="article body"> <div class="c-pdf-download u-clear-both"> <a href="//genomemedicine.biomedcentral.com/counter/pdf/10.1186/s13073-024-01405-5.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="pdf-link" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external download> <span class="c-pdf-download__text">Download PDF</span> <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"/></svg> </a> </div> </div> </div> <article lang="en"> <div class="c-article-header"> <ul class="c-article-identifiers" data-test="article-identifier"> <li class="c-article-identifiers__item" data-test="article-category">Research</li> <li class="c-article-identifiers__item"> <a href="https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research" data-track="click" data-track-action="open access" data-track-label="link" class="u-color-open-access" data-test="open-access">Open access</a> </li> <li class="c-article-identifiers__item">Published: <time datetime="2024-11-15">15 November 2024</time></li> </ul> <h1 class="c-article-title" data-test="article-title" data-article-title="">Efficacy and safety of novel multiple-chain DAP-CAR-T cells targeting mesothelin in ovarian cancer and mesothelioma: a single-arm, open-label and first-in-human study</h1> <ul class="c-article-author-list c-article-author-list--short" data-test="authors-list" data-component-authors-activator="authors-list"><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Tongpeng-Xu-Aff1" data-author-popup="auth-Tongpeng-Xu-Aff1" data-author-search="Xu, Tongpeng" data-corresp-id="c1">Tongpeng Xu<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-mail-medium"></use></svg></a><sup class="u-js-hide"><a href="#Aff1">1</a></sup><sup class="u-js-hide"> <a href="#na1">na1</a></sup>, </li><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Tian-Tian-Aff2" data-author-popup="auth-Tian-Tian-Aff2" data-author-search="Tian, Tian">Tian Tian</a><sup class="u-js-hide"><a href="#Aff2">2</a></sup><sup class="u-js-hide"> <a href="#na1">na1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Chen-Wang-Aff3" data-author-popup="auth-Chen-Wang-Aff3" data-author-search="Wang, Chen">Chen Wang</a><sup class="u-js-hide"><a href="#Aff3">3</a></sup><sup class="u-js-hide"> <a href="#na1">na1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Xiaofeng-Chen-Aff1" data-author-popup="auth-Xiaofeng-Chen-Aff1" data-author-search="Chen, Xiaofeng">Xiaofeng Chen</a><sup class="u-js-hide"><a href="#Aff1">1</a></sup><sup class="u-js-hide"> <a href="#na1">na1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Xiangrong-Zuo-Aff5" data-author-popup="auth-Xiangrong-Zuo-Aff5" data-author-search="Zuo, Xiangrong">Xiangrong Zuo</a><sup class="u-js-hide"><a href="#Aff5">5</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Hanyu-Zhou-Aff1-Aff4" data-author-popup="auth-Hanyu-Zhou-Aff1-Aff4" data-author-search="Zhou, Hanyu">Hanyu Zhou</a><sup class="u-js-hide"><a href="#Aff1">1</a>,<a href="#Aff4">4</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Jianan-Bai-Aff6" data-author-popup="auth-Jianan-Bai-Aff6" data-author-search="Bai, Jianan">Jianan Bai</a><sup class="u-js-hide"><a href="#Aff6">6</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Chenhui-Zhao-Aff1" data-author-popup="auth-Chenhui-Zhao-Aff1" data-author-search="Zhao, Chenhui">Chenhui Zhao</a><sup class="u-js-hide"><a href="#Aff1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Sujie-Fu-Aff7" data-author-popup="auth-Sujie-Fu-Aff7" data-author-search="Fu, Sujie">Sujie Fu</a><sup class="u-js-hide"><a href="#Aff7">7</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Chongqi-Sun-Aff1" data-author-popup="auth-Chongqi-Sun-Aff1" data-author-search="Sun, Chongqi">Chongqi Sun</a><sup class="u-js-hide"><a href="#Aff1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Ting-Wang-Aff1" data-author-popup="auth-Ting-Wang-Aff1" data-author-search="Wang, Ting">Ting Wang</a><sup class="u-js-hide"><a href="#Aff1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Ling-Zhu-Aff8" data-author-popup="auth-Ling-Zhu-Aff8" data-author-search="Zhu, Ling">Ling Zhu</a><sup class="u-js-hide"><a href="#Aff8">8</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Jingzhi-Zhang-Aff3" data-author-popup="auth-Jingzhi-Zhang-Aff3" data-author-search="Zhang, Jingzhi">Jingzhi Zhang</a><sup class="u-js-hide"><a href="#Aff3">3</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Enxiu-Wang-Aff3" data-author-popup="auth-Enxiu-Wang-Aff3" data-author-search="Wang, Enxiu" data-corresp-id="c2">Enxiu Wang<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-mail-medium"></use></svg></a><sup class="u-js-hide"><a href="#Aff3">3</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Ming-Sun-Aff9" data-author-popup="auth-Ming-Sun-Aff9" data-author-search="Sun, Ming" data-corresp-id="c3">Ming Sun<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-mail-medium"></use></svg></a><sup class="u-js-hide"><a href="#Aff9">9</a></sup> & </li><li class="c-article-author-list__show-more" aria-label="Show all 16 authors for this article" title="Show all 16 authors for this article">…</li><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Yongqian-Shu-Aff1" data-author-popup="auth-Yongqian-Shu-Aff1" data-author-search="Shu, Yongqian" data-corresp-id="c4">Yongqian Shu<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-mail-medium"></use></svg></a><sup class="u-js-hide"><a href="#Aff1">1</a></sup> </li></ul><button aria-expanded="false" class="c-article-author-list__button"><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-down-medium"></use></svg><span>Show authors</span></button> <p class="c-article-info-details" data-container-section="info"> <a data-test="journal-link" href="/" data-track="click" data-track-action="journal homepage" data-track-category="article body" data-track-label="link"><i data-test="journal-title">Genome Medicine</i></a> <b data-test="journal-volume"><span class="u-visually-hidden">volume</span> 16</b>, Article number: <span data-test="article-number">133</span> (<span data-test="article-publication-year">2024</span>) <a href="#citeas" class="c-article-info-details__cite-as u-hide-print" data-track="click" data-track-action="cite this article" data-track-label="link">Cite this article</a> </p> <div class="c-article-metrics-bar__wrapper u-clear-both"> <ul class="c-article-metrics-bar u-list-reset"> <li class=" c-article-metrics-bar__item" data-test="access-count"> <p class="c-article-metrics-bar__count">556 <span class="c-article-metrics-bar__label">Accesses</span></p> </li> <li class="c-article-metrics-bar__item" data-test="altmetric-score"> <p class="c-article-metrics-bar__count">1 <span class="c-article-metrics-bar__label">Altmetric</span></p> </li> <li class="c-article-metrics-bar__item"> <p class="c-article-metrics-bar__details"><a href="/articles/10.1186/s13073-024-01405-5/metrics" data-track="click" data-track-action="view metrics" data-track-label="link" rel="nofollow">Metrics <span class="u-visually-hidden">details</span></a></p> </li> </ul> </div> </div> <section aria-labelledby="Abs1" data-title="Abstract" lang="en"><div class="c-article-section" id="Abs1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Abs1">Abstract</h2><div class="c-article-section__content" id="Abs1-content"><h3 class="c-article__sub-heading" data-test="abstract-sub-heading">Background</h3><p>Despite remarkable achievements in applying chimeric antigen receptor (CAR)-T cells to treat hematological malignancies, they remain much less effective against solid tumors, facing several challenges affecting their clinical use. We previously showed that multichain DNAX-activating protein (DAP) CAR structures could enhance the safety and efficacy of CAR-T cells when used against solid tumors. In particular, mesothelin (MSLN)-targeted CAR-T cell therapy has therapeutic potential in MSLN-positive solid tumors, including ovarian cancer and mesothelioma.</p><h3 class="c-article__sub-heading" data-test="abstract-sub-heading">Methods</h3><p><i>In vitro</i> cell killing assays and xenograft model were utilized to determine the anti-tumor efficacy of MSLN targeting DAP-CAR-T cells and other CAR-T cells. ELISA and flow cytometry analysis were used to assess the cytokine secretion capacity and proliferation ability. Eight patients with MSLN expression were enrolled to evaluate the safety and efficacy of MSLN-DAP CAR-T cell therapy. Single-cell sequencing was performed to explore the dynamics of immune cells in patients during treatment and to identify the transcriptomic signatures associated with efficacy and toxicity.</p><h3 class="c-article__sub-heading" data-test="abstract-sub-heading">Results</h3><p>We found that multichain DAP-CAR formed by combining a natural killer cell immunoglobulin-like receptor truncator and DAP12 exhibited better cytotoxicity and tumor-killing capacity than other natural killer cell-activated receptors associated with DAP12, DAP10, or CD3Z. The safety and efficacy of MSLN-DAP CAR-T cell therapy in patients with ovarian cancer and mesothelioma were evaluated in a single-arm, open-label clinical trial (ChiCTR2100046544); two patients achieved partial response, while four patients had a stable disease status. Furthermore, single-cell sequencing analysis indicated that KT032 CAR-T cell infusion could recruit more immune cells and temporarily remodel the TME.</p><h3 class="c-article__sub-heading" data-test="abstract-sub-heading">Conclusions</h3><p>Our study highlights the safety and therapeutic efficacy of multiple-chain DAP-CAR-T cell therapy targeting MSLN to treat patients with ovarian cancer and mesothelioma.</p><h3 class="c-article__sub-heading" data-test="abstract-sub-heading">Trial registration</h3><p>ChiCTR.org.cn, <a href="https://www.chictr.org.cn/ChiCTR2100046544">ChiCTR2100046544</a>. May 21, 2021.</p></div></div></section> <section data-title="Background"><div class="c-article-section" id="Sec1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec1">Background</h2><div class="c-article-section__content" id="Sec1-content"><p>Chimeric antigen receptor (CAR)-T cell therapy has been revolutionary, achieving remarkably effective and durable clinical outcomes against hematological malignancies [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 1" title="Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11:69." href="/articles/10.1186/s13073-024-01405-5#ref-CR1" id="ref-link-section-d125265713e770">1</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 2" title="Holstein SA, Lunning MA. CAR T-cell therapy in hematologic malignancies: a voyage in progress. Clin Pharmacol Ther. 2020;107:112–22." href="/articles/10.1186/s13073-024-01405-5#ref-CR2" id="ref-link-section-d125265713e773">2</a>]. In a recent clinical trial, patients with relapsed or refractory multiple myeloma treated with ciltacabtagene autoleucel (cilta-cel; a humanized anti-B-cell maturation antigen CAR-T cell therapy) achieved overall remission rates and stringent complete response rates of up to 84.6% and 73.1%, respectively, while their progression-free survival at 12 months was 75.9% [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 3" title="San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, Fernandez de Larrea C, Martinez-Lopez J, Moreau P, Touzeau C, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389:335–47." href="/articles/10.1186/s13073-024-01405-5#ref-CR3" id="ref-link-section-d125265713e776">3</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 4" title="Qu X, An G, Sui W, Wang T, Zhang X, Yang J, Zhang Y, Zhang L, Zhu D, Huang J, et al. Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma. Journal For Immunotherapy of Cancer. 2022;10:e005145." href="/articles/10.1186/s13073-024-01405-5#ref-CR4" id="ref-link-section-d125265713e779">4</a>]. However, CAR-T cell therapy shows limited efficacy against solid tumors due to their complexity. The most substantial obstacle to their use is the limited availability of suitable tumor-associated antigens [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 5" title="Martinez M, Moon EK. CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front Immunol. 2019;10:128." href="/articles/10.1186/s13073-024-01405-5#ref-CR5" id="ref-link-section-d125265713e782">5</a>]. Theoretically, the ideal antigen would be uniformly overexpressed on malignant cells with little or no expression on healthy cells, thus avoiding off-target toxicity [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 6" title="Qu C, Zhang H, Cao H, Tang L, Mo H, Liu F, Zhang L, Yi Z, Long L, Yan L, et al. Tumor buster - where will the CAR-T cell therapy “missile” go? Mol Cancer. 2022;21:201." href="/articles/10.1186/s13073-024-01405-5#ref-CR6" id="ref-link-section-d125265713e786">6</a>]. Moreover, an immunosuppressive tumor microenvironment and inaccessible tumor sites limit the efficacy of CAR-T cells [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Antonucci L, Canciani G, Mastronuzzi A, Carai A, Del Baldo G, Del Bufalo F. CAR-T therapy for pediatric high-grade gliomas: peculiarities, current investigations and future strategies. Front Immunol. 2022;13:867154." href="#ref-CR7" id="ref-link-section-d125265713e789">7</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Yu T, Yu SK, Xiang Y, Lu KH, Sun M. Revolution of CAR engineering for next-generation immunotherapy in solid tumors. Front Immunol. 2022;13:936496." href="#ref-CR8" id="ref-link-section-d125265713e789_1">8</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 9" title="Hong M, Clubb JD, Chen YY. Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell. 2020;38:473–88." href="/articles/10.1186/s13073-024-01405-5#ref-CR9" id="ref-link-section-d125265713e792">9</a>]. Considering these barriers, optimizing CAR structure may play a critical role in improving the ability of CAR-T cells to eradicate solid tumors.</p><p>CARs comprise an extracellular binding (generally a single-stranded variable fragment [scFv]), a transmembrane, a spacer, and one or more cytoplasmic domains [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 10" title="Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3:388–98." href="/articles/10.1186/s13073-024-01405-5#ref-CR10" id="ref-link-section-d125265713e798">10</a>]. ScFv is used to develop CAR-T therapies because of its small size, high affinity, and antigen specificity [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 11" title="Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, Song M, Miele MM, Li Z, Wang P, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018;36:847–56." href="/articles/10.1186/s13073-024-01405-5#ref-CR11" id="ref-link-section-d125265713e801">11</a>]. It comprises the antibody V<sub>H</sub> and V<sub>L</sub> regions connected by a linker. However, the variable structural domain of scFv (V<sub>H</sub>-V<sub>L</sub>) may induce CAR aggregation and trigger a cytotoxic signaling cascade that leads to T cell exhaustion [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 12" title="Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, Smith JP, Walker AJ, Kohler ME, Venkateshwara VR, et al. 4–1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21:581–90." href="/articles/10.1186/s13073-024-01405-5#ref-CR12" id="ref-link-section-d125265713e813">12</a>]. Nanoantibodies (also known as VHH) can avoid the above shortcomings [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13" title="Muyldermans S. Nanobodies: natural single-domain antibodies. Annu Rev Biochem. 2013;82:775–97." href="/articles/10.1186/s13073-024-01405-5#ref-CR13" id="ref-link-section-d125265713e816">13</a>]. Thus, VHH antibodies are currently used as alternatives to scFv as the target structural domain for CAR [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 14" title="Safarzadeh Kozani P, Naseri A, Mirarefin SMJ, Salem F, Nikbakht M, Evazi Bakhshi S, Safarzadeh Kozani P. Nanobody-based CAR-T cells for cancer immunotherapy. Biomarker Research. 2022;10:24." href="/articles/10.1186/s13073-024-01405-5#ref-CR14" id="ref-link-section-d125265713e819">14</a>]. Additionally, some studies have genetically engineered CAR-T cells by recruiting chemokines, such as chemokine (C–C motif) ligand (CCL19) and interleukin (IL)-7, and synthesizing T cell receptor/synthetic T cell receptor and antigen receptor double-chain chimeric receptors to enhance the antitumor capacity of conventional CAR-T cells [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 15" title="Adachi K, Kano Y, Nagai T, Okuyama N, Sakoda Y, Tamada K. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat Biotechnol. 2018;36:346–51." href="/articles/10.1186/s13073-024-01405-5#ref-CR15" id="ref-link-section-d125265713e822">15</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 16" title="Wang J, Zhang X, Zhou Z, Liu Y, Yu L, Jia L, Yang J, Li J, Yu H, Li W, et al. A novel adoptive synthetic TCR and antigen receptor (STAR) T-Cell therapy for B-Cell acute lymphoblastic leukemia. Am J Hematol. 2022;97(8):992–1004." href="/articles/10.1186/s13073-024-01405-5#ref-CR16" id="ref-link-section-d125265713e825">16</a>]. Our previous studies have demonstrated that multichain CAR structures, such as killer cell immunoglobulin-like receptors (KIR)-CAR/DNAX-activating protein (DAP12), could enhance the safety and efficacy of CAR-T cells for solid tumors; in particular, multichain CAR-T targeting mesothelin (MSLN) significantly improved T cell depletion [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 17" title="Wang E, Wang L-C, Tsai C-Y, Bhoj V, Gershenson Z, Moon E, Newick K, Sun J, Lo A, Baradet T, et al. Generation of potent T-cell immunotherapy for cancer using DAP12-based, multichain, chimeric immunoreceptors. Cancer Immunol Res. 2015;3:815–26." href="/articles/10.1186/s13073-024-01405-5#ref-CR17" id="ref-link-section-d125265713e829">17</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 18" title="Xu T, Wang C, Chen X, Bai J, Wang E, Sun M. Coexpression of c-Jun in multiple-chain DAP-CAR-engineered T-cells for solid tumor therapy. Immunotherapy. 2022;14:1457–66." href="/articles/10.1186/s13073-024-01405-5#ref-CR18" id="ref-link-section-d125265713e832">18</a>]. MSLN is a glycosylated phosphatidylinositol-anchored membrane glycoprotein that is usually confined to tumor differentiation antigens on the mesothelium [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 19" title="Pastan I, Hassan R. Discovery of mesothelin and exploiting it as a target for immunotherapy. Can Res. 2014;74:2907–12." href="/articles/10.1186/s13073-024-01405-5#ref-CR19" id="ref-link-section-d125265713e835">19</a>]. Specifically, the level of MSLN in the serum, which is considered a tumor marker, is elevated in ovarian cancer and mesothelioma [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 20" title="Yuan J, Kashiwagi S, Reeves P, Nezivar J, Yang Y, Arrifin NH, Nguyen M, Jean-Mary G, Tong X, Uppal P, et al. A novel mycobacterial Hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma. J Hematol Oncol. 2014;7:15." href="/articles/10.1186/s13073-024-01405-5#ref-CR20" id="ref-link-section-d125265713e838">20</a>]. MSLN is significantly overexpressed in various solid tumors but is either unexpressed or expressed at very low levels in normal tissues [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 21" title="Klampatsa A, Dimou V, Albelda SM. Mesothelin-targeted CAR-T cell therapy for solid tumors. Expert Opin Biol Ther. 2021;21:473–86." href="/articles/10.1186/s13073-024-01405-5#ref-CR21" id="ref-link-section-d125265713e841">21</a>]. Thus, MSLN has emerged as an attractive target for developing novel immunotherapies. Previous studies have indicated that MSLN-targeted CAR-T cells can treat ovarian cancer, while anti-MSLN CAR-T cells show promise for improving the prognosis of patients with malignant mesothelioma [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22" title="Schoutrop E, El-Serafi I, Poiret T, Zhao Y, Gultekin O, He R, Moyano-Galceran L, Carlson JW, Lehti K, Hassan M, et al. Mesothelin-specific CAR T cells target ovarian cancer. Can Res. 2021;81:3022–35." href="/articles/10.1186/s13073-024-01405-5#ref-CR22" id="ref-link-section-d125265713e844">22</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 23" title="Castelletti L, Yeo D, van Zandwijk N, Rasko JEJ. Anti-mesothelin CAR T cell therapy for malignant mesothelioma. Biomarker Research. 2021;9:11." href="/articles/10.1186/s13073-024-01405-5#ref-CR23" id="ref-link-section-d125265713e848">23</a>]. Based on these findings, we designed a human anti-MSLN CAR and conducted a clinical trial in patients with MSLN-expressing ovarian cancer or mesothelioma to further explore the clinical safety and feasibility of MSLN CAR-T cell therapy (ClinicalTrials.gov: ChiCTR2100046544) at the First Affiliated Hospital of Nanjing Medical University, China, between August 2021 and February 2024.</p><p>Our current lack of a comprehensive description of T cell behavior <i>in vivo</i> has complicated research and hindered the widespread application of CAR-T cell therapy, which has various adverse reactions and low remission rates. Therefore, a more thorough exploration of the mechanism of CAR-induced T cell activation will help us understand the reasons for the success or failure of CAR-T cell immune responses. Single-cell RNA sequencing (scRNA-seq) technology has progressed rapidly and has become a major tool for deciphering immune cell phenotypes in immunotherapy [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 24" title="Castellanos-Rueda R, Di Roberto RB, Schlatter FS, Reddy ST. Leveraging single-cell sequencing for chimeric antigen receptor T cell therapies. Trends Biotechnol. 2021;39:1308–20." href="/articles/10.1186/s13073-024-01405-5#ref-CR24" id="ref-link-section-d125265713e857">24</a>]. In addition, scRNA-seq can help identify the behavioral and molecular profiles of CAR-T cells before and after treatment. Therefore, we performed scRNA-seq analyses on CAR-T cells, tissue, and blood (pre- and post-treatment) samples from patients receiving MSLN-targeted CAR-T cell (KT032) therapy. We attempted to determine the transcriptional profile of cells associated with CAR-T cell infusion.</p></div></div></section><section data-title="Methods"><div class="c-article-section" id="Sec2-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec2">Methods</h2><div class="c-article-section__content" id="Sec2-content"><h3 class="c-article__sub-heading" id="Sec3">Study design </h3><p>This was a researcher-initiated, single-arm, open-label, single-center, first-in-human clinical trial (ChiCTR2100046544) designed to evaluate the safety and efficacy of KT032 in patients with mesothelin-expressing advanced solid tumors between August 2021 and February 2024, at the First Affiliated Hospital of Nanjing Medical University. Tumor biopsies were evaluated for mesothelin (MSLN) expression at enrolment, followed by leukapheresis and KT032 manufacture. Positron emission tomography (PET) or computerized tomography (CT) scans were performed at baseline and at 1, 2, 3, and 6 months after KT032 infusion. The primary objective of this phase I study was to evaluate safety and efficacy. The secondary objective was to assess the efficacy of this treatment by determining the objective response rate, disease control rate, duration of response, PFS, and OS. Responding patients included those who achieved partial or complete response, whereas non-responders included those with PD. The exploratory objective was correlating responses with KT032 expansion, persistence, and functionality. For the phase I dose escalation part of the study, patients received a single intravenous infusion dose with or without LD. The protocol-specific DLs were 0.5 × 10<sup>6</sup>/kg, 1 × 10<sup>6</sup>/kg, and 1.5 × 10<sup>6</sup>/kg. Informed consent was obtained from all participants in the clinical trial, as stated in the clinical trial protocol. Participants were not compensated for their participation in the clinical trial. The trial was approved by the institutional review boards of the participating center, and all patients provided written informed consent. The participating site was Jiangsu Province Hospital, Jiang Su, China. Eight subjects with ovarian cancer and mesothelioma were enrolled from August 31, 2021, to September 16, 2022.</p><h3 class="c-article__sub-heading" id="Sec4">Patient eligibility</h3><p>Eligibility for the study required patients to meet all the following criteria: Ages ranging from 18 to 70 years, regardless of sex. Histologically or pathologically diagnosed advanced ovarian cancer or malignant mesothelioma. Recurrence after receiving second-line or higher treatment, such as chemotherapy or targeted drugs. The tumor was pathologically reviewed with confirmed positive mesothelin expression on ≥ 15% of tumor cells using immunohistochemistry. The patients had at least one lesion that met the evaluable and measurable criteria defined by RECIST version 1.1. ECOG performance status of 0 or 1. The patient must have adequate organ function according to the following laboratory values: left ventricular ejection fraction ≥ 40% as measured using resting echocardiogram; creatinine ≤ 200 μmol/L; absolute neutrophil count ≥ 1.5 × 10<sup>9</sup>/L; platelets ≥ 80 × 10<sup>9</sup>/L; hemoglobin ≥ 80 g/L; oxygen saturation of blood > 91%; total bilirubin ≤ 2 × ULN; alanine aminotransferase, and aspartate aminotransferase ≤ 2.5 × ULN. Venous access with venous or leukapheresis. The patients voluntarily participated in the study and signed an informed consent form.</p><p>Patients who met any of the following criteria were excluded from the study. Pregnant and lactating women. Patients who underwent chemotherapy or radiotherapy within 3 days before leukapheresis. Patients were administered systemic steroid drugs within the first 5 days of the blood collection period (excluding those who had recently or are currently using inhaled steroids). Patients were administered drugs that stimulated bone marrow hematopoietic cell generation within 5 days before blood collection. Patients who had previously used gene or cell therapy products. Patients who had a history of epilepsy or other central nervous system diseases. Active infection with HIV, hepatitis B, hepatitis C, or human T lymphotropic virus. Patients who suffered from other tumors in the past 5 years. Patients with severe pleural and ascitic fluid. Patients who had active or uncontrollable infections requiring systemic treatment within 14 days before enrollment. Patients who received other antitumor treatments (excluding pretreatment chemotherapy) within 2 weeks before the start of the study. Patients who were unable or unwilling to comply with the study protocol requirements, as judged by the researchers.</p><h3 class="c-article__sub-heading" id="Sec5">IHC analysis</h3><p>Mesothelin expression was assessed in all patients by pathology laboratory of Jiangsu Provincial Hospital using a validated IHC assay performed on 3 ~ 5 mm-thick sections of formalin-fixed paraffin-embedded (FFPE) tumor tissue. Immunostaining was performed which is a monoclonal primary antibody that binds to mesothelin in paraffin-embedded tissue sections. Mesothelin protein expression was determined using both the percentage of stained viable tumor cells and the staining intensity. Study eligibility required biopsy tissue to express membranous mesothelin in at least 15% of the viable tumor cells at a staining intensity of 2 + .</p><h3 class="c-article__sub-heading" id="Sec6">KT032 manufacturing, preconditioning, and bridging therapy</h3><p>The autologous MSLN-targeted CAR-T cells (KT032) were manufactured in the GMP facility at Nanjing CART Medical Technology Co., Ltd. Subjects completed single apheresis at the clinical center and transported to the GMP facility. Then, PBMCs were isolated and purified by Ficoll density gradient centrifugation. CD3 + T cells were separated and seeded in culture medium supplemented with human IL-2. CD3/CD28 dynabeads were used for T cell activation. After 24 h of activation, T cells were transduced with a lentivirus encoding MSLN-targeted CAR. T cells were expanded in the presence of Optimizer medium (Gibco) and IL-2. KT032 was harvested and formulated after the cell quantity reached the required dose. The in-process and release tests were performed for each lot of KT032 cells. After release, the patients received an infusion of KT032 (day 0, week 0) within 7 days of preconditioning therapy. Nonsteroidal anti-inflammatory drugs and antihistamines were administered within half an hour of cell infusion. Preconditioning therapy was administered as follows: fludarabine on days –4 and –3; cyclophosphamide on days –4, –3, and –2. Bridging chemotherapy was allowed for patients whose tumor burden was heavy or who had the potential to rapidly progress, according to the investigators’ discretion during the KT032 manufacturing period. Investigators could also individualize the regimen according to the patient’s previous antitumor therapy and clinical condition.</p><h3 class="c-article__sub-heading" id="Sec7">KT032 detection using qPCR in peripheral blood</h3><p>The persistence of KT032 cells in peripheral blood was determined by quantifying the junction region between the 4-1BB and T2A regions of the lentivirus transgene using qPCR. Patient samples (2 mL of peripheral blood) were collected in K2EDTA tubes at baseline and after infusion. gDNA was extracted using the QIAamp DNA Midi Kit (Qiagen, Hilden, Germany). The standard curve for transcript copy number was established by amplifying a tenfold serial dilution of a plasmid encoding KT032 CAR from 4 × 10<sup>6</sup> to 40 copies. The number of transgene copies per microgram of gDNA was determined using a 7500 Fast (Thermo Fisher Scientific) instrument, with samples in triplicate.</p><h3 class="c-article__sub-heading" id="Sec8">KT032 detection using flow cytometry in peripheral blood</h3><p>Peripheral whole blood samples were used to lyse red blood cells stained with Mouse Anti-Human CD45-PE (BD Biosciences, 555483), mouse anti-human CD3-FITC (BD Biosciences, 555332), Biotin-SP (long spacer) AffiniPure Goat Anti-Mouse IgG, F(ab') fragment specific (Jackson, 115–065-072) antibodies, and streptavidin-APC (SouthernBiotech, 7100-11 M) for CAR detection. Flow cytometry was performed using a NovoCyte 3110 instrument (Agilent).</p><h3 class="c-article__sub-heading" id="Sec9">Cytokine measurement</h3><p>Baseline and post-infusion peripheral blood samples were collected from patients and processed for plasma. Plasma was analyzed for the following cytokines: IL-2, IL-4, IL-6, IL-10, TNF-α, and IFN-γ using a BD cytokine cytometric bead array kit and conducted according to the manufacturer’s guidelines.</p><h3 class="c-article__sub-heading" id="Sec10">Single-cell sequencing</h3><p>The single-cell suspension was counted using a Countess® II Automated Cell Counter based on trypan blue staining. The optimum concentration of cells should be at least 700 cells/µL and the proportion of living cells was more than 80% by quality control. The cell suspension, barcoded gel beads, and partitioning oil were loaded onto a 10 × Genomics Chromium Chip that generates single-cell Gel Bead-In-EMlusion (GEMs). Captured cells were lysed, and the transcripts were barcoded using reverse transcription inside individual GEMs. Then, cDNA and cell barcodes were PCR-amplified. The scRNA-seq libraries were constructed using Chromium Next GEM Single Cell 5’ Reagent Kits v2.0 (PN-1000395 and PN-1000352) and sequenced on an Illumina NovaSeq6000 platform to generate 2 × 150-bp paired-end reads. The single cell by gene matrices for each sample were calculated by using Cell Ranger (version 5.0.0) with the human reference genome version GRCh38. Before cell clustering by using the Seurat R package (version 3.1.1), high-quality cells were preserved by the following parameters: first, each sample was multicell-filtered using DoubletFinder software, followed by further filtering based on the number of genes identified, the number of unique molecular identifiers (UMIs), and the proportion of mitochondrial genes expressed in individual cells. In ovarian cancer, cells that were expressing 200 to 7800 genes, less than 56,000 UMIs, and mitochondrial gene percent of < 25% for further analysis. In mesothelioma, the number of genes expressed per cell ranged from 200 to 10,000 and less than 30,000 UMIs per cell, and mitochondrial gene expression of < 20% was retained. In manufactured CAR-T cells, the number of genes expressed per cell ranged from 210 to 7000, the number of UMIs per cell < 54,000, and maximum mitochondrial content of 15% as a high cutoff. Gene expression of filtered matrices was normalized through “LogNormalize” method and used Harmony for data merging and batch effect correction. For visualization of the high-dimension data, principal component analysis (PCA) was performed for dimensional reduction with top2000 highly variable genes selected by FindVariableFeature. Cell clustering was used FindClusters with 10 PCs and 0.5 resolution parameter. Cell’s cluster information was generated to visualize with the same PCs using Uniform Manifold Approximation and Projection (UMAP).</p><h3 class="c-article__sub-heading" id="Sec11">Gene differential expression and enrichment analysis</h3><p>In the Seurat package, FindMarkers was used to analyze the differences between the two groups of cells. The threshold is | log<sub>2</sub>FC |≥ 1, and the ratio of cells expressing the target gene in any group is ≥ 0.1. The MAST obstacle model was used to test the significance of differences. Significant <i>p</i>-values of the differentially expressed genes were corrected using Seurat’s Benjamini–Hochberg method. Genes with corrected <i>p</i>-values ≤ 0.05 were selected as significant DEGs and were used for subsequent enrichment analysis. Gene Ontology (GO) is an internationally standardized gene functional classification system with three ontologies: molecular function, cellular component, and biological process. To reveal the biological function of DEPs, all peak-related genes were mapped to GO terms in the GO database [GO.db 3.8.2 (April 26, 2019)]. Gene numbers were calculated for every term and significantly enriched GO terms in DEG compared with the genome background were defined by a hypergeometric test. Genes interact with each other to perform specific biological functions. Pathway-based analysis helps further understand the biological functions of genes. The Kyoto Encyclopedia of Genes and Genomes is a major public pathway-related database (Release 94). Pathway enrichment analysis identified significantly enriched metabolic pathways or signal transduction pathways in the DEGs compared with the whole genome background.</p><h3 class="c-article__sub-heading" id="Sec12">Xenograft model</h3><p>The NOD/ShiLtJGpt-Prkdcem26Cd52Il2rgem26Cd22/Gpt (NSG) mice were purchased from Gempharmatech (Nanjing, China) and raised under SPF condition. Subcutaneous xenografts were established by injecting 1 × 107 SKOV3 cells suspended in 200 µl PBS subcutaneously into nude mice (Gempharmatech, Nanjing, China). Tumor volumes were examined twice a week using the following formula: volume (mm3) = length × width2/2. Mice were humanely euthanized with carbon dioxide (CO<sub>2</sub>) inhalation method according to ethical guidelines at the designated time point of 5 weeks after inoculation. The study was approved by the Institutional Ethics Committee of Nanjing Medical University (IACUC2103036).</p><h3 class="c-article__sub-heading" id="Sec13">Statistical analysis</h3><p>Experimental data were analyzed using GraphPad Prism version 8.0 and the SPSS software package. Differences between groups were assessed using unpaired Student’s <i>t</i>-tests or two-way ANOVA, with statistical significance defined as a <i>P</i> < 0.05. The results are presented as mean with standard deviation, and error bars were labeled in the graphs to illustrate the differences in measurements between replicates.</p></div></div></section><section data-title="Results"><div class="c-article-section" id="Sec14-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec14">Results</h2><div class="c-article-section__content" id="Sec14-content"><h3 class="c-article__sub-heading" id="Sec15">MSLN-KIR CAR-T cells show robust cytotoxicity and antitumor efficacy <i>in vitro</i> and <i>in vivo</i> </h3><p>Besides KIR-activation receptors, other activation receptors exist on the membranes of natural killer (NK) cells, including NKP44, NKP46, NKP30, and NKG2D. The functionality of these receptors in the CAR form of the NKR complex, instead of in the KIR, remains unknown. Here, we engineered new multiple-chain MSLN targeting CARs, each containing only one of the NKP44, NKP46, NKP30, or NKG2D intracellular, transmembrane, and short extracellular domains (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/10.1186/s13073-024-01405-5#Fig1">1</a>A). As shown in Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/10.1186/s13073-024-01405-5#Fig1">1</a>B, flow cytometry revealed that all CARs were successfully expressed and presented to the T cell membrane, with the highest positivity for the KIR CAR. No significant differences were observed in the proliferative capacity of T cells transduced with different CAR structures (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/10.1186/s13073-024-01405-5#Fig1">1</a>C). Furthermore, all CAR-T cells showed robust tumor cell-killing ability against MSLN high-expressing OVCAR3 cells; however, KIR CAR-T cells were significantly better at killing MSLN low-expressing SKOV3 cells (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/10.1186/s13073-024-01405-5#Fig1">1</a>D). Additionally, KIR CAR-T cells secreted more interferon (IFN)-γ than other CAR-T cells under SKOV3 cell stimulation. In contrast, the secretion of IFN-γ by 30 CAR-T and two-dimensional (2D) CAR-T cells was relatively lower than that in other CAR-T cells when co-cultured with OVCAR3 cells (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/10.1186/s13073-024-01405-5#Fig1">1</a>E). Moreover, KIR CAR-T cells secreted a higher level of IL-2 following stimulation with OVCAR3 cells than 30 CAR-T and 2D CAR-T cells (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/10.1186/s13073-024-01405-5#Fig1">1</a>F). Moreover, the Tcm ratio of KIR CAR-T cells was higher than that of the other CAR-T cells (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/10.1186/s13073-024-01405-5#Fig1">1</a>G). Since the cytotoxicity and cytokine secretion capacity of 2D CAR-T cells were poor, our subsequent <i>in vivo</i> efficacy assessments did not include 2D CAR-T cells. In the SKOV3 subcutaneous xenograft model, mice were infused with different CAR-T cells or control non-transduced (NTD) cells. As shown in Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/10.1186/s13073-024-01405-5#Fig1">1</a>H, only KIR CAR-T cells substantially inhibited or eradicated tumors, whereas the other CAR-T cells merely slowed tumor growth. In conclusion, KIR CAR confers T cells with stronger cytotoxic and antitumor effects than other activated NKR CARs, which could be a potential therapeutic strategy for inducing MSLN expression in patients with cancer.</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-1" data-title="Fig. 1"><figure><figcaption><b id="Fig1" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 1</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/10.1186/s13073-024-01405-5/figures/1" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13073-024-01405-5/MediaObjects/13073_2024_1405_Fig1_HTML.png?as=webp"><img aria-describedby="Fig1" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13073-024-01405-5/MediaObjects/13073_2024_1405_Fig1_HTML.png" alt="figure 1" loading="lazy" width="685" height="435"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-1-desc"><p>Killer cell immunoglobulin-like receptor (KIR) Chimeric antigen receptor (CAR) is the optimal CAR structure based on natural killer (NK) cell activation receptors. <b>A</b> CAR design based on various NK cell activation receptor combinations. <b>B</b> Flow cytometric analysis of CAR-positive T cell percentage 7 days after lentiviral transduction. <b>C</b> Expansion of different CAR-T and control non-transduced (NTD) cells. <b>D</b> xCELLigence RTCA system evaluation of <i>in vitro</i> cytotoxicity of different MSLN CAR-T and NTD cells against SKOV37 and OVCAR3 cells. <b>E</b> ELISA analysis of IFN-γ secretion by different MSLN CAR-T cells following co-culture with SKOV37 and OVCAR3 cells (E:T, 2:1). <b>F</b> ELISA analysis of IL-2 secretion by different MSLN CAR-T cells following co-culture with OVCAR3 cells (E:T, 2:1). <b>G</b> Flow cytometry-based gating strategy for identifying Tn, Tcm, Tem, and Tef subsets in NTD and different MSLN CAR-T cells. <b>H</b> Tumor growth curves demonstrating the antitumor efficacy of NTD or different MSLN CAR-T cells in a SKOV3-derived xenograft model. Statistical significance: **<i>P</i> < 0.01</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/10.1186/s13073-024-01405-5/figures/1" data-track-dest="link:Figure1 Full size image" aria-label="Full size image figure 1" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><h3 class="c-article__sub-heading" id="Sec16">Efficacy of MSLN-KIR CAR-T cells as a treatment for ovarian cancer and mesothelioma</h3><p>To evaluate the safety and efficacy of MSLN-KIR CAR-T cells (KT032) in ovarian cancer and mesothelioma therapy, we conducted a single-arm, open-label clinical trial at the First Affiliated Hospital of Nanjing Medical University, China, between August 2021 and February 2024. Nine MSLN-positive patients with advanced recurrent refractory ovarian cancer (eight patients) or mesothelioma (one patient) were enrolled in the trial after MSLN screening, and signed informed consent forms were obtained from all participants from August 2021 to September 2022. All nine patients underwent leukapheresis, which failed in one patient with ovarian cancer (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/10.1186/s13073-024-01405-5#Fig2">2</a>A). All eight patients with successful leukapheresis had previously received at least two prior standard lines of therapy, which are shown in Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/10.1186/s13073-024-01405-5#Tab1">1</a>. MSLN KIR CAR-T cells were manufactured via lentiviral transduction in the GMP facility at Nanjing CART Medical Technology Co., Ltd., then cryopreserved and transferred to the First Affiliated Hospital of Nanjing Medical University. Among the eight patients, three received a low dose (0.5 × 10<sup>6</sup> cells/kg), two received a medium dose (1.0 × 10<sup>6</sup> cells/kg), and three received a high dose (1.5 × 10<sup>6</sup> cells/kg) of CAR-T cells, which were infusion following fludarabine- and cyclophosphamide-mediated lymphodepletion. We adjusted the doses of fludarabine (50–93 mg∙m<sup>−2</sup> day<sup>−1</sup>, 1 day) and cyclophosphamide (500–930 mg∙m<sup>−2</sup> day<sup>−1</sup>, 1 day) according to the physical condition of each patient (Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/10.1186/s13073-024-01405-5#Tab1">1</a>). As of the evaluation cutoff date (28 days after infusion), two of eight patients discontinued this study after their CAR-T cell infusion due to rapid disease progression (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/10.1186/s13073-024-01405-5#Fig2">2</a>A).</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-2" data-title="Fig. 2"><figure><figcaption><b id="Fig2" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 2</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/10.1186/s13073-024-01405-5/figures/2" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13073-024-01405-5/MediaObjects/13073_2024_1405_Fig2_HTML.png?as=webp"><img aria-describedby="Fig2" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13073-024-01405-5/MediaObjects/13073_2024_1405_Fig2_HTML.png" alt="figure 2" loading="lazy" width="685" height="377"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-2-desc"><p><b>A</b>–<b>I</b> Evaluation of the efficacy and safety of KT032 in patients with ovarian cancer and mesothelioma. <b>A</b> The study schema is shown. Subjects were screened for enrolment, underwent leukapheresis for CAR-T cell manufacturing, and infused with varying doses of CAR-T cells. <b>B</b> A swimmer plot was drawn to show patients’ response and time to disease progression in months. <b>C</b> A waterfall plot was drawn to show the determined percent change in tumor burden. <b>D</b> CT images showing the longest dimension of an initially responding tumor lesion at baseline, and at different time points after receiving KT032 cell infusion</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/10.1186/s13073-024-01405-5/figures/2" data-track-dest="link:Figure2 Full size image" aria-label="Full size image figure 2" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><div class="c-article-table" data-test="inline-table" data-container-section="table" id="table-1"><figure><figcaption class="c-article-table__figcaption"><b id="Tab1" data-test="table-caption">Table 1 Patient characteristics</b></figcaption><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="table-link" data-track="click" data-track-action="view table" data-track-label="button" rel="nofollow" href="/articles/10.1186/s13073-024-01405-5/tables/1" aria-label="Full size table 1"><span>Full size table</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>Of the six evaluable patients, two achieved partial response (PR), and four achieved stable disease (SD) status. However, all the six patients progressed within 9 months, and two patients were still alive until the latest follow-up. The median progression-free survival (PFS) was 5.5 months, and the median overall survival (OS) was 10.5 months (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/10.1186/s13073-024-01405-5#Fig2">2</a>B and C). An enhanced computed tomography (CT) scan indicated that liver metastases were reduced by 31% and peritoneal effusion disappeared in Patient 1. Patient 2 exhibited a 42% reduction in the total maximum diameter of the measurable lesion. Meanwhile, the changes in tumor lesions or metastases were not significant in other patients (− 18.7% to + 4.56%) (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/10.1186/s13073-024-01405-5#Fig2">2</a>D–I). Notably, the level of cancer antigen 125 (CA125) in Patient 1 was significantly decreased from 1687 U/mL to 150 U/mL 32 d after CAR-T therapy, while Patients 2 and 3 also showed a decrease in CA125 after CAR-T treatment, albeit with a rebound increase observed at day 20. For Patients 4 and 5, CAR-T therapy failed to reduce the CA125 level (Additional file2: Fig S1A-B).</p><h3 class="c-article__sub-heading" id="Sec17">Pharmacokinetics and safety of MSLN-KIR CAR-T cells</h3><p>Flow cytometry and qPCR analysis showed that MSLN-KIR CAR-T cells in the peripheral blood peaked at approximately 7 days (6–10 days) after infusion (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/10.1186/s13073-024-01405-5#Fig3">3</a>A). However, the peak of CAR-T cell expansion represented by flow cytometry was not very consistent with data from the qPCR analysis, which may be due to the discrepancy in total cell count in peripheral blood. Activation and expansion of MSLN-KIR CAR-T cells induced the secretion of high levels of cytokines IL6 and IFNγ in five of six patients (besides Patient 6, who showed slight changes in IL6 and IFNγ levels), while levels of TNFα, IL2, IL4, and IL10, etc. were slightly affected by CAR-T cell treatment. As a result, all five patients besides Patient 6, developed cytokine release syndrome (CRS) (one patient with grade 3, four patients with grade 1) accompanied by high levels of IL-6 and IFNγ (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/10.1186/s13073-024-01405-5#Fig3">3</a>B–G); accordingly, corticosteroids, indomethacin, or tocilizumab (8 mg/kg) were used to treat CRS. Among the five patients with CRS, Patient 1 experienced immune pneumonia and received mechanical ventilation and high-dose corticosteroids prednisone (1 g/day) combined with tocilizumab (8 mg/kg). The patient’s condition improved significantly after treatment. Moreover, CT evaluation indicated that immune-related pneumonia was relieved (Additional file2: Fig S1C). Notably, the proliferation of CAR-T cells was limited due to the high-dose corticosteroids in this patient, while the number of CAR-T cells increased again (constituting 6.65% of the total peripheral blood T cells) on the 25th day after infusion, indicating that CAR-T cell activity may be restored by the withdrawal of corticosteroids (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/10.1186/s13073-024-01405-5#Fig3">3</a>A and B). The other most common adverse effects during the MSLN-KIR CAR-T cell therapy were nausea, which was observed in 83% (5/6 patients), and no immune effector cell-associated neurotoxicity syndrome was observed in any patients. Other adverse events related to the MSLN-KIR CAR-T cell treatments were summarized in Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/10.1186/s13073-024-01405-5#Tab2">2</a>.</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-3" data-title="Fig. 3"><figure><figcaption><b id="Fig3" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 3</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/10.1186/s13073-024-01405-5/figures/3" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13073-024-01405-5/MediaObjects/13073_2024_1405_Fig3_HTML.png?as=webp"><img aria-describedby="Fig3" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13073-024-01405-5/MediaObjects/13073_2024_1405_Fig3_HTML.png" alt="figure 3" loading="lazy" width="685" height="454"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-3-desc"><p>KT032 cell pharmacokinetics and cytokine levels in peripheral blood of patients. <b>A</b> The pharmacokinetics of KT032 cell copy number in patients were evaluated using qPCR. The pharmacokinetics of KT032 cells in patients’ peripheral blood were assessed using qPCR and flow cytometry. <b>B</b> ELISA analysis of IFN-γ levels in patients’ peripheral blood. <b>C</b> ELISA analysis of TNFα levels in patients’ peripheral blood. <b>D</b> ELISA analysis of IL-2 levels in patients’ peripheral blood. <b>E</b> ELISA analysis of IL-4 levels in patients’ peripheral blood. <b>F</b> ELISA analysis of IL-6 levels in patients’ peripheral blood. <b>G</b> ELISA analysis of IL-10 levels in patients’ peripheral blood</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/10.1186/s13073-024-01405-5/figures/3" data-track-dest="link:Figure3 Full size image" aria-label="Full size image figure 3" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><div class="c-article-table" data-test="inline-table" data-container-section="table" id="table-2"><figure><figcaption class="c-article-table__figcaption"><b id="Tab2" data-test="table-caption">Table 2 Summary of reported adverse events related to KT032 cells by grade reported in more than one subject (unless<b> ≥ </b>grade 3)</b></figcaption><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="table-link" data-track="click" data-track-action="view table" data-track-label="button" rel="nofollow" href="/articles/10.1186/s13073-024-01405-5/tables/2" aria-label="Full size table 2"><span>Full size table</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><h3 class="c-article__sub-heading" id="Sec18">Associations between MSLN CAR-T cell subtypes and clinical response</h3><p>The proportion of CAR-positive T cells in the manufactured CAR-T products and the CD4/CD8 ratio of CAR-T cells were not related to patient responses. We hypothesized that subpopulations and functional gene signatures of individual CAR-T products may influence patient outcomes; hence, we conducted scRNA-seq on MSLN CAR-T cells produced from four patients. Cryopreserved CAR-T cells from four patients with ovarian cancer undergoing treatment were thawed and prepared for scRNA-seq. The number of CAR-T cells that passed the initial quality control ranged from 8093 to 9498 per patient. Further dimensionality reduction and unsupervised clustering analysis showed that 12 clusters (0–11) were identified, and CAR-T cells belonging to each cluster were detectable in all four patients. Next, we evaluated the differences in the clusters and transcriptomic signatures of the KT032 products from patients who had a good response (R) compared with those who did not. Patients 1 (HUME) and 4 (YUQI) were defined as having a good response, as Patient 1 achieved PR, while Patient 4 demonstrated signs of tumor lysis, as evaluated using CT during the two weeks after KT032 treatment. Meanwhile, Patients 5 (YLFE) and 6 (SXME) were defined as not responding, since both were determined to have progressed using fluorodeoxyglucose positron emission tomography. No significant differences in CD4 + and CD8 + T cell subsets were observed between the two patient groups (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/10.1186/s13073-024-01405-5#Fig4">4</a>A–C). Differential gene expression analysis showed significant upregulation of GSTM1 and NOTCH2NLB gene expression in CAR-T cells from the responding patients (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/10.1186/s13073-024-01405-5#Fig4">4</a>D). GSTM11 is essential for controlling the intracellular redox state of immune cells, while NOTCH2NLB is functionally similar to the intracellular structural domain (NICD) of Notch1 and activates the Notch signaling pathway. These findings indicate that the control of the intracellular redox state and the Notch signaling pathway may be important for the long-term antitumor activity of MSLN-KIR CAR-T cells.</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-4" data-title="Fig. 4"><figure><figcaption><b id="Fig4" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 4</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/10.1186/s13073-024-01405-5/figures/4" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13073-024-01405-5/MediaObjects/13073_2024_1405_Fig4_HTML.png?as=webp"><img aria-describedby="Fig4" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13073-024-01405-5/MediaObjects/13073_2024_1405_Fig4_HTML.png" alt="figure 4" loading="lazy" width="685" height="387"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-4-desc"><p>Single-cell sequencing analysis of the properties of KT032 from different patients. <b>A</b> The bar chart shows the proportional distribution (left) and the absolute distribution (right) of various T cell types in four cases with KT032 cell transfusion. <b>B</b> The bubble plot displays the expression levels of key marker genes in various types of T cells with KT032 cell transfusion. The size of the bubbles represents the percentage of gene expression in the cells, and the color of the bubbles represents the average level of gene expression. <b>C</b> The distribution of various types of T cells in the <i>t</i>-distributed stochastic neighbor embedding (tSNE) plot for four cases with KT032 cell transfusion. <b>D</b> The volcano plot of the differential analysis shows the upregulated and downregulated genes in various T cell clusters with KT032 cell transfusion products compared with PR samples. Upregulated genes are shown in red, downregulated genes in blue, and the symbols of the top five genes with the largest differences in upregulation and downregulation are labeled. The differential threshold is set as fold change > 2 and <i>P</i> < 0.05</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/10.1186/s13073-024-01405-5/figures/4" data-track-dest="link:Figure4 Full size image" aria-label="Full size image figure 4" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><h3 class="c-article__sub-heading" id="Sec19">Gene expression signatures of immune and cancer cells in the ovarian cancer tumor microenvironment (TME) after MSLN-CAR-T cells infusion determined using scRNA-seq</h3><p>To further explore whether immune cell components and their gene signatures in the immune microenvironment of patients with ovarian cancer correlated with clinical responses, we first compared the representation of immune cell types and functional states between one patient with PR and one with SD. As shown in Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/10.1186/s13073-024-01405-5#Fig5">5</a>A, T cells, fibroblasts, and pericytes were significantly enriched within the TME of the patient who achieved PR, while epithelial cells were enriched within the TME of the patient with SD. Moreover, dimensionality reduction and unsupervised clustering analysis identified 11 CD4 + and CD8 + T cell clusters in both patients, but patients with PR had relatively higher proportions of CD4 naive, CD4 Teff, CD4 Tcm, and CD8 naive cells, while patients with SD had much more CD8 Teff cells, including CD8 Teff, CD8 Teff CD74, and CD8 Teff mitotic cells (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/10.1186/s13073-024-01405-5#Fig5">5</a>A–D). This suggests that more T cells, especially CD4 clusters, within the TME may be associated with a good response to CAR-T cell infusion.</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-5" data-title="Fig. 5"><figure><figcaption><b id="Fig5" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 5</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/10.1186/s13073-024-01405-5/figures/5" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13073-024-01405-5/MediaObjects/13073_2024_1405_Fig5_HTML.png?as=webp"><img aria-describedby="Fig5" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13073-024-01405-5/MediaObjects/13073_2024_1405_Fig5_HTML.png" alt="figure 5" loading="lazy" width="685" height="634"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-5-desc"><p>Single-cell sequencing analysis of the properties of the immune and tumor cells after infusion of KT032 in patients with ovarian cancer. <b>A</b> The bar chart shows the proportional distribution of various cell types in tumor samples from patients with ovarian cancer before and after KT032 treatment. <b>B</b> The bar chart shows the proportional distribution of various T cells in tumor samples from patients with ovarian cancer before and after KT032 treatment. <b>C</b> The tSNE plot illustrates the distribution of different types of T cells in tumor samples from patients with ovarian cancer before and after KT032 treatment. <b>D</b> The bubble plot displays the expression levels of key marker genes for different types of T cells in tumors from patients with ovarian cancer. The size of the bubbles represents the percentage of gene expression in the cells, while the color represents the average level of gene expression. <b>E</b> The volcano plot of the differential analysis shows the upregulated and downregulated genes in various T cell clusters of tumors from patients with ovarian cancer after treatment compared with before treatment. Upregulated genes are shown in red, downregulated genes in blue, and the symbols of the top five genes with the largest differential expression are labeled. The differential threshold is fold change (FC) > 2 and <i>P</i> <0.05. <b>F</b> The bar chart illustrates the proportional distribution of different myeloid cells in tumor samples from patients with ovarian cancer before and after CAR-T treatment. <b>G</b> The bar chart displays the proportional distribution of different malignant cells in tumor samples from patients with ovarian cancer before and after CAR-T treatment. <b>H</b> The tSNE plot shows the distribution of different malignant cells in tumor samples of patients with ovarian cancer before and after CAR-T treatment. <b>I</b> The bubble plot shows the expression levels of the top five upregulated genes in various malignant cells in ovarian cancer tumor samples. The size of the bubbles represents the percentage of gene expression in the cells, while the color represents the average level of gene expression. <b>J</b> The volcano plot of differential analysis shows the upregulated and downregulated genes in tumor samples from patients with ovarian cancer after treatment compared with before treatment. Upregulated genes are shown in red, downregulated genes in blue, and the symbols of the top five genes with the largest differential expression are labeled. The differential threshold is FC > 2 and <i>P</i> < 0.05</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/10.1186/s13073-024-01405-5/figures/5" data-track-dest="link:Figure5 Full size image" aria-label="Full size image figure 5" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>The proportions of myeloid cells, T cells, and NK_NKT cells increased while that of epithelial cells decreased (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/10.1186/s13073-024-01405-5#Fig5">5</a>A). For T cell clusters, only the proportions of CD4 + Tregs and CD8 + Tact cells increased slightly, while other clusters were not significantly influenced by CAR-T cell infusion (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/10.1186/s13073-024-01405-5#Fig5">5</a>B). Differentially expressed gene (DEG) enrichment analysis showed that these DEGs in CD4 + Tregs post-CAR-T cell infusion were enriched in response to cytokine, cytokine-mediated signaling pathways, immune response, etc., indicating that CAR-T cells and their secreted cytokines may influence Treg cell phenotypes (Additional file2: Fig S2A). Moreover, T cells from patients with PR showed a higher expression of IL12RB2, GZMB, and IL10, indicating greater cytotoxicity and immunomodulatory properties (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/10.1186/s13073-024-01405-5#Fig5">5</a>E). Furthermore, patients with PR had much more MDSC-like macrophages but less CD24-TAM abundance compared with patients with SD. In contrast, the proportions of FN1-TAM and MDSC-like macrophages increased after CAR-T cell therapy (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/10.1186/s13073-024-01405-5#Fig5">5</a>F and Additional file2: Fig S2B-E). Further analysis demonstrated that dysregulated genes in these CD24-TAM cells were enriched in antigen processing and presentation of peptide antigen via MHC class I, cellular response to interferon-gamma, myeloid leukocyte mediated immunity, etc., which indicated that CAR-T cell therapy might induce the transformation of the TAM (Additional file2: Fig S2F). Moreover, the DEGs in MDSC-like macrophages post CAR-T cell treatment were enriched in immune response, cellular response to cytokine stimulus, response to cytokines, etc. as well as CD4 + Tregs (Additional file2: Fig S2G), which indicated that CAR-T cells would alter the pre-existing suppressive tumor microenvironment. These findings indicate that CAR-T cell infusion may recruit more immune cells and temporarily remodel the TME.</p><p>In addition, to investigate which genes in tumor cells may influence ovarian cancer cell resistance to MSLN-DAP CAR-T cell-mediated killing, we compared the changes in tumor cell subpopulations and gene expression profiles after CAR-T cell infusion. Seven clusters were identified by dimensionality reduction and unsupervised clustering analysis (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/10.1186/s13073-024-01405-5#Fig5">5</a>G–I). As shown in Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/10.1186/s13073-024-01405-5#Fig5">5</a>J, patients with PR had fewer M0 tumor cells that highly expressed FLOR3, PAGE2B, PAGE2, and C19orf33, and more M1 cells that had low expression of FLOR3, PAGE2B, PAGE2, and C19orf33 compared with patients with SD. The number of M2 cluster cells with high expression of NFKB1, MIR222HG, and LINC00472 was significantly decreased in both patients, while there was an increase in the number of M3 cluster cells that expressed CCL4, NKG7, and CD53. These findings suggest that tumor cells expressing NFKB1, MIR222HG, and LINC00472 may be more sensitive to MSLN-DAP CAR-T cell killing, whereas tumor cells expressing CCL4, NKG7, and CD53 may be resistant to MSLN-DAP CAR-T cell-mediated eradication.</p><h3 class="c-article__sub-heading" id="Sec20">Gene expression signatures of immune and cancer cells in mesothelioma after MSLN-CAR-T cell infusion</h3><p>We further explored the representation of immune cell types and functional states in patients with mesothelioma who had the longest survival times of 15 and 45 days after CAR-T cell infusion. As shown in Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/10.1186/s13073-024-01405-5#Fig6">6</a>A–B, dimensionality reduction and unsupervised clustering analysis showed significant enrichment of NK cells, endothelial cells, and pericytes within the TME 45 days after CAR-T cell therapy compared with 15 days. Conversely, the ratio of mesothelial to myeloid cells decreased, whereas the proportion of T cells did not. Compared with day 15, the increased endothelial cells highly expressed KLF4, BMP4, and FCN3 and had low expression of CHI3L1, HLA-DRA, and PRG4, while the NK cells had upregulated ZNF420 expression, and the pericytes showed increased levels of SNAI1, EFNA1, and BRD9 (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/10.1186/s13073-024-01405-5#Fig6">6</a>C). Moreover, a total of seven clusters of CD4 + and CD8 + T cells were identified, and relatively higher proportions of CD8 + Tact and a lower ratio of CD8 Mitotic characterized in the TME 45 days after CAR-T cell therapy compared with 15 days (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/10.1186/s13073-024-01405-5#Fig6">6</a>D). These altered genes were enriched for protein binding, NADH dehydrogenase (ubiquinone) activity, and catalytic activity (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/10.1186/s13073-024-01405-5#Fig6">6</a>E). Additionally, seven clusters of mesothelioma cells were identified using dimensionality reduction and unsupervised clustering analyses. As shown in Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/10.1186/s13073-024-01405-5#Fig6">6</a>F and G, the ratio of M1 clusters with highly expressed SPATC1L, DDX52, BMPR2, and TMEM126B increased 45 days after CAR-T cell infusion, while the ratio of M3 clusters with highly expressed EPGN, NRK, WFDC2, and PRR9 decreased. Moreover, the DEGs in the specimen 45 days after CAR-T cell therapy were enriched in C–C motif chemokine receptor 1 chemokine receptor binding, chemokine receptor binding, and T cell receptor binding (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/10.1186/s13073-024-01405-5#Fig6">6</a>H), indicating that CAR-T cell treatment may recruit and reactivate immune cells in the TME, which in turn induces an antitumor immune response.</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-6" data-title="Fig. 6"><figure><figcaption><b id="Fig6" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 6</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/10.1186/s13073-024-01405-5/figures/6" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13073-024-01405-5/MediaObjects/13073_2024_1405_Fig6_HTML.png?as=webp"><img aria-describedby="Fig6" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13073-024-01405-5/MediaObjects/13073_2024_1405_Fig6_HTML.png" alt="figure 6" loading="lazy" width="685" height="538"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-6-desc"><p>Single-cell sequencing analysis of the properties of the immune and tumor cells after infusion of KT032 in a patient with mesothelioma. <b>A</b> The bar chart shows the proportional distribution of different cell types in tumor samples from patients with mesothelioma after KT032 therapy in two stages. <b>B</b> The tSNE plot illustrates the distribution of different cell types in tumor samples from patients with mesothelioma after KT032 therapy in two stages. <b>C</b> The volcano plot of differential analysis displays the upregulated and downregulated genes in tumor samples from patients with mesothelioma after KT032 therapy in stage two compared with stage one. Upregulated genes are shown in red, downregulated genes in blue, and the top five genes with the largest differences in upregulation or downregulation are labeled with their symbols. The differential threshold is FC > 2 and <i>P</i> < 0.05. <b>D</b> The bar chart presents the proportional distribution of different T cell types in tumor samples from patients with mesothelioma after KT032 therapy in two stages. <b>E</b> The bubble plot shows the top 20 enriched pathways (<i>q</i>-value) for differentially expressed genes between CD8+ mitotic T cells (left) and CD8+ Tact cells (right) in tumor samples from patients with mesothelioma after KT032 therapy in two stages. <b>F</b> The bar chart displays the proportional distribution of different malignant cell types in tumor samples from patients with mesothelioma after KT032 therapy in two stages. <b>G</b> The heatmap illustrates the expression levels of the top five upregulated genes in different malignant cell types in tumor samples from patients with mesothelioma. The color represents the average gene expression level. <b>H</b> The bubble plot shows the top 20 enriched pathways (<i>q</i>-value) for upregulated genes in the M3 subgroup (left) and M4 subgroup (right) of tumor samples from patients with mesothelioma after KT032 therapy</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/10.1186/s13073-024-01405-5/figures/6" data-track-dest="link:Figure6 Full size image" aria-label="Full size image figure 6" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div></div></div></section><section data-title="Discussion"><div class="c-article-section" id="Sec21-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec21">Discussion</h2><div class="c-article-section__content" id="Sec21-content"><p>Immunotherapy has become a new hope in humanity’s fight against cancer, and CAR-T therapy has been one of the most promising tumor immunotherapies to emerge in recent years. Since the FDA’s approval of the first CAR-T cell product in 2017, six CAR-T products have since been approved for treating B-cell lymphoma and multiple myeloma, two targeting the B-cell maturation antigen and four targeting CD19. Despite the success of CAR-T cells in treating hematological tumors and the significant prolongation of patient survival, they have not achieved comparable therapeutic effects when used to treat solid tumors. In addition to the lack of specific antigens and tumor heterogeneity, the complex microenvironment of solid tumors is the most significant limitation of CAR-T cell therapy. To improve the efficacy of CAR-T cell therapy in solid tumors, Zheng et al. utilized DAP10/DAP12 to replace 41BB or CD28 and CD3ζ as an alternative costimulation/signaling combination. This led to a significant decrease in IFNγ and IL-2 secretion and showed significantly more cytotoxicity <i>in vitro</i> and <i>in vivo</i> than standard BBZ CAR T cell constructs [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 25" title="Zheng L, Ren L, Kouhi A, Khawli LA, Hu P, Kaslow HR, Epstein AL. A humanized Lym-1 CAR with novel DAP10/DAP12 signaling domains demonstrates reduced tonic signaling and increased antitumor activity in B-cell lymphoma models. Clin Cancer Res. 2020;26:3694–706." href="/articles/10.1186/s13073-024-01405-5#ref-CR25" id="ref-link-section-d125265713e3003">25</a>]. In our previous studies, we developed a multichain DAP-CAR mimicking properties of natural immune receptors by using a full-length immune-activated receptor-associated protein (DAP12) to replace CD3ζ as the activation domain, retaining its transmembrane structure and the immunoreceptor tyrosine-based activation motifs. This was combined with the NK cell-activated receptor (a truncated form of KIR2DS2) and the co-stimulatory molecule 4-1BB, which does not depend on CD3ζ signaling and thus resists the inhibition of CAR expression by the TME. The safety of the DAP12 CAR structure was evaluated by clinical trials with patients with B-cell acute lymphoblastic leukemia. In this study, we compared the ability of other NCR structures to activate T cells and found that DAP-CAR was the optimal structure. To this end, we conducted a clinical trial in patients with ovarian cancer and mesothelioma to evaluate the safety and efficacy of MSLN-targeted DAP-CAR-T cells. MSLN-DAP CAR-T cells achieved a 33.3% (2/6) objective response rate and a 100% disease control rate in six patients over 3 months, demonstrating its potential for clinical application.</p><p>Adverse events mainly included fever, leukopenia, and erythropenia; additionally, one patient had a pulmonary infection. Neurotoxicity and CRS are the hallmark clinical toxicity events associated with CAR-T cell therapy [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 26" title="Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15:47–62." href="/articles/10.1186/s13073-024-01405-5#ref-CR26" id="ref-link-section-d125265713e3009">26</a>]. CRS is usually observed in patients within one week following treatment and is characterized by fever, hypotension, and neurological deficits, accompanied by drastic increases in cytokine levels, such as IL-6 and TNF-γ [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 27" title="Fischer JW, Bhattarai N. CAR-T cell therapy: mechanism, management, and mitigation of inflammatory toxicities. Front Immunol. 2021;12:693016." href="/articles/10.1186/s13073-024-01405-5#ref-CR27" id="ref-link-section-d125265713e3012">27</a>]. In this study, we found that IL-6 levels were elevated in patients on the day of CRS symptoms. Moreover, we observed a negative correlation between the efficacy of CAR-T cell therapy and adverse immune events. This evidence supports our findings, as some studies have suggested that a certain degree of toxicity is expected to produce an effective response to therapy [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 28" title="Chohan KL, Siegler EL, Kenderian SS. CAR-T cell therapy: the efficacy and toxicity balance. Curr Hematol Malig Rep. 2023;18:9–18." href="/articles/10.1186/s13073-024-01405-5#ref-CR28" id="ref-link-section-d125265713e3015">28</a>]. However, owing to the small sample size, these findings should be interpreted cautiously. The efficacy of CAR-T cell therapy is positively correlated with the proliferative ability of T cells <i>in vivo</i> [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 29" title="Fultang L, Booth S, Yogev O, Martins da Costa B, Tubb V, Panetti S, Stavrou V, Scarpa U, Jankevics A, Lloyd G, et al. Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity. Blood. 2020;136:1155–60." href="/articles/10.1186/s13073-024-01405-5#ref-CR29" id="ref-link-section-d125265713e3021">29</a>]. Several factors, such as the number of residual lymphocytes after lymphoblastic conditioning and the use of corticosteroids, may affect the proliferation and persistence of CAR-T cells. Our study found more residual lymphocytes in Patients 5 (0.21 × 10<sup>9</sup>/L) and 6 (0.35 × 10<sup>9</sup>/L), which may be related to the poor proliferation of T cells after CAR-T cell infusion. Moreover, in Patient 1, high doses of corticosteroids were observed to inhibit CAR-T cell proliferation <i>in vivo</i>, whereas cell proliferation was restored after hormone discontinuation. Thus, strategies that enhance cell proliferation may improve patient outcomes. Another critical issue that needs to be addressed is the amount of CAR-T cell infusion. We found that an infusion of 1.0 × 10<sup>6</sup> cells/kg was relatively safe for patients. In addition, the myeloablative conditioning regimen before KT032 therapy needed to be adjusted according to the patient’s performance score. The maximal depletion of autologous lymphocytes is a prerequisite for effective KT032 therapy.</p><p>Evidence indicates that the proportion of different cell subtypes in CAR-T cells correlates with patient outcomes. In particular, a higher percentage of memory T cells usually results in better patient outcomes. However, our scRNA-seq results showed no significant differences in the proportions of each subpopulation of KT032 CAR-T cell products between patients with good or poor responses. In addition to CAR-T cell trials in solid tumors, we observed a relatively short persistence even when KT032 exhibited improved CAR-T cell expansion in the blood. Unlike CART19 cells, which can persist for months and even years after infusion in hematological malignancies, KT032 was undetectable in the peripheral blood of most patients 40 days after infusion and was undetectable in patients even 70 days after infusion. Nevertheless, while KT032 did not meet our expectations, it still exhibited prolonged <i>in vivo</i> persistence compared with BBZ CAR-T cells. Moreover, few KT032 cells were detected within the punctured tumors using scRNA-seq, suggesting infiltration is challenging for KT032 cells in solid tumor therapy. Next, we need to enhance the infiltration ability of KT032 cells by expressing additional chemokines, such as CCL7. In addition to the properties of KT032, we explored whether the heterogeneity of immune cells in the TME was associated with the outcome of KT032 therapy using scRNA-seq. T cells from patients with PR highly expressed IL12RB2, GZMB, IL10, and many more MDSC-like macrophages, but fewer CD24-TAM were observed in patients with PR. Our findings showed that KT032 CAR-T cell infusion could recruit more immune cells and temporarily remodel the TME. However, because single-cell sequencing was conducted in three patients, these findings must be verified in further clinical trials with a larger cohort.</p><p>Beatty et al. conducted a phase I study to evaluate the safety and activity of second-generation CAR-T cells against mesothelin, using the same scFv fused to 4-1BB and CD3ζ (BBZ CAR-T) in patients with ovarian cancer, malignant pleural mesothelioma, and pancreatic ductal adenocarcinoma. Although BBZ CAR-T-meso cells were well tolerated and expanded in all patients, only limited clinical activity was achieved [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 30" title="Haas AR, Tanyi JL, O’Hara MH, Gladney WL, Lacey SF, Torigian DA, Soulen MC, Tian L, McGarvey M, Nelson AM, et al. Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers. Mol Ther. 2019;27:1919–29." href="/articles/10.1186/s13073-024-01405-5#ref-CR30" id="ref-link-section-d125265713e3043">30</a>]. Similarly, Guo et al. reported three patients with ovarian cancer who received second-generation anti-MSLN CAR-T cell therapy, and no effective treatment activity was observed [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 31" title="Chen J, Hu J, Gu L, Ji F, Zhang F, Zhang M, Li J, Chen Z, Jiang L, Zhang Y, et al. Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer. Cancer Immunol Immunother. 2023;72:409–25." href="/articles/10.1186/s13073-024-01405-5#ref-CR31" id="ref-link-section-d125265713e3046">31</a>]. This, coupled with the therapeutic effects we achieved, suggests that the second-generation BBZ CAR structure may have difficulty breaking through the therapeutic barrier for solid tumors, whereas DAP-CAR might be expected to crack the door to solid tumor cell therapy.</p></div></div></section><section data-title="Conclusions"><div class="c-article-section" id="Sec22-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec22">Conclusions</h2><div class="c-article-section__content" id="Sec22-content"><p>Although the application of CAR-T cells to treat solid tumors has been attempted for several years, many clinical trials have shown that CAR-T cell therapies have not yet achieved breakthroughs in solid tumor treatment. This study demonstrated the safety, efficacy, and feasibility of administering MSLN targeting novel multiple-chain CAR-T cells in patients with ovarian cancer and mesothelioma. Moreover, we characterized the correlation between patient outcomes and the properties of CAR-T cells or heterogeneity of the TME. Our findings from the first human clinical trial of KT032 provide an optimized direction for subsequent studies to test next-generation KT032-based modified CAR-T cells targeting mesothelin solid tumors. This study has some limitations. First, additional multifaceted optimization strategies that prolong KT032 cell persistence and promote trafficking to tumors are needed to improve outcomes with KT032 cells in MSLN-expressing solid tumors. In addition, only eight patients were enrolled in this clinical trial, and more patients are needed to further verify the safety and efficacy of KT032. Furthermore, single-cell sequencing was only conducted on samples from three patients, and these results need to be verified in a larger cohort of patients.</p></div></div></section> <section data-title="Data availability"><div class="c-article-section" id="data-availability-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="data-availability">Data availability</h2><div class="c-article-section__content" id="data-availability-content"> <p>The dataset(s) supporting the findings of this study are included within the article.</p> <p>The raw sequence data generated within this study have been deposited to the Genome Sequence Archive in BIG Data Center. Raw sequencing reads are available from Beijing Institute of Genomics (BIG) HRA006416 (<a href="https://ngdc.cncb.ac.cn/search/all?&q=HRA006416">https://ngdc.cncb.ac.cn/search/all?&q=HRA006416</a>) [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 32" title="Xu T, Shu Y, et al. Characterization of mesothelin targeting novel multiple chain DAP-CAR-T cells efficacy in patients with ovarian cancer and mesothelioma through single-cell transcriptomic analysis. HRA006416. 2024. 
 https://bigd.big.ac.cn
 
 ." href="/articles/10.1186/s13073-024-01405-5#ref-CR32" id="ref-link-section-d125265713e3107">32</a>]</p> <p>The GSVA package and related code are available from <a href="https://github.com/rcastelo/GSVA">https://github.com/rcastelo/GSVA</a> [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 33" title="Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-Seq data. Github. 
 https://github.com/rcastelo/GSVA
 
 ." href="/articles/10.1186/s13073-024-01405-5#ref-CR33" id="ref-link-section-d125265713e3120">33</a>]. The CellphoneDB package and related code are available from <a href="https://github.com/Teichlab/cellphonedb">https://github.com/Teichlab/cellphonedb</a> [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 34" title="Efremova M, Vento-Tormo M, Teichmann S, Vento-Tormo R. CellphoneDB v2: inferring cell-cell communication from combined expression of multi-subunit receptor-ligand complexes. Github. 
 https://github.com/ventolab/CellphoneDB
 
 ." href="/articles/10.1186/s13073-024-01405-5#ref-CR34" id="ref-link-section-d125265713e3130">34</a>].</p> </div></div></section><div id="MagazineFulltextArticleBodySuffix"><section aria-labelledby="Bib1" data-title="References"><div class="c-article-section" id="Bib1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Bib1">References</h2><div class="c-article-section__content" id="Bib1-content"><div data-container-section="references"><ol class="c-article-references" data-track-component="outbound reference" data-track-context="references section"><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="1."><p class="c-article-references__text" id="ref-CR1">Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11:69.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41408-021-00459-7" data-track-item_id="10.1038/s41408-021-00459-7" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41408-021-00459-7" aria-label="Article reference 1" data-doi="10.1038/s41408-021-00459-7">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33824268" aria-label="PubMed reference 1">PubMed</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024391" aria-label="PubMed Central reference 1">PubMed Central</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 1" href="http://scholar.google.com/scholar_lookup?&title=CAR-T%20cell%20therapy%3A%20current%20limitations%20and%20potential%20strategies&journal=Blood%20Cancer%20J&doi=10.1038%2Fs41408-021-00459-7&volume=11&publication_year=2021&author=Sterner%2CRC&author=Sterner%2CRM"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="2."><p class="c-article-references__text" id="ref-CR2">Holstein SA, Lunning MA. CAR T-cell therapy in hematologic malignancies: a voyage in progress. Clin Pharmacol Ther. 2020;107:112–22.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1002/cpt.1674" data-track-item_id="10.1002/cpt.1674" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1002%2Fcpt.1674" aria-label="Article reference 2" data-doi="10.1002/cpt.1674">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXisVyitLnP" aria-label="CAS reference 2">CAS</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31622496" aria-label="PubMed reference 2">PubMed</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 2" href="http://scholar.google.com/scholar_lookup?&title=CAR%20T-cell%20therapy%20in%20hematologic%20malignancies%3A%20a%20voyage%20in%20progress&journal=Clin%20Pharmacol%20Ther&doi=10.1002%2Fcpt.1674&volume=107&pages=112-122&publication_year=2020&author=Holstein%2CSA&author=Lunning%2CMA"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="3."><p class="c-article-references__text" id="ref-CR3">San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, Fernandez de Larrea C, Martinez-Lopez J, Moreau P, Touzeau C, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389:335–47.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1056/NEJMoa2303379" data-track-item_id="10.1056/NEJMoa2303379" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa2303379" aria-label="Article reference 3" data-doi="10.1056/NEJMoa2303379">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3sXhs1Kgt7jL" aria-label="CAS reference 3">CAS</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=37272512" aria-label="PubMed reference 3">PubMed</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 3" href="http://scholar.google.com/scholar_lookup?&title=Cilta-cel%20or%20standard%20care%20in%20lenalidomide-refractory%20multiple%20myeloma&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa2303379&volume=389&pages=335-347&publication_year=2023&author=San-Miguel%2CJ&author=Dhakal%2CB&author=Yong%2CK&author=Spencer%2CA&author=Anguille%2CS&author=Mateos%2CMV&author=Fernandez%20de%20Larrea%2CC&author=Martinez-Lopez%2CJ&author=Moreau%2CP&author=Touzeau%2CC"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="4."><p class="c-article-references__text" id="ref-CR4">Qu X, An G, Sui W, Wang T, Zhang X, Yang J, Zhang Y, Zhang L, Zhu D, Huang J, et al. Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma. Journal For Immunotherapy of Cancer. 2022;10:e005145.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1136/jitc-2022-005145" data-track-item_id="10.1136/jitc-2022-005145" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1136%2Fjitc-2022-005145" aria-label="Article reference 4" data-doi="10.1136/jitc-2022-005145">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36100310" aria-label="PubMed reference 4">PubMed</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472147" aria-label="PubMed Central reference 4">PubMed Central</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 4" href="http://scholar.google.com/scholar_lookup?&title=Phase%201%20study%20of%20C-CAR088%2C%20a%20novel%20humanized%20anti-BCMA%20CAR%20T-cell%20therapy%20in%20relapsed%2Frefractory%20multiple%20myeloma&journal=Journal%20For%20Immunotherapy%20of%20Cancer&doi=10.1136%2Fjitc-2022-005145&volume=10&publication_year=2022&author=Qu%2CX&author=An%2CG&author=Sui%2CW&author=Wang%2CT&author=Zhang%2CX&author=Yang%2CJ&author=Zhang%2CY&author=Zhang%2CL&author=Zhu%2CD&author=Huang%2CJ"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="5."><p class="c-article-references__text" id="ref-CR5">Martinez M, Moon EK. CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front Immunol. 2019;10:128.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.3389/fimmu.2019.00128" data-track-item_id="10.3389/fimmu.2019.00128" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.3389%2Ffimmu.2019.00128" aria-label="Article reference 5" data-doi="10.3389/fimmu.2019.00128">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXhsVSht7nK" aria-label="CAS reference 5">CAS</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30804938" aria-label="PubMed reference 5">PubMed</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370640" aria-label="PubMed Central reference 5">PubMed Central</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 5" href="http://scholar.google.com/scholar_lookup?&title=CAR%20T%20cells%20for%20solid%20tumors%3A%20new%20strategies%20for%20finding%2C%20infiltrating%2C%20and%20surviving%20in%20the%20tumor%20microenvironment&journal=Front%20Immunol&doi=10.3389%2Ffimmu.2019.00128&volume=10&publication_year=2019&author=Martinez%2CM&author=Moon%2CEK"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="6."><p class="c-article-references__text" id="ref-CR6">Qu C, Zhang H, Cao H, Tang L, Mo H, Liu F, Zhang L, Yi Z, Long L, Yan L, et al. Tumor buster - where will the CAR-T cell therapy “missile” go? Mol Cancer. 2022;21:201.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="noopener" data-track-label="10.1186/s12943-022-01669-8" data-track-item_id="10.1186/s12943-022-01669-8" data-track-value="article reference" data-track-action="article reference" href="https://link.springer.com/doi/10.1186/s12943-022-01669-8" aria-label="Article reference 6" data-doi="10.1186/s12943-022-01669-8">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36261831" aria-label="PubMed reference 6">PubMed</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580202" aria-label="PubMed Central reference 6">PubMed Central</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 6" href="http://scholar.google.com/scholar_lookup?&title=Tumor%20buster%20-%20where%20will%20the%20CAR-T%20cell%20therapy%20%27missile%27%20go%3F&journal=Mol%20Cancer&doi=10.1186%2Fs12943-022-01669-8&volume=21&publication_year=2022&author=Qu%2CC&author=Zhang%2CH&author=Cao%2CH&author=Tang%2CL&author=Mo%2CH&author=Liu%2CF&author=Zhang%2CL&author=Yi%2CZ&author=Long%2CL&author=Yan%2CL"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="7."><p class="c-article-references__text" id="ref-CR7">Antonucci L, Canciani G, Mastronuzzi A, Carai A, Del Baldo G, Del Bufalo F. CAR-T therapy for pediatric high-grade gliomas: peculiarities, current investigations and future strategies. Front Immunol. 2022;13:867154.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.3389/fimmu.2022.867154" data-track-item_id="10.3389/fimmu.2022.867154" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.3389%2Ffimmu.2022.867154" aria-label="Article reference 7" data-doi="10.3389/fimmu.2022.867154">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38XhsV2ltrzO" aria-label="CAS reference 7">CAS</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=35603195" aria-label="PubMed reference 7">PubMed</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115105" aria-label="PubMed Central reference 7">PubMed Central</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 7" href="http://scholar.google.com/scholar_lookup?&title=CAR-T%20therapy%20for%20pediatric%20high-grade%20gliomas%3A%20peculiarities%2C%20current%20investigations%20and%20future%20strategies&journal=Front%20Immunol&doi=10.3389%2Ffimmu.2022.867154&volume=13&publication_year=2022&author=Antonucci%2CL&author=Canciani%2CG&author=Mastronuzzi%2CA&author=Carai%2CA&author=Baldo%2CG&author=Bufalo%2CF"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="8."><p class="c-article-references__text" id="ref-CR8">Yu T, Yu SK, Xiang Y, Lu KH, Sun M. Revolution of CAR engineering for next-generation immunotherapy in solid tumors. Front Immunol. 2022;13:936496.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.3389/fimmu.2022.936496" data-track-item_id="10.3389/fimmu.2022.936496" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.3389%2Ffimmu.2022.936496" aria-label="Article reference 8" data-doi="10.3389/fimmu.2022.936496">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38XitVOqurzM" aria-label="CAS reference 8">CAS</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=35903099" aria-label="PubMed reference 8">PubMed</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315443" aria-label="PubMed Central reference 8">PubMed Central</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 8" href="http://scholar.google.com/scholar_lookup?&title=Revolution%20of%20CAR%20engineering%20for%20next-generation%20immunotherapy%20in%20solid%20tumors&journal=Front%20Immunol&doi=10.3389%2Ffimmu.2022.936496&volume=13&publication_year=2022&author=Yu%2CT&author=Yu%2CSK&author=Xiang%2CY&author=Lu%2CKH&author=Sun%2CM"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="9."><p class="c-article-references__text" id="ref-CR9">Hong M, Clubb JD, Chen YY. Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell. 2020;38:473–88.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.ccell.2020.07.005" data-track-item_id="10.1016/j.ccell.2020.07.005" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.ccell.2020.07.005" aria-label="Article reference 9" data-doi="10.1016/j.ccell.2020.07.005">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXhsFShtLzL" aria-label="CAS reference 9">CAS</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32735779" aria-label="PubMed reference 9">PubMed</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 9" href="http://scholar.google.com/scholar_lookup?&title=Engineering%20CAR-T%20cells%20for%20next-generation%20cancer%20therapy&journal=Cancer%20Cell&doi=10.1016%2Fj.ccell.2020.07.005&volume=38&pages=473-488&publication_year=2020&author=Hong%2CM&author=Clubb%2CJD&author=Chen%2CYY"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="10."><p class="c-article-references__text" id="ref-CR10">Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3:388–98.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/2159-8290.CD-12-0548" data-track-item_id="10.1158/2159-8290.CD-12-0548" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F2159-8290.CD-12-0548" aria-label="Article reference 10" data-doi="10.1158/2159-8290.CD-12-0548">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3sXlvVCit7c%3D" aria-label="CAS reference 10">CAS</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23550147" aria-label="PubMed reference 10">PubMed</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667586" aria-label="PubMed Central reference 10">PubMed Central</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 10" href="http://scholar.google.com/scholar_lookup?&title=The%20basic%20principles%20of%20chimeric%20antigen%20receptor%20design&journal=Cancer%20Discov&doi=10.1158%2F2159-8290.CD-12-0548&volume=3&pages=388-398&publication_year=2013&author=Sadelain%2CM&author=Brentjens%2CR&author=Rivi%C3%A8re%2CI"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="11."><p class="c-article-references__text" id="ref-CR11">Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, Song M, Miele MM, Li Z, Wang P, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018;36:847–56.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/nbt.4195" data-track-item_id="10.1038/nbt.4195" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fnbt.4195" aria-label="Article reference 11" data-doi="10.1038/nbt.4195">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXhsVyltrnK" aria-label="CAS reference 11">CAS</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30102295" aria-label="PubMed reference 11">PubMed</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6126939" aria-label="PubMed Central reference 11">PubMed Central</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 11" href="http://scholar.google.com/scholar_lookup?&title=Targeted%20delivery%20of%20a%20PD-1-blocking%20scFv%20by%20CAR-T%20cells%20enhances%20anti-tumor%20efficacy%20in%20vivo&journal=Nat%20Biotechnol&doi=10.1038%2Fnbt.4195&volume=36&pages=847-856&publication_year=2018&author=Rafiq%2CS&author=Yeku%2COO&author=Jackson%2CHJ&author=Purdon%2CTJ&author=Leeuwen%2CDG&author=Drakes%2CDJ&author=Song%2CM&author=Miele%2CMM&author=Li%2CZ&author=Wang%2CP"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="12."><p class="c-article-references__text" id="ref-CR12">Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, Smith JP, Walker AJ, Kohler ME, Venkateshwara VR, et al. 4–1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21:581–90.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/nm.3838" data-track-item_id="10.1038/nm.3838" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fnm.3838" aria-label="Article reference 12" data-doi="10.1038/nm.3838">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2MXhtFemsbfE" aria-label="CAS reference 12">CAS</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25939063" aria-label="PubMed reference 12">PubMed</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4458184" aria-label="PubMed Central reference 12">PubMed Central</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 12" href="http://scholar.google.com/scholar_lookup?&title=4%E2%80%931BB%20costimulation%20ameliorates%20T%20cell%20exhaustion%20induced%20by%20tonic%20signaling%20of%20chimeric%20antigen%20receptors&journal=Nat%20Med&doi=10.1038%2Fnm.3838&volume=21&pages=581-590&publication_year=2015&author=Long%2CAH&author=Haso%2CWM&author=Shern%2CJF&author=Wanhainen%2CKM&author=Murgai%2CM&author=Ingaramo%2CM&author=Smith%2CJP&author=Walker%2CAJ&author=Kohler%2CME&author=Venkateshwara%2CVR"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="13."><p class="c-article-references__text" id="ref-CR13">Muyldermans S. Nanobodies: natural single-domain antibodies. Annu Rev Biochem. 2013;82:775–97.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1146/annurev-biochem-063011-092449" data-track-item_id="10.1146/annurev-biochem-063011-092449" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1146%2Fannurev-biochem-063011-092449" aria-label="Article reference 13" data-doi="10.1146/annurev-biochem-063011-092449">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3sXhtFOqsrrJ" aria-label="CAS reference 13">CAS</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23495938" aria-label="PubMed reference 13">PubMed</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 13" href="http://scholar.google.com/scholar_lookup?&title=Nanobodies%3A%20natural%20single-domain%20antibodies&journal=Annu%20Rev%20Biochem&doi=10.1146%2Fannurev-biochem-063011-092449&volume=82&pages=775-797&publication_year=2013&author=Muyldermans%2CS"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="14."><p class="c-article-references__text" id="ref-CR14">Safarzadeh Kozani P, Naseri A, Mirarefin SMJ, Salem F, Nikbakht M, Evazi Bakhshi S, Safarzadeh Kozani P. Nanobody-based CAR-T cells for cancer immunotherapy. Biomarker Research. 2022;10:24.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="noopener" data-track-label="10.1186/s40364-022-00371-7" data-track-item_id="10.1186/s40364-022-00371-7" data-track-value="article reference" data-track-action="article reference" href="https://link.springer.com/doi/10.1186/s40364-022-00371-7" aria-label="Article reference 14" data-doi="10.1186/s40364-022-00371-7">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=35468841" aria-label="PubMed reference 14">PubMed</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036779" aria-label="PubMed Central reference 14">PubMed Central</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 14" href="http://scholar.google.com/scholar_lookup?&title=Nanobody-based%20CAR-T%20cells%20for%20cancer%20immunotherapy&journal=Biomarker%20Research&doi=10.1186%2Fs40364-022-00371-7&volume=10&publication_year=2022&author=Safarzadeh%20Kozani%2CP&author=Naseri%2CA&author=Mirarefin%2CSMJ&author=Salem%2CF&author=Nikbakht%2CM&author=Evazi%20Bakhshi%2CS&author=Safarzadeh%20Kozani%2CP"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="15."><p class="c-article-references__text" id="ref-CR15">Adachi K, Kano Y, Nagai T, Okuyama N, Sakoda Y, Tamada K. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat Biotechnol. 2018;36:346–51.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/nbt.4086" data-track-item_id="10.1038/nbt.4086" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fnbt.4086" aria-label="Article reference 15" data-doi="10.1038/nbt.4086">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXjvVOlu74%3D" aria-label="CAS reference 15">CAS</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29505028" aria-label="PubMed reference 15">PubMed</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 15" href="http://scholar.google.com/scholar_lookup?&title=IL-7%20and%20CCL19%20expression%20in%20CAR-T%20cells%20improves%20immune%20cell%20infiltration%20and%20CAR-T%20cell%20survival%20in%20the%20tumor&journal=Nat%20Biotechnol&doi=10.1038%2Fnbt.4086&volume=36&pages=346-351&publication_year=2018&author=Adachi%2CK&author=Kano%2CY&author=Nagai%2CT&author=Okuyama%2CN&author=Sakoda%2CY&author=Tamada%2CK"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="16."><p class="c-article-references__text" id="ref-CR16">Wang J, Zhang X, Zhou Z, Liu Y, Yu L, Jia L, Yang J, Li J, Yu H, Li W, et al. A novel adoptive synthetic TCR and antigen receptor (STAR) T-Cell therapy for B-Cell acute lymphoblastic leukemia. Am J Hematol. 2022;97(8):992–1004.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1002/ajh.26586" data-track-item_id="10.1002/ajh.26586" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1002%2Fajh.26586" aria-label="Article reference 16" data-doi="10.1002/ajh.26586">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38XhvFaltr3L" aria-label="CAS reference 16">CAS</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=35491511" aria-label="PubMed reference 16">PubMed</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 16" href="http://scholar.google.com/scholar_lookup?&title=A%20novel%20adoptive%20synthetic%20TCR%20and%20antigen%20receptor%20%28STAR%29%20T-Cell%20therapy%20for%20B-Cell%20acute%20lymphoblastic%20leukemia&journal=Am%20J%20Hematol.&doi=10.1002%2Fajh.26586&volume=97&issue=8&pages=992-1004&publication_year=2022&author=Wang%2CJ&author=Zhang%2CX&author=Zhou%2CZ&author=Liu%2CY&author=Yu%2CL&author=Jia%2CL&author=Yang%2CJ&author=Li%2CJ&author=Yu%2CH&author=Li%2CW"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="17."><p class="c-article-references__text" id="ref-CR17">Wang E, Wang L-C, Tsai C-Y, Bhoj V, Gershenson Z, Moon E, Newick K, Sun J, Lo A, Baradet T, et al. Generation of potent T-cell immunotherapy for cancer using DAP12-based, multichain, chimeric immunoreceptors. Cancer Immunol Res. 2015;3:815–26.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/2326-6066.CIR-15-0054" data-track-item_id="10.1158/2326-6066.CIR-15-0054" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F2326-6066.CIR-15-0054" aria-label="Article reference 17" data-doi="10.1158/2326-6066.CIR-15-0054">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2MXhtFCktr%2FI" aria-label="CAS reference 17">CAS</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25941351" aria-label="PubMed reference 17">PubMed</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490943" aria-label="PubMed Central reference 17">PubMed Central</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 17" href="http://scholar.google.com/scholar_lookup?&title=Generation%20of%20potent%20T-cell%20immunotherapy%20for%20cancer%20using%20DAP12-based%2C%20multichain%2C%20chimeric%20immunoreceptors&journal=Cancer%20Immunol%20Res&doi=10.1158%2F2326-6066.CIR-15-0054&volume=3&pages=815-826&publication_year=2015&author=Wang%2CE&author=Wang%2CL-C&author=Tsai%2CC-Y&author=Bhoj%2CV&author=Gershenson%2CZ&author=Moon%2CE&author=Newick%2CK&author=Sun%2CJ&author=Lo%2CA&author=Baradet%2CT"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="18."><p class="c-article-references__text" id="ref-CR18">Xu T, Wang C, Chen X, Bai J, Wang E, Sun M. Coexpression of c-Jun in multiple-chain DAP-CAR-engineered T-cells for solid tumor therapy. Immunotherapy. 2022;14:1457–66.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.2217/imt-2022-0171" data-track-item_id="10.2217/imt-2022-0171" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.2217%2Fimt-2022-0171" aria-label="Article reference 18" data-doi="10.2217/imt-2022-0171">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3sXmslSitQ%3D%3D" aria-label="CAS reference 18">CAS</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36597720" aria-label="PubMed reference 18">PubMed</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 18" href="http://scholar.google.com/scholar_lookup?&title=Coexpression%20of%20c-Jun%20in%20multiple-chain%20DAP-CAR-engineered%20T-cells%20for%20solid%20tumor%20therapy&journal=Immunotherapy&doi=10.2217%2Fimt-2022-0171&volume=14&pages=1457-1466&publication_year=2022&author=Xu%2CT&author=Wang%2CC&author=Chen%2CX&author=Bai%2CJ&author=Wang%2CE&author=Sun%2CM"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="19."><p class="c-article-references__text" id="ref-CR19">Pastan I, Hassan R. Discovery of mesothelin and exploiting it as a target for immunotherapy. Can Res. 2014;74:2907–12.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/0008-5472.CAN-14-0337" data-track-item_id="10.1158/0008-5472.CAN-14-0337" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F0008-5472.CAN-14-0337" aria-label="Article reference 19" data-doi="10.1158/0008-5472.CAN-14-0337">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2cXovFalur8%3D" aria-label="CAS reference 19">CAS</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 19" href="http://scholar.google.com/scholar_lookup?&title=Discovery%20of%20mesothelin%20and%20exploiting%20it%20as%20a%20target%20for%20immunotherapy&journal=Can%20Res&doi=10.1158%2F0008-5472.CAN-14-0337&volume=74&pages=2907-2912&publication_year=2014&author=Pastan%2CI&author=Hassan%2CR"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="20."><p class="c-article-references__text" id="ref-CR20">Yuan J, Kashiwagi S, Reeves P, Nezivar J, Yang Y, Arrifin NH, Nguyen M, Jean-Mary G, Tong X, Uppal P, et al. A novel mycobacterial Hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma. J Hematol Oncol. 2014;7:15.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="noopener" data-track-label="10.1186/1756-8722-7-15" data-track-item_id="10.1186/1756-8722-7-15" data-track-value="article reference" data-track-action="article reference" href="https://link.springer.com/doi/10.1186/1756-8722-7-15" aria-label="Article reference 20" data-doi="10.1186/1756-8722-7-15">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24565018" aria-label="PubMed reference 20">PubMed</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3943805" aria-label="PubMed Central reference 20">PubMed Central</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 20" href="http://scholar.google.com/scholar_lookup?&title=A%20novel%20mycobacterial%20Hsp70-containing%20fusion%20protein%20targeting%20mesothelin%20augments%20antitumor%20immunity%20and%20prolongs%20survival%20in%20murine%20models%20of%20ovarian%20cancer%20and%20mesothelioma&journal=J%20Hematol%20Oncol&doi=10.1186%2F1756-8722-7-15&volume=7&publication_year=2014&author=Yuan%2CJ&author=Kashiwagi%2CS&author=Reeves%2CP&author=Nezivar%2CJ&author=Yang%2CY&author=Arrifin%2CNH&author=Nguyen%2CM&author=Jean-Mary%2CG&author=Tong%2CX&author=Uppal%2CP"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="21."><p class="c-article-references__text" id="ref-CR21">Klampatsa A, Dimou V, Albelda SM. Mesothelin-targeted CAR-T cell therapy for solid tumors. Expert Opin Biol Ther. 2021;21:473–86.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1080/14712598.2021.1843628" data-track-item_id="10.1080/14712598.2021.1843628" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1080%2F14712598.2021.1843628" aria-label="Article reference 21" data-doi="10.1080/14712598.2021.1843628">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXitlWkurzO" aria-label="CAS reference 21">CAS</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33176519" aria-label="PubMed reference 21">PubMed</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 21" href="http://scholar.google.com/scholar_lookup?&title=Mesothelin-targeted%20CAR-T%20cell%20therapy%20for%20solid%20tumors&journal=Expert%20Opin%20Biol%20Ther&doi=10.1080%2F14712598.2021.1843628&volume=21&pages=473-486&publication_year=2021&author=Klampatsa%2CA&author=Dimou%2CV&author=Albelda%2CSM"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="22."><p class="c-article-references__text" id="ref-CR22">Schoutrop E, El-Serafi I, Poiret T, Zhao Y, Gultekin O, He R, Moyano-Galceran L, Carlson JW, Lehti K, Hassan M, et al. Mesothelin-specific CAR T cells target ovarian cancer. Can Res. 2021;81:3022–35.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/0008-5472.CAN-20-2701" data-track-item_id="10.1158/0008-5472.CAN-20-2701" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F0008-5472.CAN-20-2701" aria-label="Article reference 22" data-doi="10.1158/0008-5472.CAN-20-2701">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXhs1GisbjM" aria-label="CAS reference 22">CAS</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 22" href="http://scholar.google.com/scholar_lookup?&title=Mesothelin-specific%20CAR%20T%20cells%20target%20ovarian%20cancer&journal=Can%20Res&doi=10.1158%2F0008-5472.CAN-20-2701&volume=81&pages=3022-3035&publication_year=2021&author=Schoutrop%2CE&author=El-Serafi%2CI&author=Poiret%2CT&author=Zhao%2CY&author=Gultekin%2CO&author=He%2CR&author=Moyano-Galceran%2CL&author=Carlson%2CJW&author=Lehti%2CK&author=Hassan%2CM"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="23."><p class="c-article-references__text" id="ref-CR23">Castelletti L, Yeo D, van Zandwijk N, Rasko JEJ. Anti-mesothelin CAR T cell therapy for malignant mesothelioma. Biomarker Research. 2021;9:11.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="noopener" data-track-label="10.1186/s40364-021-00264-1" data-track-item_id="10.1186/s40364-021-00264-1" data-track-value="article reference" data-track-action="article reference" href="https://link.springer.com/doi/10.1186/s40364-021-00264-1" aria-label="Article reference 23" data-doi="10.1186/s40364-021-00264-1">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33588928" aria-label="PubMed reference 23">PubMed</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885509" aria-label="PubMed Central reference 23">PubMed Central</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 23" href="http://scholar.google.com/scholar_lookup?&title=Anti-mesothelin%20CAR%20T%20cell%20therapy%20for%20malignant%20mesothelioma&journal=Biomarker%20Research&doi=10.1186%2Fs40364-021-00264-1&volume=9&publication_year=2021&author=Castelletti%2CL&author=Yeo%2CD&author=Zandwijk%2CN&author=Rasko%2CJEJ"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="24."><p class="c-article-references__text" id="ref-CR24">Castellanos-Rueda R, Di Roberto RB, Schlatter FS, Reddy ST. Leveraging single-cell sequencing for chimeric antigen receptor T cell therapies. Trends Biotechnol. 2021;39:1308–20.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.tibtech.2021.03.005" data-track-item_id="10.1016/j.tibtech.2021.03.005" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.tibtech.2021.03.005" aria-label="Article reference 24" data-doi="10.1016/j.tibtech.2021.03.005">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXnsV2hu7k%3D" aria-label="CAS reference 24">CAS</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33832782" aria-label="PubMed reference 24">PubMed</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 24" href="http://scholar.google.com/scholar_lookup?&title=Leveraging%20single-cell%20sequencing%20for%20chimeric%20antigen%20receptor%20T%20cell%20therapies&journal=Trends%20Biotechnol&doi=10.1016%2Fj.tibtech.2021.03.005&volume=39&pages=1308-1320&publication_year=2021&author=Castellanos-Rueda%2CR&author=Roberto%2CRB&author=Schlatter%2CFS&author=Reddy%2CST"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="25."><p class="c-article-references__text" id="ref-CR25">Zheng L, Ren L, Kouhi A, Khawli LA, Hu P, Kaslow HR, Epstein AL. A humanized Lym-1 CAR with novel DAP10/DAP12 signaling domains demonstrates reduced tonic signaling and increased antitumor activity in B-cell lymphoma models. Clin Cancer Res. 2020;26:3694–706.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/1078-0432.CCR-19-3417" data-track-item_id="10.1158/1078-0432.CCR-19-3417" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F1078-0432.CCR-19-3417" aria-label="Article reference 25" data-doi="10.1158/1078-0432.CCR-19-3417">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXitVKrt77O" aria-label="CAS reference 25">CAS</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32273277" aria-label="PubMed reference 25">PubMed</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 25" href="http://scholar.google.com/scholar_lookup?&title=A%20humanized%20Lym-1%20CAR%20with%20novel%20DAP10%2FDAP12%20signaling%20domains%20demonstrates%20reduced%20tonic%20signaling%20and%20increased%20antitumor%20activity%20in%20B-cell%20lymphoma%20models&journal=Clin%20Cancer%20Res&doi=10.1158%2F1078-0432.CCR-19-3417&volume=26&pages=3694-3706&publication_year=2020&author=Zheng%2CL&author=Ren%2CL&author=Kouhi%2CA&author=Khawli%2CLA&author=Hu%2CP&author=Kaslow%2CHR&author=Epstein%2CAL"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="26."><p class="c-article-references__text" id="ref-CR26">Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15:47–62.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/nrclinonc.2017.148" data-track-item_id="10.1038/nrclinonc.2017.148" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fnrclinonc.2017.148" aria-label="Article reference 26" data-doi="10.1038/nrclinonc.2017.148">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXhsFWnur%2FN" aria-label="CAS reference 26">CAS</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28925994" aria-label="PubMed reference 26">PubMed</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 26" href="http://scholar.google.com/scholar_lookup?&title=Chimeric%20antigen%20receptor%20T-cell%20therapy%20-%20assessment%20and%20management%20of%20toxicities&journal=Nat%20Rev%20Clin%20Oncol&doi=10.1038%2Fnrclinonc.2017.148&volume=15&pages=47-62&publication_year=2018&author=Neelapu%2CSS&author=Tummala%2CS&author=Kebriaei%2CP&author=Wierda%2CW&author=Gutierrez%2CC&author=Locke%2CFL&author=Komanduri%2CKV&author=Lin%2CY&author=Jain%2CN&author=Daver%2CN"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="27."><p class="c-article-references__text" id="ref-CR27">Fischer JW, Bhattarai N. CAR-T cell therapy: mechanism, management, and mitigation of inflammatory toxicities. Front Immunol. 2021;12:693016.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.3389/fimmu.2021.693016" data-track-item_id="10.3389/fimmu.2021.693016" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.3389%2Ffimmu.2021.693016" aria-label="Article reference 27" data-doi="10.3389/fimmu.2021.693016">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXhvFKjtrnM" aria-label="CAS reference 27">CAS</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34220853" aria-label="PubMed reference 27">PubMed</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8250150" aria-label="PubMed Central reference 27">PubMed Central</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 27" href="http://scholar.google.com/scholar_lookup?&title=CAR-T%20cell%20therapy%3A%20mechanism%2C%20management%2C%20and%20mitigation%20of%20inflammatory%20toxicities&journal=Front%20Immunol&doi=10.3389%2Ffimmu.2021.693016&volume=12&publication_year=2021&author=Fischer%2CJW&author=Bhattarai%2CN"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="28."><p class="c-article-references__text" id="ref-CR28">Chohan KL, Siegler EL, Kenderian SS. CAR-T cell therapy: the efficacy and toxicity balance. Curr Hematol Malig Rep. 2023;18:9–18.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="noopener" data-track-label="10.1007/s11899-023-00687-7" data-track-item_id="10.1007/s11899-023-00687-7" data-track-value="article reference" data-track-action="article reference" href="https://link.springer.com/doi/10.1007/s11899-023-00687-7" aria-label="Article reference 28" data-doi="10.1007/s11899-023-00687-7">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36763238" aria-label="PubMed reference 28">PubMed</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505056" aria-label="PubMed Central reference 28">PubMed Central</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 28" href="http://scholar.google.com/scholar_lookup?&title=CAR-T%20cell%20therapy%3A%20the%20efficacy%20and%20toxicity%20balance&journal=Curr%20Hematol%20Malig%20Rep.&doi=10.1007%2Fs11899-023-00687-7&volume=18&pages=9-18&publication_year=2023&author=Chohan%2CKL&author=Siegler%2CEL&author=Kenderian%2CSS"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="29."><p class="c-article-references__text" id="ref-CR29">Fultang L, Booth S, Yogev O, Martins da Costa B, Tubb V, Panetti S, Stavrou V, Scarpa U, Jankevics A, Lloyd G, et al. Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity. Blood. 2020;136:1155–60.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1182/blood.2019004500" data-track-item_id="10.1182/blood.2019004500" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1182%2Fblood.2019004500" aria-label="Article reference 29" data-doi="10.1182/blood.2019004500">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32573723" aria-label="PubMed reference 29">PubMed</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565134" aria-label="PubMed Central reference 29">PubMed Central</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 29" href="http://scholar.google.com/scholar_lookup?&title=Metabolic%20engineering%20against%20the%20arginine%20microenvironment%20enhances%20CAR-T%20cell%20proliferation%20and%20therapeutic%20activity&journal=Blood&doi=10.1182%2Fblood.2019004500&volume=136&pages=1155-1160&publication_year=2020&author=Fultang%2CL&author=Booth%2CS&author=Yogev%2CO&author=Martins%20da%20Costa%2CB&author=Tubb%2CV&author=Panetti%2CS&author=Stavrou%2CV&author=Scarpa%2CU&author=Jankevics%2CA&author=Lloyd%2CG"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="30."><p class="c-article-references__text" id="ref-CR30">Haas AR, Tanyi JL, O’Hara MH, Gladney WL, Lacey SF, Torigian DA, Soulen MC, Tian L, McGarvey M, Nelson AM, et al. Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers. Mol Ther. 2019;27:1919–29.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.ymthe.2019.07.015" data-track-item_id="10.1016/j.ymthe.2019.07.015" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.ymthe.2019.07.015" aria-label="Article reference 30" data-doi="10.1016/j.ymthe.2019.07.015">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXitFeqsb7E" aria-label="CAS reference 30">CAS</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31420241" aria-label="PubMed reference 30">PubMed</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6838875" aria-label="PubMed Central reference 30">PubMed Central</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 30" href="http://scholar.google.com/scholar_lookup?&title=Phase%20I%20study%20of%20lentiviral-transduced%20chimeric%20antigen%20receptor-modified%20T%20cells%20recognizing%20mesothelin%20in%20advanced%20solid%20cancers&journal=Mol%20Ther&doi=10.1016%2Fj.ymthe.2019.07.015&volume=27&pages=1919-1929&publication_year=2019&author=Haas%2CAR&author=Tanyi%2CJL&author=O%27Hara%2CMH&author=Gladney%2CWL&author=Lacey%2CSF&author=Torigian%2CDA&author=Soulen%2CMC&author=Tian%2CL&author=McGarvey%2CM&author=Nelson%2CAM"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="31."><p class="c-article-references__text" id="ref-CR31">Chen J, Hu J, Gu L, Ji F, Zhang F, Zhang M, Li J, Chen Z, Jiang L, Zhang Y, et al. Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer. Cancer Immunol Immunother. 2023;72:409–25.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="noopener" data-track-label="10.1007/s00262-022-03238-w" data-track-item_id="10.1007/s00262-022-03238-w" data-track-value="article reference" data-track-action="article reference" href="https://link.springer.com/doi/10.1007/s00262-022-03238-w" aria-label="Article reference 31" data-doi="10.1007/s00262-022-03238-w">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38XitlGmsL3M" aria-label="CAS reference 31">CAS</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=35925286" aria-label="PubMed reference 31">PubMed</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 31" href="http://scholar.google.com/scholar_lookup?&title=Anti-mesothelin%20CAR-T%20immunotherapy%20in%20patients%20with%20ovarian%20cancer&journal=Cancer%20Immunol%20Immunother&doi=10.1007%2Fs00262-022-03238-w&volume=72&pages=409-425&publication_year=2023&author=Chen%2CJ&author=Hu%2CJ&author=Gu%2CL&author=Ji%2CF&author=Zhang%2CF&author=Zhang%2CM&author=Li%2CJ&author=Chen%2CZ&author=Jiang%2CL&author=Zhang%2CY"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="32."><p class="c-article-references__text" id="ref-CR32">Xu T, Shu Y, et al. Characterization of mesothelin targeting novel multiple chain DAP-CAR-T cells efficacy in patients with ovarian cancer and mesothelioma through single-cell transcriptomic analysis. HRA006416. 2024. <a href="https://bigd.big.ac.cn" data-track="click_references" data-track-action="external reference" data-track-value="external reference" data-track-label="https://bigd.big.ac.cn">https://bigd.big.ac.cn</a>.</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="33."><p class="c-article-references__text" id="ref-CR33">Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-Seq data. Github. <a href="https://github.com/rcastelo/GSVA" data-track="click_references" data-track-action="external reference" data-track-value="external reference" data-track-label="https://github.com/rcastelo/GSVA">https://github.com/rcastelo/GSVA</a>.</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="34."><p class="c-article-references__text" id="ref-CR34">Efremova M, Vento-Tormo M, Teichmann S, Vento-Tormo R. CellphoneDB v2: inferring cell-cell communication from combined expression of multi-subunit receptor-ligand complexes. Github. <a href="https://github.com/ventolab/CellphoneDB" data-track="click_references" data-track-action="external reference" data-track-value="external reference" data-track-label="https://github.com/ventolab/CellphoneDB">https://github.com/ventolab/CellphoneDB</a>.</p></li></ol><p class="c-article-references__download u-hide-print"><a data-track="click" data-track-action="download citation references" data-track-label="link" rel="nofollow" href="https://citation-needed.springer.com/v2/references/10.1186/s13073-024-01405-5?format=refman&flavour=references">Download references<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-download-medium"></use></svg></a></p></div></div></div></section></div><section data-title="Acknowledgements"><div class="c-article-section" id="Ack1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Ack1">Acknowledgements</h2><div class="c-article-section__content" id="Ack1-content"><p>The authors thank the patients and their family members for their participation in the study. We also appreciate the efforts of all clinical staff and nurses who made this study feasible and patients who generously provided their samples for this study.</p></div></div></section><section data-title="Funding"><div class="c-article-section" id="Fun-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Fun">Funding</h2><div class="c-article-section__content" id="Fun-content"><p>This work was supported by grants from the National Natural Science Foundation of China (82372625 to M Sun, 82060559 to E.X. Wang, 82172889 to Y.Q. Shu, 82372593 to T.P. Xu); Natural Science Foundation of Jiangsu Province (BK20220259 to M. Sun, BK20211381 to T.P. Xu); The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School (GSKY20210112 to M. Sun); and Suzhou GuSu Health Talent Research Project (Grant number GSWS2023001 to M.S.).</p></div></div></section><section aria-labelledby="author-information" data-title="Author information"><div class="c-article-section" id="author-information-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="author-information">Author information</h2><div class="c-article-section__content" id="author-information-content"><span class="c-article-author-information__subtitle u-visually-hidden" id="author-notes">Author notes</span><ol class="c-article-author-information__list"><li class="c-article-author-information__item" id="na1"><p>Tongpeng Xu, Tian Tian, Chen Wang and Xiaofeng Chen contributed equally to this work and should be regarded as joint first authors.</p></li></ol><h3 class="c-article__sub-heading" id="affiliations">Authors and Affiliations</h3><ol class="c-article-author-affiliation__list"><li id="Aff1"><p class="c-article-author-affiliation__address">Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, 210029, People’s Republic of China</p><p class="c-article-author-affiliation__authors-list">Tongpeng Xu, Xiaofeng Chen, Hanyu Zhou, Chenhui Zhao, Chongqi Sun, Ting Wang & Yongqian Shu</p></li><li id="Aff2"><p class="c-article-author-affiliation__address">Department of Geriatric Hematology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People’s Republic of China</p><p class="c-article-author-affiliation__authors-list">Tian Tian</p></li><li id="Aff3"><p class="c-article-author-affiliation__address">Nanjing CART Medical Technology Co., Ltd, Nanjing, 210032, People’s Republic of China</p><p class="c-article-author-affiliation__authors-list">Chen Wang, Jingzhi Zhang & Enxiu Wang</p></li><li id="Aff4"><p class="c-article-author-affiliation__address">Department of Oncology, Gusu School, Suzhou Municipal Hospital, the Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, People’s Republic of China</p><p class="c-article-author-affiliation__authors-list">Hanyu Zhou</p></li><li id="Aff5"><p class="c-article-author-affiliation__address">Department of Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China</p><p class="c-article-author-affiliation__authors-list">Xiangrong Zuo</p></li><li id="Aff6"><p class="c-article-author-affiliation__address">Department of Geriatric Gastroenterology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China</p><p class="c-article-author-affiliation__authors-list">Jianan Bai</p></li><li id="Aff7"><p class="c-article-author-affiliation__address">The Second Affiliated Hospitalof , Nanjing University of Chinese Medicine, Nanjing, People’s Republic of China</p><p class="c-article-author-affiliation__authors-list">Sujie Fu</p></li><li id="Aff8"><p class="c-article-author-affiliation__address">Department of Oncology, Xishan People’s Hospital of Wuxi City, Wuxi, People’s Republic of China</p><p class="c-article-author-affiliation__authors-list">Ling Zhu</p></li><li id="Aff9"><p class="c-article-author-affiliation__address">Suzhou Cancer Center Core Laboratory, Gusu School, Suzhou Municipal Hospital, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, 215001, People’s Republic of China</p><p class="c-article-author-affiliation__authors-list">Ming Sun</p></li></ol><div class="u-js-hide u-hide-print" data-test="author-info"><span class="c-article__sub-heading">Authors</span><ol class="c-article-authors-search u-list-reset"><li id="auth-Tongpeng-Xu-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Tongpeng Xu</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="https://www.biomedcentral.com/search?query=author%23Tongpeng%20Xu" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text">You can also search for this author in <span class="c-article-identifiers"><a class="c-article-identifiers__item" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Tongpeng%20Xu" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Tongpeng%20Xu%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Tian-Tian-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Tian Tian</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="https://www.biomedcentral.com/search?query=author%23Tian%20Tian" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text">You can also search for this author in <span class="c-article-identifiers"><a class="c-article-identifiers__item" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Tian%20Tian" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Tian%20Tian%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Chen-Wang-Aff3"><span class="c-article-authors-search__title u-h3 js-search-name">Chen Wang</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="https://www.biomedcentral.com/search?query=author%23Chen%20Wang" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text">You can also search for this author in <span class="c-article-identifiers"><a class="c-article-identifiers__item" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Chen%20Wang" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Chen%20Wang%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Xiaofeng-Chen-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Xiaofeng Chen</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="https://www.biomedcentral.com/search?query=author%23Xiaofeng%20Chen" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text">You can also search for this author in <span class="c-article-identifiers"><a class="c-article-identifiers__item" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Xiaofeng%20Chen" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Xiaofeng%20Chen%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Xiangrong-Zuo-Aff5"><span class="c-article-authors-search__title u-h3 js-search-name">Xiangrong Zuo</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="https://www.biomedcentral.com/search?query=author%23Xiangrong%20Zuo" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text">You can also search for this author in <span class="c-article-identifiers"><a class="c-article-identifiers__item" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Xiangrong%20Zuo" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Xiangrong%20Zuo%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Hanyu-Zhou-Aff1-Aff4"><span class="c-article-authors-search__title u-h3 js-search-name">Hanyu Zhou</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="https://www.biomedcentral.com/search?query=author%23Hanyu%20Zhou" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text">You can also search for this author in <span class="c-article-identifiers"><a class="c-article-identifiers__item" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Hanyu%20Zhou" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Hanyu%20Zhou%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Jianan-Bai-Aff6"><span class="c-article-authors-search__title u-h3 js-search-name">Jianan Bai</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="https://www.biomedcentral.com/search?query=author%23Jianan%20Bai" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text">You can also search for this author in <span class="c-article-identifiers"><a class="c-article-identifiers__item" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Jianan%20Bai" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Jianan%20Bai%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Chenhui-Zhao-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Chenhui Zhao</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="https://www.biomedcentral.com/search?query=author%23Chenhui%20Zhao" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text">You can also search for this author in <span class="c-article-identifiers"><a class="c-article-identifiers__item" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Chenhui%20Zhao" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Chenhui%20Zhao%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Sujie-Fu-Aff7"><span class="c-article-authors-search__title u-h3 js-search-name">Sujie Fu</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="https://www.biomedcentral.com/search?query=author%23Sujie%20Fu" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text">You can also search for this author in <span class="c-article-identifiers"><a class="c-article-identifiers__item" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Sujie%20Fu" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Sujie%20Fu%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Chongqi-Sun-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Chongqi Sun</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="https://www.biomedcentral.com/search?query=author%23Chongqi%20Sun" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text">You can also search for this author in <span class="c-article-identifiers"><a class="c-article-identifiers__item" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Chongqi%20Sun" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Chongqi%20Sun%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Ting-Wang-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Ting Wang</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="https://www.biomedcentral.com/search?query=author%23Ting%20Wang" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text">You can also search for this author in <span class="c-article-identifiers"><a class="c-article-identifiers__item" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Ting%20Wang" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Ting%20Wang%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Ling-Zhu-Aff8"><span class="c-article-authors-search__title u-h3 js-search-name">Ling Zhu</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="https://www.biomedcentral.com/search?query=author%23Ling%20Zhu" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text">You can also search for this author in <span class="c-article-identifiers"><a class="c-article-identifiers__item" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Ling%20Zhu" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Ling%20Zhu%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Jingzhi-Zhang-Aff3"><span class="c-article-authors-search__title u-h3 js-search-name">Jingzhi Zhang</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="https://www.biomedcentral.com/search?query=author%23Jingzhi%20Zhang" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text">You can also search for this author in <span class="c-article-identifiers"><a class="c-article-identifiers__item" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Jingzhi%20Zhang" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Jingzhi%20Zhang%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Enxiu-Wang-Aff3"><span class="c-article-authors-search__title u-h3 js-search-name">Enxiu Wang</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="https://www.biomedcentral.com/search?query=author%23Enxiu%20Wang" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text">You can also search for this author in <span class="c-article-identifiers"><a class="c-article-identifiers__item" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Enxiu%20Wang" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Enxiu%20Wang%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Ming-Sun-Aff9"><span class="c-article-authors-search__title u-h3 js-search-name">Ming Sun</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="https://www.biomedcentral.com/search?query=author%23Ming%20Sun" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text">You can also search for this author in <span class="c-article-identifiers"><a class="c-article-identifiers__item" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Ming%20Sun" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Ming%20Sun%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Yongqian-Shu-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Yongqian Shu</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="https://www.biomedcentral.com/search?query=author%23Yongqian%20Shu" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text">You can also search for this author in <span class="c-article-identifiers"><a class="c-article-identifiers__item" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Yongqian%20Shu" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Yongqian%20Shu%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li></ol></div><h3 class="c-article__sub-heading" id="contributions">Contributions</h3><p>Concept and design, T.X., E.W., M.S. and Y.S.; provision of study materials or patients, H.Z., X.Z., X.C., C.Z., S.F., C.S., T.W.; collection and assembly of data, all authors; data analysis and interpretation, T.X., C.W., J.Z., M.S. and Y.S.; manuscript writing and critical evaluation. All authors read and approved the final manuscript.</p><h3 class="c-article__sub-heading" id="corresponding-author">Corresponding authors</h3><p id="corresponding-author-list">Correspondence to <a id="corresp-c1" href="mailto:tongpeng_xu_njmu@163.com">Tongpeng Xu</a>, <a id="corresp-c2" href="mailto:wangenxiu@cart-med.com">Enxiu Wang</a>, <a id="corresp-c3" href="mailto:sunming348@hotmail.com">Ming Sun</a> or <a id="corresp-c4" href="mailto:shuyongqian@csco.org.cn">Yongqian Shu</a>.</p></div></div></section><section data-title="Ethics declarations"><div class="c-article-section" id="ethics-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="ethics">Ethics declarations</h2><div class="c-article-section__content" id="ethics-content"> <h3 class="c-article__sub-heading" id="FPar2">Ethics approval and consent to participate</h3> <p>This study was approved by the Institution Review Board of The First Affiliated Hospital of Nanjing Medical University (2021-SR-084). This study conformed to the principles of the Helsinki Declaration. Healthy donors or patients consented to participate in the study. All participants provided written informed consent prior to participation. The animal experiment in this study was approved by the Institutional Ethics Committee of Nanjing Medical University (IACUC2103036).</p> <h3 class="c-article__sub-heading" id="FPar3">Consent for publication</h3> <p>All participants provided written informed consent for publication.</p> <h3 class="c-article__sub-heading" id="FPar4">Competing interests</h3> <p>Authors EX-W, C-W, and JZ-Z were employed by Nanjing CART Medical Technology Co., Ltd. The other authors declare that they have no competing interests.</p> </div></div></section><section data-title="Additional information"><div class="c-article-section" id="additional-information-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="additional-information">Additional information</h2><div class="c-article-section__content" id="additional-information-content"><h3 class="c-article__sub-heading">Publisher’s Note</h3><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></div></div></section><section data-title="Supplementary Information"><div class="c-article-section" id="Sec23-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec23">Supplementary Information</h2><div class="c-article-section__content" id="Sec23-content"><div data-test="supplementary-info"><div id="figshareContainer" class="c-article-figshare-container" data-test="figshare-container"></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM1"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="additional file 1. the other detail methods and ma" href="https://static-content.springer.com/esm/art%3A10.1186%2Fs13073-024-01405-5/MediaObjects/13073_2024_1405_MOESM1_ESM.docx" data-supp-info-image="">Additional file 1. The other detail Methods and Materials.</a></h3></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM2"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="13073_2024_1405_moesm2_esm.docx" href="https://static-content.springer.com/esm/art%3A10.1186%2Fs13073-024-01405-5/MediaObjects/13073_2024_1405_MOESM2_ESM.docx" data-supp-info-image="">13073_2024_1405_MOESM2_ESM.docx</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Additional file 2. Fig S1. Assessment of CA125 levels and immune pneumonia; Fig S2. Single cell sequencing analysis of the TME alteration after MSLN-CAR-T cells therapy.</p></div></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM3"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="additional file 3. protocol." href="https://static-content.springer.com/esm/art%3A10.1186%2Fs13073-024-01405-5/MediaObjects/13073_2024_1405_MOESM3_ESM.docx" data-supp-info-image="">Additional file 3. Protocol.</a></h3></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM4"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="additional file 4. consort checklist." href="https://static-content.springer.com/esm/art%3A10.1186%2Fs13073-024-01405-5/MediaObjects/13073_2024_1405_MOESM4_ESM.doc" data-supp-info-image="">Additional file 4. CONSORT Checklist.</a></h3></div></div></div></div></section><section data-title="Rights and permissions"><div class="c-article-section" id="rightslink-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="rightslink">Rights and permissions</h2><div class="c-article-section__content" id="rightslink-content"> <p><b>Open Access</b> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="http://creativecommons.org/licenses/by-nc-nd/4.0/" rel="license">http://creativecommons.org/licenses/by-nc-nd/4.0/</a>.</p> <p class="c-article-rights"><a data-track="click" data-track-action="view rights and permissions" data-track-label="link" href="https://s100.copyright.com/AppDispatchServlet?title=Efficacy%20and%20safety%20of%20novel%20multiple-chain%20DAP-CAR-T%20cells%20targeting%20mesothelin%20in%20ovarian%20cancer%20and%20mesothelioma%3A%20a%20single-arm%2C%20open-label%20and%20first-in-human%20study&author=Tongpeng%20Xu%20et%20al&contentID=10.1186%2Fs13073-024-01405-5&copyright=The%20Author%28s%29&publication=1756-994X&publicationDate=2024-11-15&publisherName=SpringerNature&orderBeanReset=true&oa=CC%20BY-NC-ND">Reprints and permissions</a></p></div></div></section><section aria-labelledby="article-info" data-title="About this article"><div class="c-article-section" id="article-info-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="article-info">About this article</h2><div class="c-article-section__content" id="article-info-content"><div class="c-bibliographic-information"><div class="u-hide-print c-bibliographic-information__column c-bibliographic-information__column--border"><a data-crossmark="10.1186/s13073-024-01405-5" target="_blank" rel="noopener" href="https://crossmark.crossref.org/dialog/?doi=10.1186/s13073-024-01405-5" data-track="click" data-track-action="Click Crossmark" data-track-label="link" data-test="crossmark"><img loading="lazy" width="57" height="81" alt="Check for updates. Verify currency and authenticity via CrossMark" src="data:image/svg+xml;base64,<svg height="81" width="57" xmlns="http://www.w3.org/2000/svg"><g fill="none" fill-rule="evenodd"><path d="m17.35 35.45 21.3-14.2v-17.03h-21.3" fill="#989898"/><path d="m38.65 35.45-21.3-14.2v-17.03h21.3" fill="#747474"/><path d="m28 .5c-12.98 0-23.5 10.52-23.5 23.5s10.52 23.5 23.5 23.5 23.5-10.52 23.5-23.5c0-6.23-2.48-12.21-6.88-16.62-4.41-4.4-10.39-6.88-16.62-6.88zm0 41.25c-9.8 0-17.75-7.95-17.75-17.75s7.95-17.75 17.75-17.75 17.75 7.95 17.75 17.75c0 4.71-1.87 9.22-5.2 12.55s-7.84 5.2-12.55 5.2z" fill="#535353"/><path d="m41 36c-5.81 6.23-15.23 7.45-22.43 2.9-7.21-4.55-10.16-13.57-7.03-21.5l-4.92-3.11c-4.95 10.7-1.19 23.42 8.78 29.71 9.97 6.3 23.07 4.22 30.6-4.86z" fill="#9c9c9c"/><path d="m.2 58.45c0-.75.11-1.42.33-2.01s.52-1.09.91-1.5c.38-.41.83-.73 1.34-.94.51-.22 1.06-.32 1.65-.32.56 0 1.06.11 1.51.35.44.23.81.5 1.1.81l-.91 1.01c-.24-.24-.49-.42-.75-.56-.27-.13-.58-.2-.93-.2-.39 0-.73.08-1.05.23-.31.16-.58.37-.81.66-.23.28-.41.63-.53 1.04-.13.41-.19.88-.19 1.39 0 1.04.23 1.86.68 2.46.45.59 1.06.88 1.84.88.41 0 .77-.07 1.07-.23s.59-.39.85-.68l.91 1c-.38.43-.8.76-1.28.99-.47.22-1 .34-1.58.34-.59 0-1.13-.1-1.64-.31-.5-.2-.94-.51-1.31-.91-.38-.4-.67-.9-.88-1.48-.22-.59-.33-1.26-.33-2.02zm8.4-5.33h1.61v2.54l-.05 1.33c.29-.27.61-.51.96-.72s.76-.31 1.24-.31c.73 0 1.27.23 1.61.71.33.47.5 1.14.5 2.02v4.31h-1.61v-4.1c0-.57-.08-.97-.25-1.21-.17-.23-.45-.35-.83-.35-.3 0-.56.08-.79.22-.23.15-.49.36-.78.64v4.8h-1.61zm7.37 6.45c0-.56.09-1.06.26-1.51.18-.45.42-.83.71-1.14.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.36c.07.62.29 1.1.65 1.44.36.33.82.5 1.38.5.29 0 .57-.04.83-.13s.51-.21.76-.37l.55 1.01c-.33.21-.69.39-1.09.53-.41.14-.83.21-1.26.21-.48 0-.92-.08-1.34-.25-.41-.16-.76-.4-1.07-.7-.31-.31-.55-.69-.72-1.13-.18-.44-.26-.95-.26-1.52zm4.6-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.07.45-.31.29-.5.73-.58 1.3zm2.5.62c0-.57.09-1.08.28-1.53.18-.44.43-.82.75-1.13s.69-.54 1.1-.71c.42-.16.85-.24 1.31-.24.45 0 .84.08 1.17.23s.61.34.85.57l-.77 1.02c-.19-.16-.38-.28-.56-.37-.19-.09-.39-.14-.61-.14-.56 0-1.01.21-1.35.63-.35.41-.52.97-.52 1.67 0 .69.17 1.24.51 1.66.34.41.78.62 1.32.62.28 0 .54-.06.78-.17.24-.12.45-.26.64-.42l.67 1.03c-.33.29-.69.51-1.08.65-.39.15-.78.23-1.18.23-.46 0-.9-.08-1.31-.24-.4-.16-.75-.39-1.05-.7s-.53-.69-.7-1.13c-.17-.45-.25-.96-.25-1.53zm6.91-6.45h1.58v6.17h.05l2.54-3.16h1.77l-2.35 2.8 2.59 4.07h-1.75l-1.77-2.98-1.08 1.23v1.75h-1.58zm13.69 1.27c-.25-.11-.5-.17-.75-.17-.58 0-.87.39-.87 1.16v.75h1.34v1.27h-1.34v5.6h-1.61v-5.6h-.92v-1.2l.92-.07v-.72c0-.35.04-.68.13-.98.08-.31.21-.57.4-.79s.42-.39.71-.51c.28-.12.63-.18 1.04-.18.24 0 .48.02.69.07.22.05.41.1.57.17zm.48 5.18c0-.57.09-1.08.27-1.53.17-.44.41-.82.72-1.13.3-.31.65-.54 1.04-.71.39-.16.8-.24 1.23-.24s.84.08 1.24.24c.4.17.74.4 1.04.71s.54.69.72 1.13c.19.45.28.96.28 1.53s-.09 1.08-.28 1.53c-.18.44-.42.82-.72 1.13s-.64.54-1.04.7-.81.24-1.24.24-.84-.08-1.23-.24-.74-.39-1.04-.7c-.31-.31-.55-.69-.72-1.13-.18-.45-.27-.96-.27-1.53zm1.65 0c0 .69.14 1.24.43 1.66.28.41.68.62 1.18.62.51 0 .9-.21 1.19-.62.29-.42.44-.97.44-1.66 0-.7-.15-1.26-.44-1.67-.29-.42-.68-.63-1.19-.63-.5 0-.9.21-1.18.63-.29.41-.43.97-.43 1.67zm6.48-3.44h1.33l.12 1.21h.05c.24-.44.54-.79.88-1.02.35-.24.7-.36 1.07-.36.32 0 .59.05.78.14l-.28 1.4-.33-.09c-.11-.01-.23-.02-.38-.02-.27 0-.56.1-.86.31s-.55.58-.77 1.1v4.2h-1.61zm-47.87 15h1.61v4.1c0 .57.08.97.25 1.2.17.24.44.35.81.35.3 0 .57-.07.8-.22.22-.15.47-.39.73-.73v-4.7h1.61v6.87h-1.32l-.12-1.01h-.04c-.3.36-.63.64-.98.86-.35.21-.76.32-1.24.32-.73 0-1.27-.24-1.61-.71-.33-.47-.5-1.14-.5-2.02zm9.46 7.43v2.16h-1.61v-9.59h1.33l.12.72h.05c.29-.24.61-.45.97-.63.35-.17.72-.26 1.1-.26.43 0 .81.08 1.15.24.33.17.61.4.84.71.24.31.41.68.53 1.11.13.42.19.91.19 1.44 0 .59-.09 1.11-.25 1.57-.16.47-.38.85-.65 1.16-.27.32-.58.56-.94.73-.35.16-.72.25-1.1.25-.3 0-.6-.07-.9-.2s-.59-.31-.87-.56zm0-2.3c.26.22.5.37.73.45.24.09.46.13.66.13.46 0 .84-.2 1.15-.6.31-.39.46-.98.46-1.77 0-.69-.12-1.22-.35-1.61-.23-.38-.61-.57-1.13-.57-.49 0-.99.26-1.52.77zm5.87-1.69c0-.56.08-1.06.25-1.51.16-.45.37-.83.65-1.14.27-.3.58-.54.93-.71s.71-.25 1.08-.25c.39 0 .73.07 1 .2.27.14.54.32.81.55l-.06-1.1v-2.49h1.61v9.88h-1.33l-.11-.74h-.06c-.25.25-.54.46-.88.64-.33.18-.69.27-1.06.27-.87 0-1.56-.32-2.07-.95s-.76-1.51-.76-2.65zm1.67-.01c0 .74.13 1.31.4 1.7.26.38.65.58 1.15.58.51 0 .99-.26 1.44-.77v-3.21c-.24-.21-.48-.36-.7-.45-.23-.08-.46-.12-.7-.12-.45 0-.82.19-1.13.59-.31.39-.46.95-.46 1.68zm6.35 1.59c0-.73.32-1.3.97-1.71.64-.4 1.67-.68 3.08-.84 0-.17-.02-.34-.07-.51-.05-.16-.12-.3-.22-.43s-.22-.22-.38-.3c-.15-.06-.34-.1-.58-.1-.34 0-.68.07-1 .2s-.63.29-.93.47l-.59-1.08c.39-.24.81-.45 1.28-.63.47-.17.99-.26 1.54-.26.86 0 1.51.25 1.93.76s.63 1.25.63 2.21v4.07h-1.32l-.12-.76h-.05c-.3.27-.63.48-.98.66s-.73.27-1.14.27c-.61 0-1.1-.19-1.48-.56-.38-.36-.57-.85-.57-1.46zm1.57-.12c0 .3.09.53.27.67.19.14.42.21.71.21.28 0 .54-.07.77-.2s.48-.31.73-.56v-1.54c-.47.06-.86.13-1.18.23-.31.09-.57.19-.76.31s-.33.25-.41.4c-.09.15-.13.31-.13.48zm6.29-3.63h-.98v-1.2l1.06-.07.2-1.88h1.34v1.88h1.75v1.27h-1.75v3.28c0 .8.32 1.2.97 1.2.12 0 .24-.01.37-.04.12-.03.24-.07.34-.11l.28 1.19c-.19.06-.4.12-.64.17-.23.05-.49.08-.76.08-.4 0-.74-.06-1.02-.18-.27-.13-.49-.3-.67-.52-.17-.21-.3-.48-.37-.78-.08-.3-.12-.64-.12-1.01zm4.36 2.17c0-.56.09-1.06.27-1.51s.41-.83.71-1.14c.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.37c.08.62.29 1.1.65 1.44.36.33.82.5 1.38.5.3 0 .58-.04.84-.13.25-.09.51-.21.76-.37l.54 1.01c-.32.21-.69.39-1.09.53s-.82.21-1.26.21c-.47 0-.92-.08-1.33-.25-.41-.16-.77-.4-1.08-.7-.3-.31-.54-.69-.72-1.13-.17-.44-.26-.95-.26-1.52zm4.61-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.08.45-.31.29-.5.73-.57 1.3zm3.01 2.23c.31.24.61.43.92.57.3.13.63.2.98.2.38 0 .65-.08.83-.23s.27-.35.27-.6c0-.14-.05-.26-.13-.37-.08-.1-.2-.2-.34-.28-.14-.09-.29-.16-.47-.23l-.53-.22c-.23-.09-.46-.18-.69-.3-.23-.11-.44-.24-.62-.4s-.33-.35-.45-.55c-.12-.21-.18-.46-.18-.75 0-.61.23-1.1.68-1.49.44-.38 1.06-.57 1.83-.57.48 0 .91.08 1.29.25s.71.36.99.57l-.74.98c-.24-.17-.49-.32-.73-.42-.25-.11-.51-.16-.78-.16-.35 0-.6.07-.76.21-.17.15-.25.33-.25.54 0 .14.04.26.12.36s.18.18.31.26c.14.07.29.14.46.21l.54.19c.23.09.47.18.7.29s.44.24.64.4c.19.16.34.35.46.58.11.23.17.5.17.82 0 .3-.06.58-.17.83-.12.26-.29.48-.51.68-.23.19-.51.34-.84.45-.34.11-.72.17-1.15.17-.48 0-.95-.09-1.41-.27-.46-.19-.86-.41-1.2-.68z" fill="#535353"/></g></svg>"></a></div><div class="c-bibliographic-information__column"><h3 class="c-article__sub-heading" id="citeas">Cite this article</h3><p class="c-bibliographic-information__citation">Xu, T., Tian, T., Wang, C. <i>et al.</i> Efficacy and safety of novel multiple-chain DAP-CAR-T cells targeting mesothelin in ovarian cancer and mesothelioma: a single-arm, open-label and first-in-human study. <i>Genome Med</i> <b>16</b>, 133 (2024). https://doi.org/10.1186/s13073-024-01405-5</p><p class="c-bibliographic-information__download-citation u-hide-print"><a data-test="citation-link" data-track="click" data-track-action="download article citation" data-track-label="link" data-track-external="" rel="nofollow" href="https://citation-needed.springer.com/v2/references/10.1186/s13073-024-01405-5?format=refman&flavour=citation">Download citation<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-download-medium"></use></svg></a></p><ul class="c-bibliographic-information__list" data-test="publication-history"><li class="c-bibliographic-information__list-item"><p>Received<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2024-02-06">06 February 2024</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Accepted<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2024-11-04">04 November 2024</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Published<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2024-11-15">15 November 2024</time></span></p></li><li class="c-bibliographic-information__list-item c-bibliographic-information__list-item--full-width"><p><abbr title="Digital Object Identifier">DOI</abbr><span class="u-hide">: </span><span class="c-bibliographic-information__value">https://doi.org/10.1186/s13073-024-01405-5</span></p></li></ul><div data-component="share-box"><div class="c-article-share-box u-display-none" hidden=""><h3 class="c-article__sub-heading">Share this article</h3><p class="c-article-share-box__description">Anyone you share the following link with will be able to read this content:</p><button class="js-get-share-url c-article-share-box__button" type="button" id="get-share-url" data-track="click" data-track-label="button" data-track-external="" data-track-action="get shareable link">Get shareable link</button><div class="js-no-share-url-container u-display-none" hidden=""><p class="js-c-article-share-box__no-sharelink-info c-article-share-box__no-sharelink-info">Sorry, a shareable link is not currently available for this article.</p></div><div class="js-share-url-container u-display-none" hidden=""><p class="js-share-url c-article-share-box__only-read-input" id="share-url" data-track="click" data-track-label="button" data-track-action="select share url"></p><button class="js-copy-share-url c-article-share-box__button--link-like" type="button" id="copy-share-url" data-track="click" data-track-label="button" data-track-action="copy share url" data-track-external="">Copy to clipboard</button></div><p class="js-c-article-share-box__additional-info c-article-share-box__additional-info"> Provided by the Springer Nature SharedIt content-sharing initiative </p></div></div><h3 class="c-article__sub-heading">Keywords</h3><ul class="c-article-subject-list"><li class="c-article-subject-list__subject"><span><a href="/search?query=MSLN&facet-discipline="Biomedicine"" data-track="click" data-track-action="view keyword" data-track-label="link">MSLN</a></span></li><li class="c-article-subject-list__subject"><span><a href="/search?query=CAR-T%20cells&facet-discipline="Biomedicine"" data-track="click" data-track-action="view keyword" data-track-label="link">CAR-T cells</a></span></li><li class="c-article-subject-list__subject"><span><a href="/search?query=Ovarian%20cancer&facet-discipline="Biomedicine"" data-track="click" data-track-action="view keyword" data-track-label="link">Ovarian cancer</a></span></li><li class="c-article-subject-list__subject"><span><a href="/search?query=Mesothelioma&facet-discipline="Biomedicine"" data-track="click" data-track-action="view keyword" data-track-label="link">Mesothelioma</a></span></li><li class="c-article-subject-list__subject"><span><a href="/search?query=Safety&facet-discipline="Biomedicine"" data-track="click" data-track-action="view keyword" data-track-label="link">Safety</a></span></li><li class="c-article-subject-list__subject"><span><a href="/search?query=Efficacy&facet-discipline="Biomedicine"" data-track="click" data-track-action="view keyword" data-track-label="link">Efficacy</a></span></li></ul><div data-component="article-info-list"></div></div></div></div></div></section> </article> </main> <div class="c-article-extras u-text-sm u-hide-print" data-container-type="reading-companion" data-track-component="reading companion"> <aside> <div data-test="download-article-link-wrapper" class="js-context-bar-sticky-point-desktop" data-track-context="reading companion"> <div class="c-pdf-download u-clear-both"> <a href="//genomemedicine.biomedcentral.com/counter/pdf/10.1186/s13073-024-01405-5.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="pdf-link" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external download> <span class="c-pdf-download__text">Download PDF</span> <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"/></svg> </a> </div> </div> <div class="c-article-associated-content__container"> <section> <h2 class="c-article-associated-content__title u-mb-24">Associated content</h2> <div class="c-article-associated-content__collection collection u-mb-24"> <section> <p class="c-article-associated-content__collection-label u-sans-serif u-text-bold u-mb-8">Collection</p> <h3 class="c-article-associated-content__collection-title u-h3 u-mb-8"> <a href="https://www.biomedcentral.com/collections/ctr" class="u-link-inherit" data-track="click" data-track-action="view collection" data-track-category="associated content" data-track-label="collection" data-test="collection-link">Clinical trials resource</a> </h3> </section> </div> </section> </div> <script> window.dataLayer = window.dataLayer || []; window.dataLayer[0] = window.dataLayer[0] || {}; window.dataLayer[0].content = window.dataLayer[0].content || {}; window.dataLayer[0].content.associatedContentTypes = "collection"; window.dataLayer[0].content.collections = "ctr"; </script> <div class="c-reading-companion"> <div class="c-reading-companion__sticky" data-component="reading-companion-sticky" data-test="reading-companion-sticky"> <div class="c-reading-companion__panel c-reading-companion__sections c-reading-companion__panel--active" id="tabpanel-sections"> <div class="js-ad u-lazy-ad-wrapper u-mt-16 u-hide" data-component-mpu> <aside class="adsbox c-ad c-ad--300x250 u-mt-16" data-component-mpu> <div class="c-ad__inner"> <p class="c-ad__label">Advertisement</p> <div id="div-gpt-ad-MPU1" data-ad-type="MPU1" data-test="MPU1-ad" data-pa11y-ignore data-gpt data-gpt-unitpath="/270604982/bmc/genomemedicine/articles" data-gpt-sizes="300x250" data-gpt-targeting="pos=MPU1;doi=10.1186/s13073-024-01405-5;type=article;kwrd=MSLN,CAR-T cells,Ovarian cancer,Mesothelioma,Safety,Efficacy;pmc=B12008,L15030,L15001,H00007,B11001,L15010;sponsored=ctr;" > <noscript> <a href="//pubads.g.doubleclick.net/gampad/jump?iu=/270604982/bmc/genomemedicine/articles&sz=300x250&pos=MPU1&doi=10.1186/s13073-024-01405-5&type=article&kwrd=MSLN,CAR-T cells,Ovarian cancer,Mesothelioma,Safety,Efficacy&pmc=B12008,L15030,L15001,H00007,B11001,L15010&sponsored=ctr&"> <img data-test="gpt-advert-fallback-img" src="//pubads.g.doubleclick.net/gampad/ad?iu=/270604982/bmc/genomemedicine/articles&sz=300x250&pos=MPU1&doi=10.1186/s13073-024-01405-5&type=article&kwrd=MSLN,CAR-T cells,Ovarian cancer,Mesothelioma,Safety,Efficacy&pmc=B12008,L15030,L15001,H00007,B11001,L15010&sponsored=ctr&" alt="Advertisement" width="300" height="250"> </a> </noscript> </div> </div> </aside> </div> </div> <div class="c-reading-companion__panel c-reading-companion__figures c-reading-companion__panel--full-width" id="tabpanel-figures"></div> <div class="c-reading-companion__panel c-reading-companion__references c-reading-companion__panel--full-width" id="tabpanel-references"></div> </div> </div> </aside> </div> </div> <div class="c-journal-footer"> <div class="c-journal-footer__inner"> <div class="c-journal-footer__summary"> <h4 class="c-journal-title c-journal-title--footer"> <span class="c-journal-title__text">Genome Medicine</span> </h4> <p class="c-journal-footer__issn">ISSN: 1756-994X</p> </div> <div class="c-journal-footer__contact"> <h4 class="c-journal-footer__contact-title ">Contact us</h4> <ul class="c-journal-footer__contact-list"> <li class="c-journal-footer__contact-item">General enquiries: <a href="mailto:journalsubmissions@springernature.com">journalsubmissions@springernature.com</a></li> </ul> </div> </div> </div> <img rel="nofollow" class='tracker' style='display:none' src='/track/article/10.1186/s13073-024-01405-5' alt=""/> <footer> <div class="c-publisher-footer u-color-inherit" data-test="publisher-footer"> <div class="u-container"> <div class="u-display-flex u-flex-wrap u-justify-content-space-between" data-test="publisher-footer-menu"> <div class="u-display-flex"> <ul class="c-list-group c-list-group--sm u-mr-24 u-mb-16"> <li class="c-list-group__item"> <a class="u-gray-link" href="https://blogs.biomedcentral.com/">Read more on our blogs</a> </li> <li class="c-list-group__item"> <a class="u-gray-link" href="//www.biomedcentral.com/login">Receive BMC newsletters</a> </li> <li class="c-list-group__item"> <a class="u-gray-link" href="//www.biomedcentral.com/account">Manage article alerts</a> </li> <li class="c-list-group__item"> <a class="u-gray-link" href="https://authorservices.springernature.com/go/sn/?utm_source=Website&utm_medium=BMC&utm_campaign=SNAS+Referrals+2022&utm_id=ref2022">Language editing for authors</a> </li> <li class="c-list-group__item"> <a class="u-gray-link" href="https://authorservices.springernature.com/go/sn/?utm_source=Website&utm_medium=BMC&utm_campaign=SNAS+Referrals+2022&utm_id=ref2022">Scientific editing for authors</a> </li> </ul> <ul class="c-list-group c-list-group--sm u-mr-24 u-mb-16"> <li class="c-list-group__item"> <a class="u-gray-link" href="//www.biomedcentral.com/about/policies">Policies</a> </li> <li class="c-list-group__item"> <a class="u-gray-link" href="//www.biomedcentral.com/accessibility">Accessibility</a> </li> <li class="c-list-group__item"> <a class="u-gray-link" href="//www.biomedcentral.com/about/press-centre">Press center</a> </li> </ul> <ul class="c-list-group c-list-group--sm u-mr-24 u-mb-16"> <li class="c-list-group__item"> <a class="u-gray-link" href="https://support.biomedcentral.com/support/home">Support and Contact</a> </li> <li class="c-list-group__item"> <a class="u-gray-link" href="https://biomedcentral.typeform.com/to/VLXboo">Leave feedback</a> </li> <li class="c-list-group__item"> <a class="u-gray-link" href="//www.biomedcentral.com/about/jobs">Careers</a> </li> </ul> </div> <div class="u-mb-24"> <h3 id="social-menu" class="u-text-sm u-reset-margin u-text-normal">Follow BMC</h3> <ul class="u-display-flex u-list-reset" data-test="footer-social-links"> <li class="u-mt-8 u-mr-8"> <a href="https://twitter.com/biomedcentral" data-track="click" data-track-category="Social" data-track-action="Clicked BMC Twitter" class="u-gray-link"> <span class="u-visually-hidden">BMC Twitter page</span> <svg class="u-icon u-text-lg" width="24" height="24" aria-hidden="true" focusable="false"> <use xlink:href="#icon-twitter-bordered"></use> </svg> </a> </li> <li class="u-mt-8 u-mr-8"> <a href="https://www.facebook.com/BioMedCentral" data-track="click" data-track-category="Social" data-track-action="Clicked BMC Facebook" class="u-gray-link"> <span class="u-visually-hidden">BMC Facebook page</span> <svg class="u-icon u-text-lg" width="24" height="24" aria-hidden="true" focusable="false"> <use xlink:href="#icon-facebook-bordered"></use> </svg> </a> </li> <li class="u-mt-8 u-mr-8"> <a href="http://www.weibo.com/biomedcentral" data-track="click" data-track-category="Social" data-track-action="Clicked BMC Weibo" class="u-gray-link"> <span class="u-visually-hidden">BMC Weibo page</span> <svg class="u-icon u-text-lg" width="24" height="24" aria-hidden="true" focusable="false"> <use xlink:href="#icon-weibo-bordered"></use> </svg> </a> </li> </ul> </div> </div> <p class="u-reset-margin"> By using this website, you agree to our <a class="u-gray-link" href="//www.biomedcentral.com/terms-and-conditions">Terms and Conditions</a>, <a class="u-gray-link" href="https://www.springernature.com/ccpa">Your US state privacy rights</a>, <a class="u-gray-link" href="//www.biomedcentral.com/privacy-statement">Privacy statement</a> and <a class="u-gray-link" href="//www.biomedcentral.com/cookies" data-test="cookie-link">Cookies</a> policy. <a class="u-gray-link" data-cc-action="preferences" href="javascript:void(0);">Your privacy choices/Manage cookies</a> we use in the preference centre. </p> </div> </div> <div class="c-corporate-footer"> <div class="u-container"> <img src=/static/images/logo-springernature-acb40b85fb.svg class="c-corporate-footer__logo" alt="Springer Nature" itemprop="logo" role="img"> <p class="c-corporate-footer__legal" data-test="copyright"> © 2024 BioMed Central Ltd unless otherwise stated. Part of <a class="c-corporate-footer__link" href="https://www.springernature.com" itemscope itemtype="http://schema.org/Organization" itemid="#parentOrganization">Springer Nature</a>. </p> </div> </div> </footer> </div> <div class="u-visually-hidden" aria-hidden="true"> <?xml version="1.0" encoding="UTF-8"?><!DOCTYPE svg PUBLIC "-//W3C//DTD SVG 1.1//EN" "http://www.w3.org/Graphics/SVG/1.1/DTD/svg11.dtd"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><defs><path id="a" d="M0 .74h56.72v55.24H0z"/></defs><symbol id="icon-access" viewBox="0 0 18 18"><path d="m14 8c.5522847 0 1 .44771525 1 1v7h2.5c.2761424 0 .5.2238576.5.5v1.5h-18v-1.5c0-.2761424.22385763-.5.5-.5h2.5v-7c0-.55228475.44771525-1 1-1s1 .44771525 1 1v6.9996556h8v-6.9996556c0-.55228475.4477153-1 1-1zm-8 0 2 1v5l-2 1zm6 0v7l-2-1v-5zm-2.42653766-7.59857636 7.03554716 4.92488299c.4162533.29137735.5174853.86502537.226108 1.28127873-.1721584.24594054-.4534847.39241464-.7536934.39241464h-14.16284822c-.50810197 0-.92-.41189803-.92-.92 0-.30020869.1464741-.58153499.39241464-.75369337l7.03554714-4.92488299c.34432015-.2410241.80260453-.2410241 1.14692468 0zm-.57346234 2.03988748-3.65526982 2.55868888h7.31053962z" fill-rule="evenodd"/></symbol><symbol id="icon-account" viewBox="0 0 18 18"><path d="m10.2379028 16.9048051c1.3083556-.2032362 2.5118471-.7235183 3.5294683-1.4798399-.8731327-2.5141501-2.0638925-3.935978-3.7673711-4.3188248v-1.27684611c1.1651924-.41183641 2-1.52307546 2-2.82929429 0-1.65685425-1.3431458-3-3-3-1.65685425 0-3 1.34314575-3 3 0 1.30621883.83480763 2.41745788 2 2.82929429v1.27684611c-1.70347856.3828468-2.89423845 1.8046747-3.76737114 4.3188248 1.01762123.7563216 2.22111275 1.2766037 3.52946833 1.4798399.40563808.0629726.81921174.0951949 1.23790281.0951949s.83226473-.0322223 1.2379028-.0951949zm4.3421782-2.1721994c1.4927655-1.4532925 2.419919-3.484675 2.419919-5.7326057 0-4.418278-3.581722-8-8-8s-8 3.581722-8 8c0 2.2479307.92715352 4.2793132 2.41991895 5.7326057.75688473-2.0164459 1.83949951-3.6071894 3.48926591-4.3218837-1.14534283-.70360829-1.90918486-1.96796271-1.90918486-3.410722 0-2.209139 1.790861-4 4-4s4 1.790861 4 4c0 1.44275929-.763842 2.70711371-1.9091849 3.410722 1.6497664.7146943 2.7323812 2.3054378 3.4892659 4.3218837zm-5.580081 3.2673943c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"/></symbol><symbol id="icon-alert" viewBox="0 0 18 18"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill-rule="evenodd"/></symbol><symbol id="icon-arrow-broad" viewBox="0 0 16 16"><path d="m6.10307866 2.97190702v7.69043288l2.44965196-2.44676915c.38776071-.38730439 1.0088052-.39493524 1.38498697-.01919617.38609051.38563612.38643641 1.01053024-.00013864 1.39665039l-4.12239817 4.11754683c-.38616704.3857126-1.01187344.3861062-1.39846576-.0000311l-4.12258206-4.11773056c-.38618426-.38572979-.39254614-1.00476697-.01636437-1.38050605.38609047-.38563611 1.01018509-.38751562 1.4012233.00306241l2.44985644 2.4469734v-8.67638639c0-.54139983.43698413-.98042709.98493125-.98159081l7.89910522-.0043627c.5451687 0 .9871152.44142642.9871152.98595351s-.4419465.98595351-.9871152.98595351z" fill-rule="evenodd" transform="matrix(-1 0 0 -1 14 15)"/></symbol><symbol id="icon-arrow-down" viewBox="0 0 16 16"><path d="m3.28337502 11.5302405 4.03074001 4.176208c.37758093.3912076.98937525.3916069 1.367372-.0000316l4.03091977-4.1763942c.3775978-.3912252.3838182-1.0190815.0160006-1.4001736-.3775061-.39113013-.9877245-.39303641-1.3700683.003106l-2.39538585 2.4818345v-11.6147896l-.00649339-.11662112c-.055753-.49733869-.46370161-.88337888-.95867408-.88337888-.49497246 0-.90292107.38604019-.95867408.88337888l-.00649338.11662112v11.6147896l-2.39518594-2.4816273c-.37913917-.39282218-.98637524-.40056175-1.35419292-.0194697-.37750607.3911302-.37784433 1.0249269.00013556 1.4165479z" fill-rule="evenodd"/></symbol><symbol id="icon-arrow-left" viewBox="0 0 16 16"><path d="m4.46975946 3.28337502-4.17620792 4.03074001c-.39120768.37758093-.39160691.98937525.0000316 1.367372l4.1763942 4.03091977c.39122514.3775978 1.01908149.3838182 1.40017357.0160006.39113012-.3775061.3930364-.9877245-.00310603-1.3700683l-2.48183446-2.39538585h11.61478958l.1166211-.00649339c.4973387-.055753.8833789-.46370161.8833789-.95867408 0-.49497246-.3860402-.90292107-.8833789-.95867408l-.1166211-.00649338h-11.61478958l2.4816273-2.39518594c.39282216-.37913917.40056173-.98637524.01946965-1.35419292-.39113012-.37750607-1.02492687-.37784433-1.41654791.00013556z" fill-rule="evenodd"/></symbol><symbol id="icon-arrow-right" viewBox="0 0 16 16"><path d="m11.5302405 12.716625 4.176208-4.03074003c.3912076-.37758093.3916069-.98937525-.0000316-1.367372l-4.1763942-4.03091981c-.3912252-.37759778-1.0190815-.38381821-1.4001736-.01600053-.39113013.37750607-.39303641.98772445.003106 1.37006824l2.4818345 2.39538588h-11.6147896l-.11662112.00649339c-.49733869.055753-.88337888.46370161-.88337888.95867408 0 .49497246.38604019.90292107.88337888.95867408l.11662112.00649338h11.6147896l-2.4816273 2.39518592c-.39282218.3791392-.40056175.9863753-.0194697 1.3541929.3911302.3775061 1.0249269.3778444 1.4165479-.0001355z" fill-rule="evenodd"/></symbol><symbol id="icon-arrow-sub" viewBox="0 0 16 16"><path d="m7.89692134 4.97190702v7.69043288l-2.44965196-2.4467692c-.38776071-.38730434-1.0088052-.39493519-1.38498697-.0191961-.38609047.3856361-.38643643 1.0105302.00013864 1.3966504l4.12239817 4.1175468c.38616704.3857126 1.01187344.3861062 1.39846576-.0000311l4.12258202-4.1177306c.3861843-.3857298.3925462-1.0047669.0163644-1.380506-.3860905-.38563612-1.0101851-.38751563-1.4012233.0030624l-2.44985643 2.4469734v-8.67638639c0-.54139983-.43698413-.98042709-.98493125-.98159081l-7.89910525-.0043627c-.54516866 0-.98711517.44142642-.98711517.98595351s.44194651.98595351.98711517.98595351z" fill-rule="evenodd"/></symbol><symbol id="icon-arrow-up" viewBox="0 0 16 16"><path d="m12.716625 4.46975946-4.03074003-4.17620792c-.37758093-.39120768-.98937525-.39160691-1.367372.0000316l-4.03091981 4.1763942c-.37759778.39122514-.38381821 1.01908149-.01600053 1.40017357.37750607.39113012.98772445.3930364 1.37006824-.00310603l2.39538588-2.48183446v11.61478958l.00649339.1166211c.055753.4973387.46370161.8833789.95867408.8833789.49497246 0 .90292107-.3860402.95867408-.8833789l.00649338-.1166211v-11.61478958l2.39518592 2.4816273c.3791392.39282216.9863753.40056173 1.3541929.01946965.3775061-.39113012.3778444-1.02492687-.0001355-1.41654791z" fill-rule="evenodd"/></symbol><symbol id="icon-article" viewBox="0 0 18 18"><path d="m13 15v-12.9906311c0-.0073595-.0019884-.0093689.0014977-.0093689l-11.00158888.00087166v13.00506804c0 .5482678.44615281.9940603.99415146.9940603h10.27350412c-.1701701-.2941734-.2675644-.6357129-.2675644-1zm-12 .0059397v-13.00506804c0-.5562408.44704472-1.00087166.99850233-1.00087166h11.00299537c.5510129 0 .9985023.45190985.9985023 1.0093689v2.9906311h3v9.9914698c0 1.1065798-.8927712 2.0085302-1.9940603 2.0085302h-12.01187942c-1.09954652 0-1.99406028-.8927712-1.99406028-1.9940603zm13-9.0059397v9c0 .5522847.4477153 1 1 1s1-.4477153 1-1v-9zm-10-2h7v4h-7zm1 1v2h5v-2zm-1 4h7v1h-7zm0 2h7v1h-7zm0 2h7v1h-7z" fill-rule="evenodd"/></symbol><symbol id="icon-audio" viewBox="0 0 18 18"><path d="m13.0957477 13.5588459c-.195279.1937043-.5119137.193729-.7072234.0000551-.1953098-.193674-.1953346-.5077061-.0000556-.7014104 1.0251004-1.0168342 1.6108711-2.3905226 1.6108711-3.85745208 0-1.46604976-.5850634-2.83898246-1.6090736-3.85566829-.1951894-.19379323-.1950192-.50782531.0003802-.70141028.1953993-.19358497.512034-.19341614.7072234.00037709 1.2094886 1.20083761 1.901635 2.8250555 1.901635 4.55670148 0 1.73268608-.6929822 3.35779608-1.9037571 4.55880738zm2.1233994 2.1025159c-.195234.193749-.5118687.1938462-.7072235.0002171-.1953548-.1936292-.1954528-.5076613-.0002189-.7014104 1.5832215-1.5711805 2.4881302-3.6939808 2.4881302-5.96012998 0-2.26581266-.9046382-4.3883241-2.487443-5.95944795-.1952117-.19377107-.1950777-.50780316.0002993-.70141031s.5120117-.19347426.7072234.00029682c1.7683321 1.75528196 2.7800854 4.12911258 2.7800854 6.66056144 0 2.53182498-1.0120556 4.90597838-2.7808529 6.66132328zm-14.21898205-3.6854911c-.5523759 0-1.00016505-.4441085-1.00016505-.991944v-3.96777631c0-.54783558.44778915-.99194407 1.00016505-.99194407h2.0003301l5.41965617-3.8393633c.44948677-.31842296 1.07413994-.21516983 1.39520191.23062232.12116339.16823446.18629727.36981184.18629727.57655577v12.01603479c0 .5478356-.44778914.9919441-1.00016505.9919441-.20845738 0-.41170538-.0645985-.58133413-.184766l-5.41965617-3.8393633zm0-.991944h2.32084805l5.68047235 4.0241292v-12.01603479l-5.68047235 4.02412928h-2.32084805z" fill-rule="evenodd"/></symbol><symbol id="icon-block" viewBox="0 0 24 24"><path d="m0 0h24v24h-24z" fill-rule="evenodd"/></symbol><symbol id="icon-book" viewBox="0 0 18 18"><path d="m4 13v-11h1v11h11v-11h-13c-.55228475 0-1 .44771525-1 1v10.2675644c.29417337-.1701701.63571286-.2675644 1-.2675644zm12 1h-13c-.55228475 0-1 .4477153-1 1s.44771525 1 1 1h13zm0 3h-13c-1.1045695 0-2-.8954305-2-2v-12c0-1.1045695.8954305-2 2-2h13c.5522847 0 1 .44771525 1 1v14c0 .5522847-.4477153 1-1 1zm-8.5-13h6c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm1 2h4c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-4c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"/></symbol><symbol id="icon-broad" viewBox="0 0 24 24"><path d="m9.18274226 7.81v7.7999954l2.48162734-2.4816273c.3928221-.3928221 1.0219731-.4005617 1.4030652-.0194696.3911301.3911301.3914806 1.0249268-.0001404 1.4165479l-4.17620796 4.1762079c-.39120769.3912077-1.02508144.3916069-1.41671995-.0000316l-4.1763942-4.1763942c-.39122514-.3912251-.39767006-1.0190815-.01657798-1.4001736.39113012-.3911301 1.02337106-.3930364 1.41951349.0031061l2.48183446 2.4818344v-8.7999954c0-.54911294.4426881-.99439484.99778758-.99557515l8.00221246-.00442485c.5522847 0 1 .44771525 1 1s-.4477153 1-1 1z" fill-rule="evenodd" transform="matrix(-1 0 0 -1 20.182742 24.805206)"/></symbol><symbol id="icon-calendar" viewBox="0 0 18 18"><path d="m12.5 0c.2761424 0 .5.21505737.5.49047852v.50952148h2c1.1072288 0 2 .89451376 2 2v12c0 1.1072288-.8945138 2-2 2h-12c-1.1072288 0-2-.8945138-2-2v-12c0-1.1072288.89451376-2 2-2h1v1h-1c-.55393837 0-1 .44579254-1 1v3h14v-3c0-.55393837-.4457925-1-1-1h-2v1.50952148c0 .27088381-.2319336.49047852-.5.49047852-.2761424 0-.5-.21505737-.5-.49047852v-3.01904296c0-.27088381.2319336-.49047852.5-.49047852zm3.5 7h-14v8c0 .5539384.44579254 1 1 1h12c.5539384 0 1-.4457925 1-1zm-11 6v1h-1v-1zm3 0v1h-1v-1zm3 0v1h-1v-1zm-6-2v1h-1v-1zm3 0v1h-1v-1zm6 0v1h-1v-1zm-3 0v1h-1v-1zm-3-2v1h-1v-1zm6 0v1h-1v-1zm-3 0v1h-1v-1zm-5.5-9c.27614237 0 .5.21505737.5.49047852v.50952148h5v1h-5v1.50952148c0 .27088381-.23193359.49047852-.5.49047852-.27614237 0-.5-.21505737-.5-.49047852v-3.01904296c0-.27088381.23193359-.49047852.5-.49047852z" fill-rule="evenodd"/></symbol><symbol id="icon-cart" viewBox="0 0 18 18"><path d="m5 14c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm10 0c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm-10 1c-.55228475 0-1 .4477153-1 1s.44771525 1 1 1 1-.4477153 1-1-.44771525-1-1-1zm10 0c-.5522847 0-1 .4477153-1 1s.4477153 1 1 1 1-.4477153 1-1-.4477153-1-1-1zm-12.82032249-15c.47691417 0 .88746157.33678127.98070211.80449199l.23823144 1.19501025 13.36277974.00045554c.5522847.00001882.9999659.44774934.9999659 1.00004222 0 .07084994-.0075361.14150708-.022474.2107727l-1.2908094 5.98534344c-.1007861.46742419-.5432548.80388386-1.0571651.80388386h-10.24805106c-.59173366 0-1.07142857.4477153-1.07142857 1 0 .5128358.41361449.9355072.94647737.9932723l.1249512.0067277h10.35933776c.2749512 0 .4979349.2228539.4979349.4978051 0 .2749417-.2227336.4978951-.4976753.4980063l-10.35959736.0041886c-1.18346732 0-2.14285714-.8954305-2.14285714-2 0-.6625717.34520317-1.24989198.87690425-1.61383592l-1.63768102-8.19004794c-.01312273-.06561364-.01950005-.131011-.0196107-.19547395l-1.71961253-.00064219c-.27614237 0-.5-.22385762-.5-.5 0-.27614237.22385763-.5.5-.5zm14.53193359 2.99950224h-13.11300004l1.20580469 6.02530174c.11024034-.0163252.22327998-.02480398.33844139-.02480398h10.27064786z"/></symbol><symbol id="icon-chevron-less" viewBox="0 0 10 10"><path d="m5.58578644 4-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" fill-rule="evenodd" transform="matrix(0 -1 -1 0 9 9)"/></symbol><symbol id="icon-chevron-more" viewBox="0 0 10 10"><path d="m5.58578644 6-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4.00000002c-.39052429.3905243-1.02368927.3905243-1.41421356 0s-.39052429-1.02368929 0-1.41421358z" fill-rule="evenodd" transform="matrix(0 1 -1 0 11 1)"/></symbol><symbol id="icon-chevron-right" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"/></symbol><symbol id="icon-circle-fill" viewBox="0 0 16 16"><path d="m8 14c-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6 6 2.6862915 6 6-2.6862915 6-6 6z" fill-rule="evenodd"/></symbol><symbol id="icon-circle" viewBox="0 0 16 16"><path d="m8 12c2.209139 0 4-1.790861 4-4s-1.790861-4-4-4-4 1.790861-4 4 1.790861 4 4 4zm0 2c-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6 6 2.6862915 6 6-2.6862915 6-6 6z" fill-rule="evenodd"/></symbol><symbol id="icon-citation" viewBox="0 0 18 18"><path d="m8.63593473 5.99995183c2.20913897 0 3.99999997 1.79084375 3.99999997 3.99996146 0 1.40730761-.7267788 2.64486871-1.8254829 3.35783281 1.6240224.6764218 2.8754442 2.0093871 3.4610603 3.6412466l-1.0763845.000006c-.5310008-1.2078237-1.5108121-2.1940153-2.7691712-2.7181346l-.79002167-.329052v-1.023992l.63016577-.4089232c.8482885-.5504661 1.3698342-1.4895187 1.3698342-2.51898361 0-1.65683828-1.3431457-2.99996146-2.99999997-2.99996146-1.65685425 0-3 1.34312318-3 2.99996146 0 1.02946491.52154569 1.96851751 1.36983419 2.51898361l.63016581.4089232v1.023992l-.79002171.329052c-1.25835905.5241193-2.23817037 1.5103109-2.76917113 2.7181346l-1.07638453-.000006c.58561612-1.6318595 1.8370379-2.9648248 3.46106024-3.6412466-1.09870405-.7129641-1.82548287-1.9505252-1.82548287-3.35783281 0-2.20911771 1.790861-3.99996146 4-3.99996146zm7.36897597-4.99995183c1.1018574 0 1.9950893.89353404 1.9950893 2.00274083v5.994422c0 1.10608317-.8926228 2.00274087-1.9950893 2.00274087l-3.0049107-.0009037v-1l3.0049107.00091329c.5490631 0 .9950893-.44783123.9950893-1.00275046v-5.994422c0-.55646537-.4450595-1.00275046-.9950893-1.00275046h-14.00982141c-.54906309 0-.99508929.44783123-.99508929 1.00275046v5.9971821c0 .66666024.33333333.99999036 1 .99999036l2-.00091329v1l-2 .0009037c-1 0-2-.99999041-2-1.99998077v-5.9971821c0-1.10608322.8926228-2.00274083 1.99508929-2.00274083zm-8.5049107 2.9999711c.27614237 0 .5.22385547.5.5 0 .2761349-.22385763.5-.5.5h-4c-.27614237 0-.5-.2238651-.5-.5 0-.27614453.22385763-.5.5-.5zm3 0c.2761424 0 .5.22385547.5.5 0 .2761349-.2238576.5-.5.5h-1c-.27614237 0-.5-.2238651-.5-.5 0-.27614453.22385763-.5.5-.5zm4 0c.2761424 0 .5.22385547.5.5 0 .2761349-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238651-.5-.5 0-.27614453.2238576-.5.5-.5z" fill-rule="evenodd"/></symbol><symbol id="icon-close" viewBox="0 0 16 16"><path d="m2.29679575 12.2772478c-.39658757.3965876-.39438847 1.0328109-.00062148 1.4265779.39651227.3965123 1.03246768.3934888 1.42657791-.0006214l4.27724782-4.27724787 4.2772478 4.27724787c.3965876.3965875 1.0328109.3943884 1.4265779.0006214.3965123-.3965122.3934888-1.0324677-.0006214-1.4265779l-4.27724787-4.2772478 4.27724787-4.27724782c.3965875-.39658757.3943884-1.03281091.0006214-1.42657791-.3965122-.39651226-1.0324677-.39348875-1.4265779.00062148l-4.2772478 4.27724782-4.27724782-4.27724782c-.39658757-.39658757-1.03281091-.39438847-1.42657791-.00062148-.39651226.39651227-.39348875 1.03246768.00062148 1.42657791l4.27724782 4.27724782z" fill-rule="evenodd"/></symbol><symbol id="icon-collections" viewBox="0 0 18 18"><path d="m15 4c1.1045695 0 2 .8954305 2 2v9c0 1.1045695-.8954305 2-2 2h-8c-1.1045695 0-2-.8954305-2-2h1c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h8c.5128358 0 .9355072-.3860402.9932723-.8833789l.0067277-.1166211v-9c0-.51283584-.3860402-.93550716-.8833789-.99327227l-.1166211-.00672773h-1v-1zm-4-3c1.1045695 0 2 .8954305 2 2v9c0 1.1045695-.8954305 2-2 2h-8c-1.1045695 0-2-.8954305-2-2v-9c0-1.1045695.8954305-2 2-2zm0 1h-8c-.51283584 0-.93550716.38604019-.99327227.88337887l-.00672773.11662113v9c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h8c.5128358 0 .9355072-.3860402.9932723-.8833789l.0067277-.1166211v-9c0-.51283584-.3860402-.93550716-.8833789-.99327227zm-1.5 7c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm0-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm0-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"/></symbol><symbol id="icon-compare" viewBox="0 0 18 18"><path d="m12 3c3.3137085 0 6 2.6862915 6 6s-2.6862915 6-6 6c-1.0928452 0-2.11744941-.2921742-2.99996061-.8026704-.88181407.5102749-1.90678042.8026704-3.00003939.8026704-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6c1.09325897 0 2.11822532.29239547 3.00096303.80325037.88158756-.51107621 1.90619177-.80325037 2.99903697-.80325037zm-6 1c-2.76142375 0-5 2.23857625-5 5 0 2.7614237 2.23857625 5 5 5 .74397391 0 1.44999672-.162488 2.08451611-.4539116-1.27652344-1.1000812-2.08451611-2.7287264-2.08451611-4.5460884s.80799267-3.44600721 2.08434391-4.5463015c-.63434719-.29121054-1.34037-.4536985-2.08434391-.4536985zm6 0c-.7439739 0-1.4499967.16248796-2.08451611.45391156 1.27652341 1.10008123 2.08451611 2.72872644 2.08451611 4.54608844s-.8079927 3.4460072-2.08434391 4.5463015c.63434721.2912105 1.34037001.4536985 2.08434391.4536985 2.7614237 0 5-2.2385763 5-5 0-2.76142375-2.2385763-5-5-5zm-1.4162763 7.0005324h-3.16744736c.15614659.3572676.35283837.6927622.58425872 1.0006671h1.99892988c.23142036-.3079049.42811216-.6433995.58425876-1.0006671zm.4162763-2.0005324h-4c0 .34288501.0345146.67770871.10025909 1.0011864h3.79948181c.0657445-.32347769.1002591-.65830139.1002591-1.0011864zm-.4158423-1.99953894h-3.16831543c-.13859957.31730812-.24521946.651783-.31578599.99935097h3.79988742c-.0705665-.34756797-.1771864-.68204285-.315786-.99935097zm-1.58295822-1.999926-.08316107.06199199c-.34550042.27081213-.65446126.58611297-.91825862.93727862h2.00044041c-.28418626-.37830727-.6207872-.71499149-.99902072-.99927061z" fill-rule="evenodd"/></symbol><symbol id="icon-download-file" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm0 1h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v14.00982141c0 .5500396.44491393.9950893.99406028.9950893h12.01187942c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717zm-1.5046024 4c.27614237 0 .5.21637201.5.49209595v6.14827645l1.7462789-1.77990922c.1933927-.1971171.5125222-.19455839.7001689-.0069117.1932998.19329992.1910058.50899492-.0027774.70277812l-2.59089271 2.5908927c-.19483374.1948337-.51177825.1937771-.70556873-.0000133l-2.59099079-2.5909908c-.19484111-.1948411-.19043735-.5151448-.00279066-.70279146.19329987-.19329987.50465175-.19237083.70018565.00692852l1.74638684 1.78001764v-6.14827695c0-.27177709.23193359-.49209595.5-.49209595z" fill-rule="evenodd"/></symbol><symbol id="icon-download" viewBox="0 0 16 16"><path d="m12.9975267 12.999368c.5467123 0 1.0024733.4478567 1.0024733 1.000316 0 .5563109-.4488226 1.000316-1.0024733 1.000316h-9.99505341c-.54671233 0-1.00247329-.4478567-1.00247329-1.000316 0-.5563109.44882258-1.000316 1.00247329-1.000316zm-4.9975267-11.999368c.55228475 0 1 .44497754 1 .99589209v6.80214418l2.4816273-2.48241149c.3928222-.39294628 1.0219732-.4006883 1.4030652-.01947579.3911302.39125371.3914806 1.02525073-.0001404 1.41699553l-4.17620792 4.17752758c-.39120769.3913313-1.02508144.3917306-1.41671995-.0000316l-4.17639421-4.17771394c-.39122513-.39134876-.39767006-1.01940351-.01657797-1.40061601.39113012-.39125372 1.02337105-.3931606 1.41951349.00310701l2.48183446 2.48261871v-6.80214418c0-.55001601.44386482-.99589209 1-.99589209z" fill-rule="evenodd"/></symbol><symbol id="icon-editors" viewBox="0 0 18 18"><path d="m8.72592184 2.54588137c-.48811714-.34391207-1.08343326-.54588137-1.72592184-.54588137-1.65685425 0-3 1.34314575-3 3 0 1.02947485.5215457 1.96853646 1.3698342 2.51900785l.6301658.40892721v1.02400182l-.79002171.32905522c-1.93395773.8055207-3.20997829 2.7024791-3.20997829 4.8180274v.9009805h-1v-.9009805c0-2.5479714 1.54557359-4.79153984 3.82548288-5.7411543-1.09870406-.71297106-1.82548288-1.95054399-1.82548288-3.3578652 0-2.209139 1.790861-4 4-4 1.09079823 0 2.07961816.43662103 2.80122451 1.1446278-.37707584.09278571-.7373238.22835063-1.07530267.40125357zm-2.72592184 14.45411863h-1v-.9009805c0-2.5479714 1.54557359-4.7915398 3.82548288-5.7411543-1.09870406-.71297106-1.82548288-1.95054399-1.82548288-3.3578652 0-2.209139 1.790861-4 4-4s4 1.790861 4 4c0 1.40732121-.7267788 2.64489414-1.8254829 3.3578652 2.2799093.9496145 3.8254829 3.1931829 3.8254829 5.7411543v.9009805h-1v-.9009805c0-2.1155483-1.2760206-4.0125067-3.2099783-4.8180274l-.7900217-.3290552v-1.02400184l.6301658-.40892721c.8482885-.55047139 1.3698342-1.489533 1.3698342-2.51900785 0-1.65685425-1.3431458-3-3-3-1.65685425 0-3 1.34314575-3 3 0 1.02947485.5215457 1.96853646 1.3698342 2.51900785l.6301658.40892721v1.02400184l-.79002171.3290552c-1.93395773.8055207-3.20997829 2.7024791-3.20997829 4.8180274z" fill-rule="evenodd"/></symbol><symbol id="icon-email" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587h-14.00982141c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm0 1h-14.00982141c-.54871518 0-.99508929.44887827-.99508929 1.00585866v9.98828264c0 .5572961.44630695 1.0058587.99508929 1.0058587h14.00982141c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-.0049107 2.55749512v1.44250488l-7 4-7-4v-1.44250488l7 4z" fill-rule="evenodd"/></symbol><symbol id="icon-error" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm2.8630343 4.71100931-2.8630343 2.86303426-2.86303426-2.86303426c-.39658757-.39658757-1.03281091-.39438847-1.4265779-.00062147-.39651227.39651226-.39348876 1.03246767.00062147 1.4265779l2.86303426 2.86303426-2.86303426 2.8630343c-.39658757.3965875-.39438847 1.0328109-.00062147 1.4265779.39651226.3965122 1.03246767.3934887 1.4265779-.0006215l2.86303426-2.8630343 2.8630343 2.8630343c.3965875.3965876 1.0328109.3943885 1.4265779.0006215.3965122-.3965123.3934887-1.0324677-.0006215-1.4265779l-2.8630343-2.8630343 2.8630343-2.86303426c.3965876-.39658757.3943885-1.03281091.0006215-1.4265779-.3965123-.39651227-1.0324677-.39348876-1.4265779.00062147z" fill-rule="evenodd"/></symbol><symbol id="icon-ethics" viewBox="0 0 18 18"><path d="m6.76384967 1.41421356.83301651-.8330165c.77492941-.77492941 2.03133823-.77492941 2.80626762 0l.8330165.8330165c.3750728.37507276.8837806.58578644 1.4142136.58578644h1.3496361c1.1045695 0 2 .8954305 2 2v1.34963611c0 .53043298.2107137 1.03914081.5857864 1.41421356l.8330165.83301651c.7749295.77492941.7749295 2.03133823 0 2.80626762l-.8330165.8330165c-.3750727.3750728-.5857864.8837806-.5857864 1.4142136v1.3496361c0 1.1045695-.8954305 2-2 2h-1.3496361c-.530433 0-1.0391408.2107137-1.4142136.5857864l-.8330165.8330165c-.77492939.7749295-2.03133821.7749295-2.80626762 0l-.83301651-.8330165c-.37507275-.3750727-.88378058-.5857864-1.41421356-.5857864h-1.34963611c-1.1045695 0-2-.8954305-2-2v-1.3496361c0-.530433-.21071368-1.0391408-.58578644-1.4142136l-.8330165-.8330165c-.77492941-.77492939-.77492941-2.03133821 0-2.80626762l.8330165-.83301651c.37507276-.37507275.58578644-.88378058.58578644-1.41421356v-1.34963611c0-1.1045695.8954305-2 2-2h1.34963611c.53043298 0 1.03914081-.21071368 1.41421356-.58578644zm-1.41421356 1.58578644h-1.34963611c-.55228475 0-1 .44771525-1 1v1.34963611c0 .79564947-.31607052 1.55871121-.87867966 2.12132034l-.8330165.83301651c-.38440512.38440512-.38440512 1.00764896 0 1.39205408l.8330165.83301646c.56260914.5626092.87867966 1.3256709.87867966 2.1213204v1.3496361c0 .5522847.44771525 1 1 1h1.34963611c.79564947 0 1.55871121.3160705 2.12132034.8786797l.83301651.8330165c.38440512.3844051 1.00764896.3844051 1.39205408 0l.83301646-.8330165c.5626092-.5626092 1.3256709-.8786797 2.1213204-.8786797h1.3496361c.5522847 0 1-.4477153 1-1v-1.3496361c0-.7956495.3160705-1.5587112.8786797-2.1213204l.8330165-.83301646c.3844051-.38440512.3844051-1.00764896 0-1.39205408l-.8330165-.83301651c-.5626092-.56260913-.8786797-1.32567087-.8786797-2.12132034v-1.34963611c0-.55228475-.4477153-1-1-1h-1.3496361c-.7956495 0-1.5587112-.31607052-2.1213204-.87867966l-.83301646-.8330165c-.38440512-.38440512-1.00764896-.38440512-1.39205408 0l-.83301651.8330165c-.56260913.56260914-1.32567087.87867966-2.12132034.87867966zm3.58698944 11.4960218c-.02081224.002155-.04199226.0030286-.06345763.002542-.98766446-.0223875-1.93408568-.3063547-2.75885125-.8155622-.23496767-.1450683-.30784554-.4531483-.16277726-.688116.14506827-.2349677.45314827-.3078455.68811595-.1627773.67447084.4164161 1.44758575.6483839 2.25617384.6667123.01759529.0003988.03495764.0017019.05204365.0038639.01713363-.0017748.03452416-.0026845.05212715-.0026845 2.4852814 0 4.5-2.0147186 4.5-4.5 0-1.04888973-.3593547-2.04134635-1.0074477-2.83787157-.1742817-.21419731-.1419238-.5291218.0722736-.70340353.2141973-.17428173.5291218-.14192375.7034035.07227357.7919032.97327203 1.2317706 2.18808682 1.2317706 3.46900153 0 3.0375661-2.4624339 5.5-5.5 5.5-.02146768 0-.04261937-.0013529-.06337445-.0039782zm1.57975095-10.78419583c.2654788.07599731.419084.35281842.3430867.61829728-.0759973.26547885-.3528185.419084-.6182973.3430867-.37560116-.10752146-.76586237-.16587951-1.15568824-.17249193-2.5587807-.00064534-4.58547766 2.00216524-4.58547766 4.49928198 0 .62691557.12797645 1.23496.37274865 1.7964426.11035133.2531347-.0053975.5477984-.25853224.6581497-.25313473.1103514-.54779841-.0053975-.65814974-.2585322-.29947131-.6869568-.45606667-1.43097603-.45606667-2.1960601 0-3.05211432 2.47714695-5.50006595 5.59399617-5.49921198.48576182.00815502.96289603.0795037 1.42238033.21103795zm-1.9766658 6.41091303 2.69835-2.94655317c.1788432-.21040373.4943901-.23598862.7047939-.05714545.2104037.17884318.2359886.49439014.0571454.70479387l-3.01637681 3.34277395c-.18039088.1999106-.48669547.2210637-.69285412.0478478l-1.93095347-1.62240047c-.21213845-.17678204-.24080048-.49206439-.06401844-.70420284.17678204-.21213844.49206439-.24080048.70420284-.06401844z" fill-rule="evenodd"/></symbol><symbol id="icon-expand"><path d="M7.498 11.918a.997.997 0 0 0-.003-1.411.995.995 0 0 0-1.412-.003l-4.102 4.102v-3.51A1 1 0 0 0 .98 10.09.992.992 0 0 0 0 11.092V17c0 .554.448 1.002 1.002 1.002h5.907c.554 0 1.002-.45 1.002-1.003 0-.539-.45-.978-1.006-.978h-3.51zm3.005-5.835a.997.997 0 0 0 .003 1.412.995.995 0 0 0 1.411.003l4.103-4.103v3.51a1 1 0 0 0 1.001 1.006A.992.992 0 0 0 18 6.91V1.002A1 1 0 0 0 17 0h-5.907a1.003 1.003 0 0 0-1.002 1.003c0 .539.45.978 1.006.978h3.51z" fill-rule="evenodd"/></symbol><symbol id="icon-explore" viewBox="0 0 18 18"><path d="m9 17c4.418278 0 8-3.581722 8-8s-3.581722-8-8-8-8 3.581722-8 8 3.581722 8 8 8zm0 1c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9zm0-2.5c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5c2.969509 0 5.400504-2.3575119 5.497023-5.31714844.0090007-.27599565.2400359-.49243782.5160315-.48343711.2759957.0090007.4924378.2400359.4834371.51603155-.114093 3.4985237-2.9869632 6.284554-6.4964916 6.284554zm-.29090657-12.99359748c.27587424-.01216621.50937715.20161139.52154336.47748563.01216621.27587423-.20161139.50937715-.47748563.52154336-2.93195733.12930094-5.25315116 2.54886451-5.25315116 5.49456849 0 .27614237-.22385763.5-.5.5s-.5-.22385763-.5-.5c0-3.48142406 2.74307146-6.34074398 6.20909343-6.49359748zm1.13784138 8.04763908-1.2004882-1.20048821c-.19526215-.19526215-.19526215-.51184463 0-.70710678s.51184463-.19526215.70710678 0l1.20048821 1.2004882 1.6006509-4.00162734-4.50670359 1.80268144-1.80268144 4.50670359zm4.10281269-6.50378907-2.6692597 6.67314927c-.1016411.2541026-.3029834.4554449-.557086.557086l-6.67314927 2.6692597 2.66925969-6.67314926c.10164107-.25410266.30298336-.45544495.55708602-.55708602z" fill-rule="evenodd"/></symbol><symbol id="icon-filter" viewBox="0 0 16 16"><path d="m14.9738641 0c.5667192 0 1.0261359.4477136 1.0261359 1 0 .24221858-.0902161.47620768-.2538899.65849851l-5.6938314 6.34147206v5.49997973c0 .3147562-.1520673.6111434-.4104543.7999971l-2.05227171 1.4999945c-.45337535.3313696-1.09655869.2418269-1.4365902-.1999993-.13321514-.1730955-.20522717-.3836284-.20522717-.5999978v-6.99997423l-5.69383133-6.34147206c-.3731872-.41563511-.32996891-1.0473954.09653074-1.41107611.18705584-.15950448.42716133-.2474224.67571519-.2474224zm-5.9218641 8.5h-2.105v6.491l.01238459.0070843.02053271.0015705.01955278-.0070558 2.0532976-1.4990996zm-8.02585008-7.5-.01564945.00240169 5.83249953 6.49759831h2.313l5.836-6.499z"/></symbol><symbol id="icon-home" viewBox="0 0 18 18"><path d="m9 5-6 6v5h4v-4h4v4h4v-5zm7 6.5857864v4.4142136c0 .5522847-.4477153 1-1 1h-5v-4h-2v4h-5c-.55228475 0-1-.4477153-1-1v-4.4142136c-.25592232 0-.51184464-.097631-.70710678-.2928932l-.58578644-.5857864c-.39052429-.3905243-.39052429-1.02368929 0-1.41421358l8.29289322-8.29289322 8.2928932 8.29289322c.3905243.39052429.3905243 1.02368928 0 1.41421358l-.5857864.5857864c-.1952622.1952622-.4511845.2928932-.7071068.2928932zm-7-9.17157284-7.58578644 7.58578644.58578644.5857864 7-6.99999996 7 6.99999996.5857864-.5857864z" fill-rule="evenodd"/></symbol><symbol id="icon-image" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm-3.49645283 10.1752453-3.89407257 6.7495552c.11705545.048464.24538859.0751995.37998328.0751995h10.60290092l-2.4329715-4.2154691-1.57494129 2.7288098zm8.49779013 6.8247547c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v13.98991071l4.50814957-7.81026689 3.08089884 5.33809539 1.57494129-2.7288097 3.5875735 6.2159812zm-3.0059397-11c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm0 1c-.5522847 0-1 .44771525-1 1s.4477153 1 1 1 1-.44771525 1-1-.4477153-1-1-1z" fill-rule="evenodd"/></symbol><symbol id="icon-info" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm0 7h-1.5l-.11662113.00672773c-.49733868.05776511-.88337887.48043643-.88337887.99327227 0 .47338693.32893365.86994729.77070917.97358929l.1126697.01968298.11662113.00672773h.5v3h-.5l-.11662113.0067277c-.42082504.0488782-.76196299.3590206-.85696816.7639815l-.01968298.1126697-.00672773.1166211.00672773.1166211c.04887817.4208251.35902055.761963.76398144.8569682l.1126697.019683.11662113.0067277h3l.1166211-.0067277c.4973387-.0577651.8833789-.4804365.8833789-.9932723 0-.4733869-.3289337-.8699473-.7707092-.9735893l-.1126697-.019683-.1166211-.0067277h-.5v-4l-.00672773-.11662113c-.04887817-.42082504-.35902055-.76196299-.76398144-.85696816l-.1126697-.01968298zm0-3.25c-.69035594 0-1.25.55964406-1.25 1.25s.55964406 1.25 1.25 1.25 1.25-.55964406 1.25-1.25-.55964406-1.25-1.25-1.25z" fill-rule="evenodd"/></symbol><symbol id="icon-institution" viewBox="0 0 18 18"><path d="m7 16.9998189v-2.0003623h4v2.0003623h2v-3.0005434h-8v3.0005434zm-3-10.00181122h-1.52632364c-.27614237 0-.5-.22389817-.5-.50009056 0-.13995446.05863589-.27350497.16166338-.36820841l1.23156713-1.13206327h-2.36690687v12.00217346h3v-2.0003623h-3v-1.0001811h3v-1.0001811h1v-4.00072448h-1zm10 0v2.00036224h-1v4.00072448h1v1.0001811h3v1.0001811h-3v2.0003623h3v-12.00217346h-2.3695309l1.2315671 1.13206327c.2033191.186892.2166633.50325042.0298051.70660631-.0946863.10304615-.2282126.16169266-.3681417.16169266zm3-3.00054336c.5522847 0 1 .44779634 1 1.00018112v13.00235456h-18v-13.00235456c0-.55238478.44771525-1.00018112 1-1.00018112h3.45499992l4.20535144-3.86558216c.19129876-.17584288.48537447-.17584288.67667324 0l4.2053514 3.86558216zm-4 3.00054336h-8v1.00018112h8zm-2 6.00108672h1v-4.00072448h-1zm-1 0v-4.00072448h-2v4.00072448zm-3 0v-4.00072448h-1v4.00072448zm8-4.00072448c.5522847 0 1 .44779634 1 1.00018112v2.00036226h-2v-2.00036226c0-.55238478.4477153-1.00018112 1-1.00018112zm-12 0c.55228475 0 1 .44779634 1 1.00018112v2.00036226h-2v-2.00036226c0-.55238478.44771525-1.00018112 1-1.00018112zm5.99868798-7.81907007-5.24205601 4.81852671h10.48411203zm.00131202 3.81834559c-.55228475 0-1-.44779634-1-1.00018112s.44771525-1.00018112 1-1.00018112 1 .44779634 1 1.00018112-.44771525 1.00018112-1 1.00018112zm-1 11.00199236v1.0001811h2v-1.0001811z" fill-rule="evenodd"/></symbol><symbol id="icon-location" viewBox="0 0 18 18"><path d="m9.39521328 16.2688008c.79596342-.7770119 1.59208152-1.6299956 2.33285652-2.5295081 1.4020032-1.7024324 2.4323601-3.3624519 2.9354918-4.871847.2228715-.66861448.3364384-1.29323246.3364384-1.8674457 0-3.3137085-2.6862915-6-6-6-3.36356866 0-6 2.60156856-6 6 0 .57421324.11356691 1.19883122.3364384 1.8674457.50313169 1.5093951 1.53348863 3.1694146 2.93549184 4.871847.74077492.8995125 1.53689309 1.7524962 2.33285648 2.5295081.13694479.1336842.26895677.2602648.39521328.3793207.12625651-.1190559.25826849-.2456365.39521328-.3793207zm-.39521328 1.7311992s-7-6-7-11c0-4 3.13400675-7 7-7 3.8659932 0 7 3.13400675 7 7 0 5-7 11-7 11zm0-8c-1.65685425 0-3-1.34314575-3-3s1.34314575-3 3-3c1.6568542 0 3 1.34314575 3 3s-1.3431458 3-3 3zm0-1c1.1045695 0 2-.8954305 2-2s-.8954305-2-2-2-2 .8954305-2 2 .8954305 2 2 2z" fill-rule="evenodd"/></symbol><symbol id="icon-minus" viewBox="0 0 16 16"><path d="m2.00087166 7h11.99825664c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-11.99825664c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"/></symbol><symbol id="icon-newsletter" viewBox="0 0 18 18"><path d="m9 11.8482489 2-1.1428571v-1.7053918h-4v1.7053918zm-3-1.7142857v-2.1339632h6v2.1339632l3-1.71428574v-6.41967746h-12v6.41967746zm10-5.3839632 1.5299989.95624934c.2923814.18273835.4700011.50320827.4700011.8479983v8.44575236c0 1.1045695-.8954305 2-2 2h-14c-1.1045695 0-2-.8954305-2-2v-8.44575236c0-.34479003.1776197-.66525995.47000106-.8479983l1.52999894-.95624934v-2.75c0-.55228475.44771525-1 1-1h12c.5522847 0 1 .44771525 1 1zm0 1.17924764v3.07075236l-7 4-7-4v-3.07075236l-1 .625v8.44575236c0 .5522847.44771525 1 1 1h14c.5522847 0 1-.4477153 1-1v-8.44575236zm-10-1.92924764h6v1h-6zm-1 2h8v1h-8z" fill-rule="evenodd"/></symbol><symbol id="icon-orcid" viewBox="0 0 18 18"><path d="m9 1c4.418278 0 8 3.581722 8 8s-3.581722 8-8 8-8-3.581722-8-8 3.581722-8 8-8zm-2.90107518 5.2732337h-1.41865256v7.1712107h1.41865256zm4.55867178.02508949h-2.99247027v7.14612121h2.91062487c.7673039 0 1.4476365-.1483432 2.0410182-.445034s1.0511995-.7152915 1.3734671-1.2558144c.3222677-.540523.4833991-1.1603247.4833991-1.85942385 0-.68545815-.1602789-1.30270225-.4808414-1.85175082-.3205625-.54904856-.7707074-.97532211-1.3504481-1.27883343-.5797408-.30351132-1.2413173-.45526471-1.9847495-.45526471zm-.1892674 1.07933542c.7877654 0 1.4143875.22336734 1.8798852.67010873.4654977.44674138.698243 1.05546001.698243 1.82617415 0 .74343221-.2310402 1.34447791-.6931277 1.80315511-.4620874.4586773-1.0750688.6880124-1.8389625.6880124h-1.46810075v-4.98745039zm-5.08652545-3.71099194c-.21825533 0-.410525.08444276-.57681478.25333081-.16628977.16888806-.24943341.36245684-.24943341.58071218 0 .22345188.08314364.41961891.24943341.58850696.16628978.16888806.35855945.25333082.57681478.25333082.233845 0 .43390938-.08314364.60019916-.24943342.16628978-.16628977.24943342-.36375592.24943342-.59240436 0-.233845-.08314364-.43131115-.24943342-.59240437s-.36635416-.24163862-.60019916-.24163862z" fill-rule="evenodd"/></symbol><symbol id="icon-plus" viewBox="0 0 16 16"><path d="m2.00087166 7h4.99912834v-4.99912834c0-.55276616.44386482-1.00087166 1-1.00087166.55228475 0 1 .44463086 1 1.00087166v4.99912834h4.9991283c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-4.9991283v4.9991283c0 .5527662-.44386482 1.0008717-1 1.0008717-.55228475 0-1-.4446309-1-1.0008717v-4.9991283h-4.99912834c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"/></symbol><symbol id="icon-print" viewBox="0 0 18 18"><path d="m16.0049107 5h-14.00982141c-.54941618 0-.99508929.4467783-.99508929.99961498v6.00077002c0 .5570958.44271433.999615.99508929.999615h1.00491071v-3h12v3h1.0049107c.5494162 0 .9950893-.4467783.9950893-.999615v-6.00077002c0-.55709576-.4427143-.99961498-.9950893-.99961498zm-2.0049107-1v-2.00208688c0-.54777062-.4519464-.99791312-1.0085302-.99791312h-7.9829396c-.55661731 0-1.0085302.44910695-1.0085302.99791312v2.00208688zm1 10v2.0018986c0 1.103521-.9019504 1.9981014-2.0085302 1.9981014h-7.9829396c-1.1092806 0-2.0085302-.8867064-2.0085302-1.9981014v-2.0018986h-1.00491071c-1.10185739 0-1.99508929-.8874333-1.99508929-1.999615v-6.00077002c0-1.10435686.8926228-1.99961498 1.99508929-1.99961498h1.00491071v-2.00208688c0-1.10341695.90195036-1.99791312 2.0085302-1.99791312h7.9829396c1.1092806 0 2.0085302.89826062 2.0085302 1.99791312v2.00208688h1.0049107c1.1018574 0 1.9950893.88743329 1.9950893 1.99961498v6.00077002c0 1.1043569-.8926228 1.999615-1.9950893 1.999615zm-1-3h-10v5.0018986c0 .5546075.44702548.9981014 1.0085302.9981014h7.9829396c.5565964 0 1.0085302-.4491701 1.0085302-.9981014zm-9 1h8v1h-8zm0 2h5v1h-5zm9-5c-.5522847 0-1-.44771525-1-1s.4477153-1 1-1 1 .44771525 1 1-.4477153 1-1 1z" fill-rule="evenodd"/></symbol><symbol id="icon-search" viewBox="0 0 22 22"><path d="M21.697 20.261a1.028 1.028 0 01.01 1.448 1.034 1.034 0 01-1.448-.01l-4.267-4.267A9.812 9.811 0 010 9.812a9.812 9.811 0 1117.43 6.182zM9.812 18.222A8.41 8.41 0 109.81 1.403a8.41 8.41 0 000 16.82z" fill-rule="evenodd"/></symbol><symbol id="icon-social-facebook" viewBox="0 0 24 24"><path d="m6.00368507 20c-1.10660471 0-2.00368507-.8945138-2.00368507-1.9940603v-12.01187942c0-1.10128908.89451376-1.99406028 1.99406028-1.99406028h12.01187942c1.1012891 0 1.9940603.89451376 1.9940603 1.99406028v12.01187942c0 1.1012891-.88679 1.9940603-2.0032184 1.9940603h-2.9570132v-6.1960818h2.0797387l.3114113-2.414723h-2.39115v-1.54164807c0-.69911803.1941355-1.1755439 1.1966615-1.1755439l1.2786739-.00055875v-2.15974763l-.2339477-.02492088c-.3441234-.03134957-.9500153-.07025255-1.6293054-.07025255-1.8435726 0-3.1057323 1.12531866-3.1057323 3.19187953v1.78079225h-2.0850778v2.414723h2.0850778v6.1960818z" fill-rule="evenodd"/></symbol><symbol id="icon-social-twitter" viewBox="0 0 24 24"><path d="m18.8767135 6.87445248c.7638174-.46908424 1.351611-1.21167363 1.6250764-2.09636345-.7135248.43394112-1.50406.74870123-2.3464594.91677702-.6695189-.73342162-1.6297913-1.19486605-2.6922204-1.19486605-2.0399895 0-3.6933555 1.69603749-3.6933555 3.78628909 0 .29642457.0314329.58673729.0942985.8617704-3.06469922-.15890802-5.78835241-1.66547825-7.60988389-3.9574208-.3174714.56076194-.49978171 1.21167363-.49978171 1.90536824 0 1.31404706.65223085 2.47224203 1.64236444 3.15218497-.60350999-.0198635-1.17401554-.1925232-1.67222562-.47366811v.04583885c0 1.83355406 1.27302891 3.36609966 2.96411421 3.71294696-.31118484.0886217-.63651445.1329326-.97441718.1329326-.2357461 0-.47149219-.0229194-.69466516-.0672303.47149219 1.5065703 1.83253297 2.6036468 3.44975116 2.632678-1.2651707 1.0160946-2.85724264 1.6196394-4.5891906 1.6196394-.29861172 0-.59093688-.0152796-.88011875-.0504227 1.63450624 1.0726291 3.57548241 1.6990934 5.66104951 1.6990934 6.79263079 0 10.50641749-5.7711113 10.50641749-10.7751859l-.0094298-.48894775c.7229547-.53478659 1.3516109-1.20250585 1.8419628-1.96190282-.6632323.30100846-1.3751855.50422736-2.1217148.59590507z" fill-rule="evenodd"/></symbol><symbol id="icon-social-youtube" viewBox="0 0 24 24"><path d="m10.1415 14.3973208-.0005625-5.19318431 4.863375 2.60554491zm9.963-7.92753362c-.6845625-.73643756-1.4518125-.73990314-1.803375-.7826454-2.518875-.18714178-6.2971875-.18714178-6.2971875-.18714178-.007875 0-3.7861875 0-6.3050625.18714178-.352125.04274226-1.1188125.04620784-1.8039375.7826454-.5394375.56084773-.7149375 1.8344515-.7149375 1.8344515s-.18 1.49597903-.18 2.99138042v1.4024082c0 1.495979.18 2.9913804.18 2.9913804s.1755 1.2736038.7149375 1.8344515c.685125.7364376 1.5845625.7133337 1.9850625.7901542 1.44.1420891 6.12.1859866 6.12.1859866s3.78225-.005776 6.301125-.1929178c.3515625-.0433198 1.1188125-.0467854 1.803375-.783223.5394375-.5608477.7155-1.8344515.7155-1.8344515s.18-1.4954014.18-2.9913804v-1.4024082c0-1.49540139-.18-2.99138042-.18-2.99138042s-.1760625-1.27360377-.7155-1.8344515z" fill-rule="evenodd"/></symbol><symbol id="icon-subject-medicine" viewBox="0 0 18 18"><path d="m12.5 8h-6.5c-1.65685425 0-3 1.34314575-3 3v1c0 1.6568542 1.34314575 3 3 3h1v-2h-.5c-.82842712 0-1.5-.6715729-1.5-1.5s.67157288-1.5 1.5-1.5h1.5 2 1 2c1.6568542 0 3-1.34314575 3-3v-1c0-1.65685425-1.3431458-3-3-3h-2v2h1.5c.8284271 0 1.5.67157288 1.5 1.5s-.6715729 1.5-1.5 1.5zm-5.5-1v-1h-3.5c-1.38071187 0-2.5-1.11928813-2.5-2.5s1.11928813-2.5 2.5-2.5h1.02786405c.46573528 0 .92507448.10843528 1.34164078.31671843l1.13382424.56691212c.06026365-1.05041141.93116291-1.88363055 1.99667093-1.88363055 1.1045695 0 2 .8954305 2 2h2c2.209139 0 4 1.790861 4 4v1c0 2.209139-1.790861 4-4 4h-2v1h2c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2h-2c0 1.1045695-.8954305 2-2 2s-2-.8954305-2-2h-1c-2.209139 0-4-1.790861-4-4v-1c0-2.209139 1.790861-4 4-4zm0-2v-2.05652691c-.14564246-.03538148-.28733393-.08714006-.42229124-.15461871l-1.15541752-.57770876c-.27771087-.13885544-.583937-.21114562-.89442719-.21114562h-1.02786405c-.82842712 0-1.5.67157288-1.5 1.5s.67157288 1.5 1.5 1.5zm4 1v1h1.5c.2761424 0 .5-.22385763.5-.5s-.2238576-.5-.5-.5zm-1 1v-5c0-.55228475-.44771525-1-1-1s-1 .44771525-1 1v5zm-2 4v5c0 .5522847.44771525 1 1 1s1-.4477153 1-1v-5zm3 2v2h2c.5522847 0 1-.4477153 1-1s-.4477153-1-1-1zm-4-1v-1h-.5c-.27614237 0-.5.2238576-.5.5s.22385763.5.5.5zm-3.5-9h1c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"/></symbol><symbol id="icon-success" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm3.4860198 4.98163161-4.71802968 5.50657859-2.62834168-2.02300024c-.42862421-.36730544-1.06564993-.30775346-1.42283677.13301307-.35718685.44076653-.29927542 1.0958383.12934879 1.46314377l3.40735508 2.7323063c.42215801.3385221 1.03700951.2798252 1.38749189-.1324571l5.38450527-6.33394549c.3613513-.43716226.3096573-1.09278382-.115462-1.46437175-.4251192-.37158792-1.0626796-.31842941-1.4240309.11873285z" fill-rule="evenodd"/></symbol><symbol id="icon-table" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587l-4.0059107-.001.001.001h-1l-.001-.001h-5l.001.001h-1l-.001-.001-3.00391071.001c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm-11.0059107 5h-3.999v6.9941413c0 .5572961.44630695 1.0058587.99508929 1.0058587h3.00391071zm6 0h-5v8h5zm5.0059107-4h-4.0059107v3h5.001v1h-5.001v7.999l4.0059107.001c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-12.5049107 9c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.2238576.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238576-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm-6-2c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.2238576.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238576-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm-6-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.22385763-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm1.499-5h-5v3h5zm-6 0h-3.00391071c-.54871518 0-.99508929.44887827-.99508929 1.00585866v1.99414134h3.999z" fill-rule="evenodd"/></symbol><symbol id="icon-tick-circle" viewBox="0 0 24 24"><path d="m12 2c5.5228475 0 10 4.4771525 10 10s-4.4771525 10-10 10-10-4.4771525-10-10 4.4771525-10 10-10zm0 1c-4.97056275 0-9 4.02943725-9 9 0 4.9705627 4.02943725 9 9 9 4.9705627 0 9-4.0294373 9-9 0-4.97056275-4.0294373-9-9-9zm4.2199868 5.36606669c.3613514-.43716226.9989118-.49032077 1.424031-.11873285s.4768133 1.02720949.115462 1.46437175l-6.093335 6.94397871c-.3622945.4128716-.9897871.4562317-1.4054264.0971157l-3.89719065-3.3672071c-.42862421-.3673054-.48653564-1.0223772-.1293488-1.4631437s.99421256-.5003185 1.42283677-.1330131l3.11097438 2.6987741z" fill-rule="evenodd"/></symbol><symbol id="icon-tick" viewBox="0 0 16 16"><path d="m6.76799012 9.21106946-3.1109744-2.58349728c-.42862421-.35161617-1.06564993-.29460792-1.42283677.12733148s-.29927541 1.04903009.1293488 1.40064626l3.91576307 3.23873978c.41034319.3393961 1.01467563.2976897 1.37450571-.0948578l6.10568327-6.660841c.3613513-.41848908.3096572-1.04610608-.115462-1.4018218-.4251192-.35571573-1.0626796-.30482786-1.424031.11366122z" fill-rule="evenodd"/></symbol><symbol id="icon-update" viewBox="0 0 18 18"><path d="m1 13v1c0 .5522847.44771525 1 1 1h14c.5522847 0 1-.4477153 1-1v-1h-1v-10h-14v10zm16-1h1v2c0 1.1045695-.8954305 2-2 2h-14c-1.1045695 0-2-.8954305-2-2v-2h1v-9c0-.55228475.44771525-1 1-1h14c.5522847 0 1 .44771525 1 1zm-1 0v1h-4.5857864l-1 1h-2.82842716l-1-1h-4.58578644v-1h5l1 1h2l1-1zm-13-8h12v7h-12zm1 1v5h10v-5zm1 1h4v1h-4zm0 2h4v1h-4z" fill-rule="evenodd"/></symbol><symbol id="icon-upload" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm0 1h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v14.00982141c0 .5500396.44491393.9950893.99406028.9950893h12.01187942c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717zm-1.85576936 4.14572769c.19483374-.19483375.51177826-.19377714.70556874.00001334l2.59099082 2.59099079c.1948411.19484112.1904373.51514474.0027906.70279143-.1932998.19329987-.5046517.19237083-.7001856-.00692852l-1.74638687-1.7800176v6.14827687c0 .2717771-.23193359.492096-.5.492096-.27614237 0-.5-.216372-.5-.492096v-6.14827641l-1.74627892 1.77990922c-.1933927.1971171-.51252214.19455839-.70016883.0069117-.19329987-.19329988-.19100584-.50899493.00277731-.70277808z" fill-rule="evenodd"/></symbol><symbol id="icon-video" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587h-14.00982141c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm0 1h-14.00982141c-.54871518 0-.99508929.44887827-.99508929 1.00585866v9.98828264c0 .5572961.44630695 1.0058587.99508929 1.0058587h14.00982141c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-8.30912922 2.24944486 4.60460462 2.73982242c.9365543.55726659.9290753 1.46522435 0 2.01804082l-4.60460462 2.7398224c-.93655425.5572666-1.69578148.1645632-1.69578148-.8937585v-5.71016863c0-1.05087579.76670616-1.446575 1.69578148-.89375851zm-.67492769.96085624v5.5750128c0 .2995102-.10753745.2442517.16578928.0847713l4.58452283-2.67497259c.3050619-.17799716.3051624-.21655446 0-.39461026l-4.58452283-2.67497264c-.26630747-.15538481-.16578928-.20699944-.16578928.08477139z" fill-rule="evenodd"/></symbol><symbol id="icon-warning" viewBox="0 0 18 18"><path d="m9 11.75c.69035594 0 1.25.5596441 1.25 1.25s-.55964406 1.25-1.25 1.25-1.25-.5596441-1.25-1.25.55964406-1.25 1.25-1.25zm.41320045-7.75c.55228475 0 1.00000005.44771525 1.00000005 1l-.0034543.08304548-.3333333 4c-.043191.51829212-.47645714.91695452-.99654578.91695452h-.15973424c-.52008864 0-.95335475-.3986624-.99654576-.91695452l-.33333333-4c-.04586475-.55037702.36312325-1.03372649.91350028-1.07959124l.04148683-.00259031zm-.41320045 14c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"/></symbol><symbol id="icon-checklist-banner" viewBox="0 0 56.69 56.69"><path style="fill:none" d="M0 0h56.69v56.69H0z"/><clipPath id="b"><use xlink:href="#a" style="overflow:visible"/></clipPath><path d="M21.14 34.46c0-6.77 5.48-12.26 12.24-12.26s12.24 5.49 12.24 12.26-5.48 12.26-12.24 12.26c-6.76-.01-12.24-5.49-12.24-12.26zm19.33 10.66 10.23 9.22s1.21 1.09 2.3-.12l2.09-2.32s1.09-1.21-.12-2.3l-10.23-9.22m-19.29-5.92c0-4.38 3.55-7.94 7.93-7.94s7.93 3.55 7.93 7.94c0 4.38-3.55 7.94-7.93 7.94-4.38-.01-7.93-3.56-7.93-7.94zm17.58 12.99 4.14-4.81" style="clip-path:url(#b);fill:none;stroke:#01324b;stroke-width:2;stroke-linecap:round"/><path d="M8.26 9.75H28.6M8.26 15.98H28.6m-20.34 6.2h12.5m14.42-5.2V4.86s0-2.93-2.93-2.93H4.13s-2.93 0-2.93 2.93v37.57s0 2.93 2.93 2.93h15.01M8.26 9.75H28.6M8.26 15.98H28.6m-20.34 6.2h12.5" style="clip-path:url(#b);fill:none;stroke:#01324b;stroke-width:2;stroke-linecap:round;stroke-linejoin:round"/></symbol><symbol id="icon-chevron-down" viewBox="0 0 16 16"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" fill-rule="evenodd" transform="matrix(0 1 -1 0 11 1)"/></symbol><symbol id="icon-eds-i-arrow-right-medium" viewBox="0 0 24 24"><path d="m12.728 3.293 7.98 7.99a.996.996 0 0 1 .281.561l.011.157c0 .32-.15.605-.384.788l-7.908 7.918a1 1 0 0 1-1.416-1.414L17.576 13H4a1 1 0 0 1 0-2h13.598l-6.285-6.293a1 1 0 0 1-.082-1.32l.083-.095a1 1 0 0 1 1.414.001Z"/></symbol><symbol id="icon-eds-i-chevron-down-medium" viewBox="0 0 16 16"><path d="m2.00087166 7h4.99912834v-4.99912834c0-.55276616.44386482-1.00087166 1-1.00087166.55228475 0 1 .44463086 1 1.00087166v4.99912834h4.9991283c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-4.9991283v4.9991283c0 .5527662-.44386482 1.0008717-1 1.0008717-.55228475 0-1-.4446309-1-1.0008717v-4.9991283h-4.99912834c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"/></symbol><symbol id="icon-eds-i-chevron-down-small" viewBox="0 0 16 16"><path d="M13.692 5.278a1 1 0 0 1 .03 1.414L9.103 11.51a1.491 1.491 0 0 1-2.188.019L2.278 6.692a1 1 0 0 1 1.444-1.384L8 9.771l4.278-4.463a1 1 0 0 1 1.318-.111l.096.081Z"/></symbol><symbol id="icon-eds-i-chevron-right-medium" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"/></symbol><symbol id="icon-eds-i-chevron-right-small" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"/></symbol><symbol id="icon-eds-i-chevron-up-medium" viewBox="0 0 16 16"><path d="m2.00087166 7h11.99825664c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-11.99825664c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"/></symbol><symbol id="icon-eds-i-close-medium" viewBox="0 0 16 16"><path d="m2.29679575 12.2772478c-.39658757.3965876-.39438847 1.0328109-.00062148 1.4265779.39651227.3965123 1.03246768.3934888 1.42657791-.0006214l4.27724782-4.27724787 4.2772478 4.27724787c.3965876.3965875 1.0328109.3943884 1.4265779.0006214.3965123-.3965122.3934888-1.0324677-.0006214-1.4265779l-4.27724787-4.2772478 4.27724787-4.27724782c.3965875-.39658757.3943884-1.03281091.0006214-1.42657791-.3965122-.39651226-1.0324677-.39348875-1.4265779.00062148l-4.2772478 4.27724782-4.27724782-4.27724782c-.39658757-.39658757-1.03281091-.39438847-1.42657791-.00062148-.39651226.39651227-.39348875 1.03246768.00062148 1.42657791l4.27724782 4.27724782z" fill-rule="evenodd"/></symbol><symbol id="icon-eds-i-download-medium" viewBox="0 0 16 16"><path d="m12.9975267 12.999368c.5467123 0 1.0024733.4478567 1.0024733 1.000316 0 .5563109-.4488226 1.000316-1.0024733 1.000316h-9.99505341c-.54671233 0-1.00247329-.4478567-1.00247329-1.000316 0-.5563109.44882258-1.000316 1.00247329-1.000316zm-4.9975267-11.999368c.55228475 0 1 .44497754 1 .99589209v6.80214418l2.4816273-2.48241149c.3928222-.39294628 1.0219732-.4006883 1.4030652-.01947579.3911302.39125371.3914806 1.02525073-.0001404 1.41699553l-4.17620792 4.17752758c-.39120769.3913313-1.02508144.3917306-1.41671995-.0000316l-4.17639421-4.17771394c-.39122513-.39134876-.39767006-1.01940351-.01657797-1.40061601.39113012-.39125372 1.02337105-.3931606 1.41951349.00310701l2.48183446 2.48261871v-6.80214418c0-.55001601.44386482-.99589209 1-.99589209z" fill-rule="evenodd"/></symbol><symbol id="icon-eds-i-info-filled-medium" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm0 7h-1.5l-.11662113.00672773c-.49733868.05776511-.88337887.48043643-.88337887.99327227 0 .47338693.32893365.86994729.77070917.97358929l.1126697.01968298.11662113.00672773h.5v3h-.5l-.11662113.0067277c-.42082504.0488782-.76196299.3590206-.85696816.7639815l-.01968298.1126697-.00672773.1166211.00672773.1166211c.04887817.4208251.35902055.761963.76398144.8569682l.1126697.019683.11662113.0067277h3l.1166211-.0067277c.4973387-.0577651.8833789-.4804365.8833789-.9932723 0-.4733869-.3289337-.8699473-.7707092-.9735893l-.1126697-.019683-.1166211-.0067277h-.5v-4l-.00672773-.11662113c-.04887817-.42082504-.35902055-.76196299-.76398144-.85696816l-.1126697-.01968298zm0-3.25c-.69035594 0-1.25.55964406-1.25 1.25s.55964406 1.25 1.25 1.25 1.25-.55964406 1.25-1.25-.55964406-1.25-1.25-1.25z" fill-rule="evenodd"/></symbol><symbol id="icon-eds-i-mail-medium" viewBox="0 0 24 24"><path d="m19.462 0c1.413 0 2.538 1.184 2.538 2.619v12.762c0 1.435-1.125 2.619-2.538 2.619h-16.924c-1.413 0-2.538-1.184-2.538-2.619v-12.762c0-1.435 1.125-2.619 2.538-2.619zm.538 5.158-7.378 6.258a2.549 2.549 0 0 1 -3.253-.008l-7.369-6.248v10.222c0 .353.253.619.538.619h16.924c.285 0 .538-.266.538-.619zm-.538-3.158h-16.924c-.264 0-.5.228-.534.542l8.65 7.334c.2.165.492.165.684.007l8.656-7.342-.001-.025c-.044-.3-.274-.516-.531-.516z"/></symbol><symbol id="icon-eds-i-menu-medium" viewBox="0 0 24 24"><path d="M21 4a1 1 0 0 1 0 2H3a1 1 0 1 1 0-2h18Zm-4 7a1 1 0 0 1 0 2H3a1 1 0 0 1 0-2h14Zm4 7a1 1 0 0 1 0 2H3a1 1 0 0 1 0-2h18Z"/></symbol><symbol id="icon-eds-i-search-medium" viewBox="0 0 24 24"><path d="M11 1c5.523 0 10 4.477 10 10 0 2.4-.846 4.604-2.256 6.328l3.963 3.965a1 1 0 0 1-1.414 1.414l-3.965-3.963A9.959 9.959 0 0 1 11 21C5.477 21 1 16.523 1 11S5.477 1 11 1Zm0 2a8 8 0 1 0 0 16 8 8 0 0 0 0-16Z"/></symbol><symbol id="icon-eds-i-user-single-medium" viewBox="0 0 24 24"><path d="M12 1a5 5 0 1 1 0 10 5 5 0 0 1 0-10Zm0 2a3 3 0 1 0 0 6 3 3 0 0 0 0-6Zm-.406 9.008a8.965 8.965 0 0 1 6.596 2.494A9.161 9.161 0 0 1 21 21.025V22a1 1 0 0 1-1 1H4a1 1 0 0 1-1-1v-.985c.05-4.825 3.815-8.777 8.594-9.007Zm.39 1.992-.299.006c-3.63.175-6.518 3.127-6.678 6.775L5 21h13.998l-.009-.268a7.157 7.157 0 0 0-1.97-4.573l-.214-.213A6.967 6.967 0 0 0 11.984 14Z"/></symbol><symbol id="icon-eds-i-warning-filled-medium" viewBox="0 0 18 18"><path d="m9 11.75c.69035594 0 1.25.5596441 1.25 1.25s-.55964406 1.25-1.25 1.25-1.25-.5596441-1.25-1.25.55964406-1.25 1.25-1.25zm.41320045-7.75c.55228475 0 1.00000005.44771525 1.00000005 1l-.0034543.08304548-.3333333 4c-.043191.51829212-.47645714.91695452-.99654578.91695452h-.15973424c-.52008864 0-.95335475-.3986624-.99654576-.91695452l-.33333333-4c-.04586475-.55037702.36312325-1.03372649.91350028-1.07959124l.04148683-.00259031zm-.41320045 14c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"/></symbol><symbol id="icon-expand-image" viewBox="0 0 18 18"><path d="m7.49754099 11.9178212c.38955542-.3895554.38761957-1.0207846-.00290473-1.4113089-.39324695-.3932469-1.02238878-.3918247-1.41130883-.0029047l-4.10273549 4.1027355.00055454-3.5103985c.00008852-.5603185-.44832171-1.006032-1.00155062-1.0059446-.53903074.0000852-.97857527.4487442-.97866268 1.0021075l-.00093318 5.9072465c-.00008751.553948.44841131 1.001882 1.00174994 1.0017946l5.906983-.0009331c.5539233-.0000875 1.00197907-.4486389 1.00206646-1.0018679.00008515-.5390307-.45026621-.9784332-1.00588841-.9783454l-3.51010549.0005545zm3.00571741-5.83449376c-.3895554.38955541-.3876196 1.02078454.0029047 1.41130883.393247.39324696 1.0223888.39182478 1.4113089.00290473l4.1027355-4.10273549-.0005546 3.5103985c-.0000885.56031852.4483217 1.006032 1.0015506 1.00594461.5390308-.00008516.9785753-.44874418.9786627-1.00210749l.0009332-5.9072465c.0000875-.553948-.4484113-1.00188204-1.0017499-1.00179463l-5.906983.00093313c-.5539233.00008751-1.0019791.44863892-1.0020665 1.00186784-.0000852.53903074.4502662.97843325 1.0058884.97834547l3.5101055-.00055449z" fill-rule="evenodd"/></symbol><symbol id="icon-github" viewBox="0 0 100 100"><path fill-rule="evenodd" clip-rule="evenodd" d="M48.854 0C21.839 0 0 22 0 49.217c0 21.756 13.993 40.172 33.405 46.69 2.427.49 3.316-1.059 3.316-2.362 0-1.141-.08-5.052-.08-9.127-13.59 2.934-16.42-5.867-16.42-5.867-2.184-5.704-5.42-7.17-5.42-7.17-4.448-3.015.324-3.015.324-3.015 4.934.326 7.523 5.052 7.523 5.052 4.367 7.496 11.404 5.378 14.235 4.074.404-3.178 1.699-5.378 3.074-6.6-10.839-1.141-22.243-5.378-22.243-24.283 0-5.378 1.94-9.778 5.014-13.2-.485-1.222-2.184-6.275.486-13.038 0 0 4.125-1.304 13.426 5.052a46.97 46.97 0 0 1 12.214-1.63c4.125 0 8.33.571 12.213 1.63 9.302-6.356 13.427-5.052 13.427-5.052 2.67 6.763.97 11.816.485 13.038 3.155 3.422 5.015 7.822 5.015 13.2 0 18.905-11.404 23.06-22.324 24.283 1.78 1.548 3.316 4.481 3.316 9.126 0 6.6-.08 11.897-.08 13.526 0 1.304.89 2.853 3.316 2.364 19.412-6.52 33.405-24.935 33.405-46.691C97.707 22 75.788 0 48.854 0z"/></symbol><symbol id="icon-springer-arrow-left"><path d="M15 7a1 1 0 000-2H3.385l2.482-2.482a.994.994 0 00.02-1.403 1.001 1.001 0 00-1.417 0L.294 5.292a1.001 1.001 0 000 1.416l4.176 4.177a.991.991 0 001.4.016 1 1 0 00-.003-1.42L3.385 7H15z"/></symbol><symbol id="icon-springer-arrow-right"><path d="M1 7a1 1 0 010-2h11.615l-2.482-2.482a.994.994 0 01-.02-1.403 1.001 1.001 0 011.417 0l4.176 4.177a1.001 1.001 0 010 1.416l-4.176 4.177a.991.991 0 01-1.4.016 1 1 0 01.003-1.42L12.615 7H1z"/></symbol><symbol id="icon-submit-open" viewBox="0 0 16 17"><path d="M12 0c1.10457 0 2 .895431 2 2v5c0 .276142-.223858.5-.5.5S13 7.276142 13 7V2c0-.512836-.38604-.935507-.883379-.993272L12 1H6v3c0 1.10457-.89543 2-2 2H1v8c0 .512836.38604.935507.883379.993272L2 15h6.5c.276142 0 .5.223858.5.5s-.223858.5-.5.5H2c-1.104569 0-2-.89543-2-2V5.828427c0-.530433.210714-1.039141.585786-1.414213L4.414214.585786C4.789286.210714 5.297994 0 5.828427 0H12Zm3.41 11.14c.250899.250899.250274.659726 0 .91-.242954.242954-.649606.245216-.9-.01l-1.863671-1.900337.001043 5.869492c0 .356992-.289839.637138-.647372.637138-.347077 0-.647371-.285256-.647371-.637138l-.001043-5.869492L9.5 12.04c-.253166.258042-.649726.260274-.9.01-.242954-.242954-.252269-.657731 0-.91l2.942184-2.951303c.250908-.250909.66127-.252277.91353-.000017L15.41 11.14ZM5 1.413 1.413 5H4c.552285 0 1-.447715 1-1V1.413ZM11 3c.276142 0 .5.223858.5.5s-.223858.5-.5.5H7.5c-.276142 0-.5-.223858-.5-.5s.223858-.5.5-.5H11Zm0 2c.276142 0 .5.223858.5.5s-.223858.5-.5.5H7.5c-.276142 0-.5-.223858-.5-.5s.223858-.5.5-.5H11Z" fill-rule="nonzero"/></symbol></svg> </div> </body> </html>